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Abstract	  
The T cell-dependent humoral immune response consists of a series of discrete stages that 
culminate in the differentiation of effector B cells, capable of secreting antibodies. These cellular 
events occur in specific microenvironments within secondary lymphoid organs. The positioning of 
B cells during the humoral response allows them to receive the appropriate cellular and genetic cues 
necessary for their subsequent differentiation. Consequently, the precise positioning of B cells is 
essential for the generation of an effective humoral response.  
The chemokine receptors, a family of G-protein coupled receptors, are responsible for directing the 
migration and organisation of lymphocytes in the immune system. It has been established that the 
chemokine receptors, CXCR5, CCR7, CXCR4 and EBI2, work together to co-ordinate the 
movement of B cells in the humoral response, by integrating stimuli from various chemokine 
ligands in the surrounding environment. Whilst a number of chemokine receptors on B cells have 
been functionally defined, others are not well understood. One such chemokine receptor, CCR6, has 
an expression pattern consistent with a role in B cell differentiation, however, the contribution of 
CCR6 to the humoral response remains undefined.  
This thesis focused on addressing the role of CCR6 in the humoral response. I hypothesised that 
CCR6 expression is necessary for efficient B cell differentiation during T cell-dependent humoral 
immune responses. Specifically, this thesis has examined 1) the expression level of CCR6 during B 
cell activation, 2) the consequences of B cell differentiation in the absence of CCR6, 3) the 
potential mechanisms that underlie the contribution of CCR6 to B cell differentiation and finally, 4) 
the relevance of CCR6 in B cell-mediated autoimmunity.  
Initially, CCR6 expression was assessed on B cells after activation with T cell-dependent antigens. 
Flow cytometry analysis demonstrated that antigen-specific B cells significantly upregulate CCR6 
expression upon activation in vitro. This finding was also confirmed in vivo. Furthermore, cell 
sorting and immunofluorescence revealed that CCR6 is expressed during T-B cell interactions in 
vivo. Consequently, this work established that CCR6 is upregulated on activated B cells.    
Considering the distinct expression of CCR6 during B cell differentiation, particularly activation, 
the impact of CCR6 on the humoral response was evaluated. B cell differentiation was quantified in 
WT and CCR6-/- mice that were challenged with the immunogen, NP-KLH, over a 6-week period. 
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Flow cytometry and immunofluorescence analysis revealed that the CCR6-/- mice generated more 
germinal centre B cells at 3 and 5 days after antigen challenge, compared to WT mice. This 
correlated with a significant reduction in the frequency of naïve B cells at days 3, 5 and 14, as well 
as a significant increase in the memory B cell population at days 3, 5, and 10, after challenge in the 
CCR6-/- mice compared to the WT mice. In addition, when extrafollicular B cells were analysed in 
MD4 and MD4.CCR6-/- mice immunised with HEL-SRBC, the MD4.CCR6-/- mice were found to 
have significantly fewer extrafollicular B cells 6 days after challenge, compared to the MD4 mice. 
Even though B cell differentiation was found to be dysregulated in the absence of CCR6, this 
dysregulation was not permanent as it only occurred early in the response, indicating a role for 
CCR6 in the initiation of the humoral response.  
 
Investigation into the potential mechanisms underlying the B cell dysregulation observed in the 
CCR6-/- mice resulted in several findings. Immunofluorescence of splenic germinal centre follicles 
showed no gross structural abnormalities in the CCR6-/- mice. In addition, qRT-PCR indicated that 
somatic hypermutation and differentiation in CCR6-/- germinal centre B cells was not affected. 
However, CCR6-/- germinal centre B cells contained significantly more Bcl-6 mRNA than WT, 
potentially accounting for the increased germinal centre response. Furthermore, this increase in Bcl-
6 mRNA was attributed to a significant increase in T follicular helper cell-secreted IL-21. Also, 
flow cytometry analysis demonstrated that the T follicular helper cell and follicular dendritic cell 
populations of CCR6-/- mice were reduced compared to WT mice, indicating that germinal centre 
affinity selection is impaired in the absence of CCR6. Despite the increased germinal centre 
response observed in the CCR6-/- mice, antibody quantification by ELISA demonstrated that the 
production of antigen-specific IgM and IgG in CCR6-/- mice was equivalent to that in WT mice. 
Additionally, an adoptive transfer model demonstrated that the loss of CCR6 on leukocytes other 
than B cells is responsible for the B cell dysregulation identified in the CCR6-/- mice. Taken 
together, the reduced extrafollicular response and increased germinal centre response likely 
counterbalance each other in the CCR6-/- mice. Hence, the loss of CCR6 does not have an overall 
detrimental effect on the humoral response. 
 
Finally, the clinical relevance of CCR6 was examined in a mouse model of systemic autoimmunity 
and in the human B cell-mediated systemic autoimmune disease, Systemic Lupus Erythematosus 
(SLE). Flow cytometry analysis showed that the FasLgld mice, which develop a spontaneous 
generalised systemic autoimmune disease, have a significantly lower frequency of CCR6+ B cells 
than WT mice. However, CCR6 expression on B cells was significantly higher in the FasLgld mice 
compared to the WT mice. This finding was examined in a preliminary study of SLE. Participants 
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diagnosed with SLE had a significantly higher expression of CCR6 on B cells, compared to healthy 
controls. The increased CCR6 expression observed in autoimmunity highlights the potential for 
chemokine receptors to be used as biomarkers and therapeutic targets of disease. 
 
Overall, this thesis presents several novel findings. It is the first to demonstrate the upregulation of 
CCR6 on activated B cells, as well as the first to define the T cell-dependent humoral response in 
CCR6-/- mice and to examine the potential of chemokine receptors to be used in clinical medicine. 
As a result of this work, I propose that CCR6 aids the organisation of activated B cells during the T 
cell-dependent humoral response. This thesis provides a significant contribution to our 
understanding of the development of efficient humoral responses and insight into how responses 
can be manipulated in disease. 	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Our knowledge of the mechanisms underlying the antibody-mediated primary immune response; 
particularly B cell differentiation, has advanced considerably since the publication of Burnet’s 
clonal selection theory. However, we have yet to fully explain how B cells are organised during the 
humoral response and how this organisation contributes to B cell fate. This information is 
significant as it will not only enhance our understanding of the mechanisms underlying an efficient 
humoral response, it will provide insights into disorders of the immune system and aid the 
generation of therapies in the future. This thesis seeks to define the contribution of the chemokine 
receptor, CCR6, to B cell differentiation in humoral immunity, and thereby make an original 
contribution to knowledge. This introduction comprises an overview of the immune system, an 
introduction to the humoral response, a critical review of the role of CCR6 in the immune system 
and in the context of autoimmunity and, finally, an outline of the research conducted.    
 
1.1. The Immune System 
The mammalian immune system is a complex biological system made up of a network of 
leukocytes that work together to generate an immune response. The immune system is composed of 
two subsystems: the innate and adaptive systems. The innate system is responsible for the 
immediate response to infection, generating a broad inflammatory response against infiltrating 
pathogens. It is also necessary for initiating the adaptive response, which specifically targets 
infiltrating pathogens. Both the innate and adaptive immune systems contain cellular and humoral 
components that fight infection.  
 
There are several different types of leukocytes that defend against infection and disease. The largest 
population of leukocytes is the granulocytes, which consist of neutrophils, eosinophils and 
basophils. The granulocytes are involved in the early innate responses where they destroy invading 
pathogens, including bacteria and parasites. The lymphocytes are the second largest population and 
consist of largely B and T cells. The lymphocytes reside in secondary lymphoid organs and are 
essential in adaptive responses, as each one is specific for one epitope of an antigen, and therefore 
enables the immune system to respond to a diverse range of pathogens. Finally, the monocytes are 
progenitors of macrophages and dendritic cells. These cells are pivotal in initiating adaptive 
responses, as they transport antigen to the lymphocytes in secondary lymphoid organs. The innate 
and adaptive systems are linked together by lymphocyte activation.  
 
A summary of the coordinated actions of the immune system, in response to infection, is depicted in 
Fig. 1.1.1. The mechanisms underlying innate responses have been reviewed elsewhere1-3. Briefly, 
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pathogens cause infection by infiltrating host cells such as epithelial cells. Infected cells release 
inflammatory proteins, such as cytokines and chemokines, which recruit innate cells to the site of 
infection (Fig. 1.1.1). Tissue resident macrophages are among the first cells to respond to infection. 
Macrophages can recognise pathogens through receptors that detect repetitive pathogen-associated 
molecular patterns. As a result, macrophages internalise and destroy pathogens through 
phagocytosis. Macrophages are also able to release inflammatory proteins, enlisting further help 
from the innate cells, including granulocytes, monocytes, lymphocytes and toxin releasing natural 
killer (NK) cells. The complement system, a large family of plasma proteins, is also activated by 
pathogens and triggers either opsonisation, the recruitment of phagocytes to the site of infection, or 
the direct lysis of pathogens and infected cells.  
 
 
 
Figure 1.1.1. The mammalian immune response 
In response to infection, cells of the innate system, particularly macrophages and granulocytes, are recruited to the sites 
of infection via inflammatory mediators, where they clear pathogens via phagocytosis. Dendritic cells are also recruited 
to process antigens. After antigen uptake, dendritic cells migrate to secondary lymphoid organs, where they present 
antigens to T cells, thereby initiating the adaptive response. Intracellular antigens presented on MHC-I molecules 
activate CD8+ T cells, which release cytotoxic granules that kill the infected cells. Extracellular antigens presented on 
MHC-II molecules activate CD4+ T cells, which support B cells during differentiation and antibody production. 
Antibodies directly bind antigens, neutralising or opsonising pathogens for destruction.  
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If pathogens evade the innate system, specialised antigen presenting cells such as dendritic cells, are 
recruited to the site of infection to initiate the adaptive response (Fig. 1.1.1). These cells are capable 
of processing pathogens into small antigens, which are then presented to lymphocytes on Major 
Histocompatibility Complexes (MHC). Depending on whether the infection is caused by an 
intracellular or extracellular pathogen, a cell- or humoral-mediated response is generated 
respectively. In the cell-mediated response, dendritic cells present antigens on MHC-I molecules to 
cluster of differentiation (CD)8+ T cells, inducing the lysis of infected cells through the release of 
cytotoxic granules (Fig. 1.1.1). In contrast, dendritic cells present antigens bound to MHC-II 
molecules to CD4+ T cells, initiating the humoral response. While CD4+ T cells become activated, 
B cells are simultaneously activated by antigen, either directly in soluble form or via antigen 
presenting cells. The activated CD4+ T cell can then support the differentiation of cognate B cells 
into antibody secreting cells (Fig. 1.1.1). Antibody secreting cells travel to the sites of infection, 
where they release large amounts of soluble antibody to neutralise pathogens and prevent further 
damage. Antibodies can also opsonise pathogens, marking them for destruction by phagocytosis. 
Another important feature of the adaptive response is the generation of memory lymphocytes, 
which are crucial for mediating responses to re-infection. Further detail on the initiation of adaptive 
immune responses is provided elsewhere4,5. 
 
1.2. Lymphocytes and Lymphoid Organs  
The human body contains approximately 2 trillion lymphocytes, which originate from 
hematopoietic stem cells (HSCs) in the bone marrow and undergo two developmental stages. The 
first stage occurs in the primary lymphoid organs. Specifically, T cells develop in the thymus, while 
B cells continue their development in the bone marrow. After maturation, naïve lymphocytes exit 
primary lymphoid organs and circulate around the body via secondary lymphoid organs, including 
the lymph nodes, spleen and mucosa associated lymphoid tissues. Once in the periphery, 
lymphocytes undergo a second stage of development, in response to antigen. If lymphocytes do not 
encounter antigen in the periphery, apoptosis will be induced. In this way, there is a constant 
turnover of lymphocytes. The recognition of antigen and differentiation of lymphocytes occurs 
within the secondary lymphoid organs, making them crucial components of the adaptive immune 
system.  
 
All secondary lymphoid organs share a similar structure. They are highly compartmentalised such 
that B cells are located together in B cell follicles and T cells assemble in adjacent zones. The 
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secondary lymphoid organs are supplied by the blood and lymph vessels, providing lymphocytes 
with direct access to antigens and antigen presenting cells (reviewed in6,7). 
 
The spleen is separated into two distinct areas, termed the red and white pulp. The red pulp is 
responsible for iron recycling and erythrocyte filtration, while the white pulp consists of leukocytes. 
The white pulp is encased by the marginal zone (MZ), and consists of distinct B cell follicles and T 
cell zones (Fig. 1.2.1). It is innervated by the central arterioles that branch from the splenic artery, 
enabling lymphocytes and antigens access via the MZ. The MZ consists of reticular fibroblasts, 
resident macrophages and B cells, which are capable of detecting and responding to blood-borne 
antigens.  
 
 
 
Figure 1.2.1.  The structure of secondary lymphoid organs 
The lymph node contains B cell follicles (blue) adjacent to T cell zones (yellow) in the paracortex. Similarly, the spleen 
contains white pulp consisting of B cell follicles (blue), as well as T cell zones (yellow) in the periarteriolar lymphoid 
sheath (PALS). Both organs are innervated by the blood and lymphatic system. 
Reproduced from Batista & Harwood (2009) Nature Reviews8. 
 
 
In contrast to the spleen, the lymph nodes are structured in layers. The lymph node is considerably 
smaller than the spleen and is largely home to T cells. The outer cortex of the lymph node contains 
B cell follicles, while the paracortex consists of T cell zones, dendritic cells and high endothelial 
venules (HEVs) (Fig. 1.2.1). Also, the inner medulla region of the lymph node contains 
macrophages. Lymphocytes and antigens transit through the lymph node via the HEVs, or the 
lymphatic vessels located at the subcapsular sinus. 
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The distinct lymphocyte compartments within secondary lymphoid organs provide niches for 
lymphocytes, facilitating both homeostasis and adaptive immune responses. For instance, the T cell 
zone is the site of T cell activation by dendritic cells, while the B cell follicle is the site of B cell 
activation and clonal expansion. The precise organisation of microenvironments within secondary 
lymphoid organs is essential for the development of a timely and efficient response, and will be 
discussed in further detail in section 1.5.  
 
1.3. B Lymphocytes 
B cells are central to the adaptive immune response and they are most notably known for their 
ability to produce antibodies. Antibody, also referred to as immunoglobulin (Ig), can be produced as 
either a membrane bound or soluble form. The membrane bound form acts as the B cell receptor 
(BCR), inducing B cell activation in response to antigen engagement, while the soluble form 
directly clears infection through neutralisation, or facilitates phagocytic destruction through 
opsonisation. 
 
1.3.1. Antibodies 
The Ig molecule is a Y-shaped glycoprotein composed of two inner heavy- and two outer light-
polypeptide chains, joined together by disulphide bonds. Each heavy and light chain is made up of a 
constant and variable domain. The constant domain of the heavy chains are fixed to the cell surface 
in the case of the BCR, while the variable domain of both heavy and light chains function as the 
antigen-binding site. There are five types of antibodies, which are specified by the constant domain 
of the Ig. The five heavy chain classes are the IgM (µ), IgD (δ), IgG (γ), IgA (α) and IgE (ε) 
isotypes, and each has a different effector function. IgM is the first antibody to be expressed and 
secreted. It is expressed on immature B cells as the BCR, as is IgD. IgM is also effective in 
activating the complement system. IgG is the most abundant antibody produced and it neutralises or 
opsonises pathogens. IgE is generated during allergic reactions and parasitic infections, inducing 
the activation of chemical-releasing mast cells. Finally, IgA is secreted at mucosal tissues and is 
most efficient at neutralisation. In addition to the five classes of antibodies, there are also two types 
of light chain – the λ or κ light chains – although, the functional significance of this distinction is 
unknown. Further detail on the structure and function of antibodies is provided elsewhere9. 
 
B cells are specialised to respond to an enormous diversity of epitopes from pathogen-derived 
antigens. This specialisation is accomplished through the recombination of Ig genes. The process of 
genetic recombination has been reviewed elsewhere9-11, however a brief summary is provided 
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below. The heavy chain variable domain is encoded by variable (V), diversity (D) and joining (J) 
gene segments, while the light chain variable domain is encoded by only V and J gene segments. 
The constant domain of each chain is encoded by a single exon for each chain class. During B cell 
development, the Ig heavy chain locus is rearranged first. The D segment is selected and joined to a 
J segment and this is followed by the joining of a V segment to the newly formed DJ segment. Once 
the VDJ genes of the heavy chain have been arranged, the light chain VJ arrangement can proceed. 
Recombination occurs via the VDJ recombinase, a multi-enzyme unit that contains a pair of 
lymphocyte specific recombination activating gene (Rag) proteins, and is collectively responsible 
for the cleavage and religation of deoxyribonucleic acid (DNA). Not only is diversity introduced 
through the selection of gene segments joined together, it is also introduced through junctional 
diversity, or the insertion or removal of nucleotides between segments, and finally, the combination 
of a rearranged heavy chain with a rearranged light chain creates further diversity. Upon exposure 
to antigen in the periphery, B cells can undergo further diversification. Class switch recombination 
(CSR) allows B cells to switch their heavy chain constant region (exon) from IgM and IgD, to an 
alternate isotype, whilst maintaining their specificity for antigen. This process also occurs by DNA 
recombination, and is, hence, irreversible. In addition, somatic hypermutation (SHM) allows B cells 
to fine tune their genetic recombination to enhance their affinity for antigen.  
 
1.3.2. B cell development  
B cell generation begins during embryonic life and continues after birth in two locations. As 
mentioned previously, B cell development is initiated in the bone marrow and continues in the 
spleen. Development occurs through a sequence of stages and is controlled by genetic and 
environmental factors. The intrinsic genetic B cell program, regulated by transcription factors, is 
essential. However, this program is influenced by environmental cues, such that the migration, 
localisation and exposure of B cells to antigen, influences the specific subset of B cells generated. 
Each stage of B cell development can be distinguished by the Ig status and phenotype of the B cell. 
Several excellent reviews exist that summarise B cell development12, particularly in the bone 
marrow13, as well as the expansion of B cells14, their Ig rearrangement15, and transcriptional 
regulation16-18. Key aspects of early B cell development, relevant to this thesis, are described in the 
following sections.  
 
B cell development in the bone marrow 
B cell development in the bone marrow is characterised by several cellular stages, which have been 
summarised in Table 1.3.2.1. Initially, B cells arise from HSCs, which are identified by the stem 
cell factor c-kit, as well as the surface markers, CD43 and CD93. The HSC population contains 
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early lymphoid progenitors that give rise to the interleukin (IL)-7Rα+ CD24+ common lymphoid 
progenitors (CLPs). The transcription factors PU.1 and Ikaros are required for commitment to the B 
cell lineage and this stage marks the beginning of Ig rearrangement, with the joining of D-J 
immunoglobulin heavy chain (IgH) segments. Specification to the early B cell progenitor, Pro-B 
cells, requires the expression of the basic helix-loop-helix proteins known as E2A, the early B cell 
factor-1 (EBF1) and the B cell specific activation protein, also known as Pax5, which leads to 
CD19 and B220 expression. The Pro-B cells also undergo V-DJ heavy chain Ig rearrangement. 
Successful expression of the pre-BCR, that is the rearranged heavy chain bound to a surrogate light 
chain, enables Pre-B cells to proliferate and subsequently arrange their immunoglobulin light chain 
(IgL) genes. There are several discrete proportions of Pro- and Pre-B cells that can be identified by 
their cell surface expression. For simplicity however, the characteristics of each fraction have been 
grouped together. The successful assembly and expression of the BCR, that is IgM, marks the 
immature B cell stage. Immature B cells with inappropriate BCR specificity or affinity, undergo 
receptor editing, anergy or apoptosis19. The remaining immature B cells are then selected to leave 
the bone marrow and enter the spleen.  
 
 
Table 1.3.2.1. Stages of B cell development in the bone marrow 
 
 
Stage 
     
 
Immunoglobulin 
Status 
 D-J IgH 
rearrangement 
V-DJ IgH 
rearrangement 
Pre-BCR 
V-J IgL 
rearrangement 
IgM+ 
IgD- 
      
 
Transcription 
Factor Profile 
PU.1 
Ikaros 
E2A 
E2A 
EBF1 
Pax5 
 
 
  
      
 
 
Surface 
Phenotype 
CD93+ 
CD43+ 
c-kit+ 
CD93+ 
CD43+ 
c-kit+ 
IL-7Rα+ 
CD24+ 
CD93+ 
CD43+ 
c-kit+ 
IL-7Rα+ 
B220+ 
CD19+ 
CD24+ 
CD93+ 
CD43+ 
IL-7Rα+ 
B220+ 
CD19+ 
IL-2Rα+ 
CD24+ 
 
CD93+ 
B220+ 
CD19+ 
CD24+ 
 
Adapted from references: 13,16-18.  
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B cell development in the periphery 
Approximately twenty million immature B cells are generated in the bone marrow daily and of 
these, only 3% are selected to survive as part of the peripheral B cell population in the spleen. 
Immature B cells generated in the bone marrow enter a transitional stage that links bone marrow 
development with peripheral development. During this stage, transitional B cells undergo negative 
selection and the remaining B cells are directed to replenish either the naïve follicular or MZ 
compartments19-22. The naïve follicular B cells are the largest population of mature B cells and they 
reside in the B cell follicle, whereas the MZ B cells are located in the MZ of secondary lymphoid 
organs. The signals that drive transitional B cells to develop into follicular or MZ B cells are 
unknown.  
 
In the periphery, follicular and MZ B cells must encounter antigen within approximately 24 hours 
to survive. This encounter induces B cells to differentiate into terminal effector cells inside 
secondary lymphoid organs. Terminal differentiation occurs through several stages. As the MZ B 
cells are located adjacent to the blood supply, they are adept at responding to blood borne antigens. 
For follicular B cells to become activated, antigen needs to be transported to B cells inside follicles. 
Furthermore, cues from antigen-activated T cells are needed to drive B cell differentiation and 
antibody production. Consequently, this process is referred to as a T cell-dependent (TD) response. 
During this process, naïve B cells differentiate into plasma and memory cells via a precursor, 
germinal centre (GC) and extrafollicular foci (EF) stage. In contrast to follicular B cells, MZ B cells 
rapidly differentiate into plasma cells in a T cell-independent (TI) manner. A summary of the key 
surface markers that identify the mature B cell subsets is displayed in Table 1.3.2.2. The process of 
TD B cell activation will be explored in further detail in the following section. 
 
 
Table 1.3.2.2. Follicular B cell subsets in the spleen  
 
Naïve  Precursor  Germinal 
Centre  
Plasma Memory Marginal 
Zone  
Extrafollicular 
Foci 
 
B220+ 
CD38+ 
GL7- 
IgM+ 
IgD+ 
IgG- 
CD23+ 
CD21/35+ 
CD95+ 
MHC-IIint 
 
B220+ 
CD38+ 
GL7+ 
 
 
B220+ 
CD38+ 
GL7- 
CD21/35+ 
CD95+ 
MHC-IIhi 
 
B220+ 
CD38- 
GL7- 
CD138+ 
 
 
B220+ 
CD38hi 
GL7+ 
IgMhi 
IgD+ 
 
B220+ 
CD21hi 
CD23- 
 
 
B220lo 
IgG1+ 
CD38- 
CD138hi 
Table compiled from previous studies:23-28.  
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As mentioned earlier, to improve antibody affinity for antigen, peripheral B cells undergo CSR and 
SHM (reviewed in29-32). These processes are directed by the enzyme activation-induced cytidine 
deaminase (AID), which acts on single-stranded DNA, whilst also reducing cell proliferation and 
exposing cells to apoptosis33-35. AID is responsible for introducing single nucleotide mutations into 
Ig genes33,36,37. Specifically, AID converts cytosine to uracil, creating a U-G mismatch in the DNA. 
Mutations introduced into the variable domain of the IgH and IgL genes, or the switch regions of 
the constant domain of IgH gene, induce SHM and CSR respectively. Proteins from the Base 
Excision Repair process repair the mutations introduced by AID, however, these processes are 
associated with low-fidelity polymerases, and consequently introduce further mutations and single 
strand breaks. If single strand breaks are converted into double stranded breaks, either 
spontaneously or via the Mismatch Repair process, then CSR is induced. This occurs when the 
double strand breaks in the switch regions are resolved and the VDJ sequence is recombined with 
an alternative switch region, such that the constant µ domain is replaced with either the γ, ε or α 
constant domain.  
 
1.4. The Humoral Immune Response 
The TD humoral response consists of a series of discrete cellular events that culminate in the 
differentiation of antibody secreting plasma cells and memory B cells. These events occur in an 
ordered fashion, at various locations within the secondary lymphoid organs. The development of the 
humoral response can be summarised in a five-staged model, as depicted in Fig. 1.4.1. Briefly, 
naïve B cells encounter antigen through the BCR, inducing activation (Fig. 1.4.1a). Activated B 
cells then migrate towards the T cell zone to interact with antigen-specific T cells (Fig. 1.4.1b). 
After receiving T cell help, the activated B cell migrates to the border of the B cell follicle, forming 
the precursor stage (Fig. 1.4.1c). The precursor B cell will undergo a short burst of proliferation and 
CSR. Next, the precursor B cell differentiates through one of two pathways. The B cell can leave 
the follicle and migrate to extrafollicular sites to form EF (Fig. 1.4.1d), or it can enter the follicle to 
establish GC follicles (Fig. 1.4.1d). Both the GC and EF facilitate clonal expansion. The EF is 
responsible for the initial production of low-affinity antibodies from short-lived effector B cells, 
while long-lived effector B cells generated in the GC, produce the more specific high-affinity 
antibodies. The GC is able to produce these high-affinity B cell clones, as it is specialised to 
improve antibody affinity through SHM and affinity selection. The cellular and molecular 
mechanisms of this model, as determined by studies in mice using protein immunisations, are 
described below. 
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Figure 1.4.1. B cell differentiation in the T cell-dependent humoral immune response  
The humoral response can be divided into five discrete stages. Initially, B cells become activated upon antigen exposure 
(a). Activated B cells then migrate toward the T cell zone, where they form T-B cell conjugate pairs (b). After receiving 
cognate T cell help, B cells migrate to the border of B cell follicles and enter a precursor state (c). Precursor B cells are 
then selected to expand into either extrafollicular foci (d) or germinal centres (e), yielding short-lived, low-affinity and 
long-lived, high-affinity effector B cells respectively.    	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1.4.1. Stage 1: B cell activation  
 
 
 
To initiate the humoral response, B cells must encounter antigen. B cells can acquire antigen several 
ways. Firstly, B cells may encounter soluble antigen directly, after it has diffused across the B cell 
follicle, or passed through a conduit system of collagen and fibroreticular cells38,39. B cells can 
encounter larger antigens directly, after they have been broken down by proteases40, or by antigen-
presenting macrophages39,41,42. Dendritic cells can also present antigen to B cells43. Finally, B cells 
that are in transit to secondary lymphoid organs can collect soluble antigen directly from 
circulation38. Despite the multiple ways in which B cells can encounter antigen, antigen acquisition 
occurs very quickly, with antigen appearing in secondary lymphoid organs within minutes of 
immunisation, and B cells internalising antigen within a couple of hours38,41. 
 
Once the B cell has bound antigen through its BCR, intracellular signalling is initiated resulting in 
antigen processing. Initially, the BCR clusters in the cell membrane, mediating the recruitment of 
intracellular proteins. The immunoreceptor tyrosine-based activation motifs (ITAMs), within the 
CD79 accessory protein of the BCR, are phosphorylated upon activation, thereby initiating 
signalling. The CD19/CD21 co-receptor is also activated, amplifying the activation signal. 
Following antigen binding, a series of protein kinases are activated, initiating the assembly of the 
signalosome via the B-cell linker protein (Blnk). This signal is then propagated through the 
signalosome, causing the release of intracellular calcium and activating the mitogen-activated 
protein kinases (MAPK) pathway. This results in the translocation of the transcription factors, 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), nuclear factor of activated 
T cells (NFAT) and activator protein-1 (AP-1), to the nucleus, facilitating antigen presentation, 
proliferation and differentiation. Further details on the process of BCR signalling is provided 
elsewhere44-48. While intracellular signalling is occurring, the BCR-antigen complex is internalised 
through endocytosis and subsequently degraded by lysozymes. This allows antigen to be collected, 
loaded onto MHC-II molecules synthesised in the endoplasmic reticulum, and trafficked to the cell 
surface for presentation to CD4+ T cells.  
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1.4.2. Stage 2: T-B cell interactions 
 
 
 
Following activation, B cells stop moving randomly throughout follicles49,50, and migrate directly to 
the border between the B cell follicle and T cell zone, known as the T-B border41,49-52. 
Simultaneously, T cells activated by antigen presenting cells within the T cell zone also migrate 
towards the T-B border49. Here, antigen-specific B and T cells physically meet, forming conjugate 
pairs50. Generally conjugates are monogamous, with one B cell interacting with one T cell at any 
one time, however, conjugates consisting of multiple T cells have been reported50,51.  
 
The T-B cell conjugates migrate at the T-B border for approximately an hour, in localised, yet 
random movements led by the B cell50,51. These interactions generally occur for the first for 2 days 
following antigen challenge, allowing B cells to consecutively interact with several T helper (Th) 
cells, prior to the next stage of differentiation50,51,53. During this time, the lymphocytes share signals 
that cue their subsequent differentiation. Activated B cells present MHC-II bound antigens to T 
cells, eliciting T cell help through the engagement of the T cell receptor54-57. To facilitate signal 
transfer, B cells form extensive surface contacts, mediated by integrins, with T cells56,58. For 
instance, the T cell adhesion molecule, lymphocyte function-associated antigen-1 (LFA-1), binds to 
intercellular adhesion molecule-1 (ICAM-1) on the B cell56,59. Mutual co-stimulation of B and T 
cells occurs through the signalling lymphocyte activation molecules (SLAM) and SLAM associated 
proteins (SAP)60,61. Activated T cells express CD40L, which is bound by CD40 on B cells, not only 
driving B cell expansion, but also inducing B cells to express CD80/8649,62-64. In turn, CD80/86 
binds CD28 on T cells, enabling both T cell expansion and the expression of CD40L, thereby 
creating a positive feedback loop61,65,66. B cell stimulation of T cells induces T helper (Th) cell 
function, that is, cytokine secretion, which further supports B cell differentiation. The microtubule-
organising centre, golgi apparatus and, the endocytic and exocytic compartments within the T and B 
cell of a conjugate pair are polarised towards each other at the point of contact57,67,68. This facilitates 
the efficient delivery of cytokines, including IL-2, IL-4 and interferon (IFN)-γ, which also promote 
B cell differentiation62,69-72.  
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1.4.3. Stage 3: Precursor B cell proliferation  
 
 
 
After B cells receive T cell help, B cells enter a precursor stage, approximately 48–72 hours after 
immunisation, prior to GC and EF differentiation28,73-75. Activated B cells migrate from the T-B 
border to the edge of B cell follicles, where they undergo an initial burst of proliferation and 
CSR74,76. Following T-B cell interactions, B cells must commit to either GC or EF differentiation – 
an important event for B cells51,77. However, the signals that drive these B cell fate decisions are 
poorly understood and remain controversial. It has been suggested that B cell selection is based on 
their original antigen-BCR interactions, such that high-affinity B cells are directed to differentiate 
into EF, while low-affinity B cells are directed to form GCs, where their affinity is then greatly 
enhanced by SHM and affinity selection75,78-80. However, it has also been reported that B cells 
which present high amounts of antigen-MHC-II complexes to T cells during T-B cell interactions, 
are selected to differentiate into GCs73. Furthermore, these decisions can also be influenced by 
cytokines secreted in the local environment77. Nonetheless, B cell clones are selected to expand and 
differentiate through the extrafollicular or GC pathway. As the extrafollicular response has a short 
life span relative to the GC response, the EF response will be discussed here first.  
 
1.4.4. Stage 4: The expansion of Extrafollicular Foci  
 
 
 
Precursor B cells committed to EF differentiation, leave the B cell follicle border to establish EF. 
The extrafollicular response produces antibody secreting cells that are short-lived and produce low-
affinity antibodies, providing an initial, rapid response to infiltrating pathogens (Fig. 1.4.4.1)81.  
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Only a few B cell clones are needed to form EF, which then proliferate extensively for 4-7 days 
following antigen challenge27,53,77. The extrafollicular response peaks at day 8 and dissipates by day 
1419,2053. During the extrafollicular response, B cells continue to undergo isotype switching via 
CSR27,53,77. Interestingly, it is thought that the EF B cells are exposed to selection pressures within 
the EF. Specifically, dendritic cells have been documented as being associated with extrafollicular 
plasmablasts, and required for their differentiation into plasma cells82. It is likely that these 
dendritic cells play a similar role to the follicular dendritic cells (FDCs) located in the GC follicle 
and that is to provide antigen for competitive selection between B cell clones53. In contrast to the 
GC, it is generally agreed that Th cells are not associated with EF. Although, there is some evidence 
from the autoimmune Murphy Roths Large (MRL)-lymphoproliferation (lpr) mouse model that 
suggests the existence of extrafollicular Th cells, which support plasma cell differentiation83. 
Overall, there is consensus that EF B cells must be able to recognise and respond appropriately to 
antigen to be selected to survive (Fig. 1.4.4.1). Following selection in the EF, B cells differentiate 
into plasmablasts and then plasma cells26,27,77,84-86. Plasma cell differentiation requires the 
transcription factor B lymphocyte maturation protein-1 (Blimp-1), which inhibits activated B cell 
function, induces proliferation, and the expression of X box binding protein-1 (XBP-1), a 
transcription factor which also promotes plasma cell differentiation87-90. In this way, plasmablasts 
transition into plasma cells. 
 
 
 
Figure 1.4.4.1. The mechanisms of the Extrafollicular response 
Activated B cells are selected to form EF in sites outside the B cell follicle. Here, B cells undergo proliferation, isotype 
switching and selection into short-lived antibody secreting cells that are of low-affinity. The key proteins associated 
with the EF response are indicated.  
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1.4.5. Stage 5: The Germinal Centre reaction 
 
 
 
Precursor B cells that are selected to differentiate into GC B cells enter the B cell follicle to 
establish GC follicles, where they generate long-lived, high-affinity plasma cells and memory B 
cells91,92. The GC follicle is a highly organised structure compared to EF. It is founded by 1–3 B 
cell clones and is capable of generating a response to more than one antigen77,93. The GC is 
specialised to improve antibody affinity through proliferation, SHM and affinity selection94-97. 
These processes are collectively referred to as the GC reaction. GC follicles appear approximately 
3–4 days following antigen challenge, and the response peaks at day 8, before decreasing and 
persisting until at least day 16 after antigen challenge27,49,53,77. GC-derived plasma and memory B 
cells are detected in the blood within a week of antigen challenge98.  
 
The dynamics of the GC response have been extensively reviewed99,100. Briefly, the GC contains 
two distinct zones, a dark zone and a light zone, which is encased by a follicular mantle. In order 
for GCs to be established, precursor B cells must upregulate their expression of the transcription 
factor B-cell lymphoma 6 (Bcl-6), prior to their migration into the B cell follicle101-103. Furthermore, 
the transcription factor, interferon regulatory factor 4 (IRF4) is also required for GC formation and 
may contribute to Bcl-6 activation104-106. Once in the dark zone, B cells undergo proliferation, CSR 
and SHM via AID expression27,53. Newly mutated B cell clones then migrate to the light zone where 
they undergo affinity selection. It is becoming clear that B cell migration in the GC and the GC 
reaction is not a simple process, as B cells are capable of migrating back and forth between the dark 
zone and light zone, undergoing several rounds of proliferation, mutation and selection95-97,100. In 
this way, B cells are competitively selected to differentiate into plasma and memory B cells (Fig. 
1.4.5.1).  
 
The selection of B cells is mediated by the FDCs and a subset of CD4+ T cells, known as the T 
Follicular helper (TFH) cells. In the GC, B cells must collect antigen from FDCs, and present it to 
TFH cells in order to elicit T cell help (Fig. 1.4.5.1). The development of FDCs and the function of 
FDC-derived cues have been extensively reviewed107,108, as has the generation of TFH cells109-111. As 
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such, only those aspects relating to B cell differentiation will be highlighted here. The FDCs play an 
important role in sustaining the GC reaction. They primarily provide a source of antigen to B cells 
for selection42, however, they also secrete cytokines and chemokines, and engage molecules on the 
surface of B cells, to support the GC reaction112-114. In fact, B cells that don’t interact with FDCs are 
eliminated by apoptosis115,116. Furthermore, the normal cessation of the GC response is due to the 
gradual exhaustion of antigen supply on the FDCs117. If B cells successfully collect antigen from 
FDCs and present it to TFH cells, the TFH cells provide (inducible T-cell costimulator) ICOS and 
CD40L signals to the GC B cell, thereby supporting B cell proliferation, CSR and affinity 
selection118-120. In addition, the TFH cells secrete cytokines, such as IL-4, IL-10, IFN-γ and IL-21, 
which also regulate antibody production through CSR, SHM and differentiation115,121-125. If GC B 
cells do not receive help from TFH cells, particularly in the form of CD40 interactions, they will 
undergo apoptosis115.  
 
 
 
Figure 1.4.5.1. The mechanisms of the Germinal Centre reaction  
Activated B cells committed to the GC fate enter the B cell follicle to establish GC follicles. The GC is structurally 
divided into the dark zone and light zone by chemokine receptors. GC B cells migrate between the dark and light zone, 
undergoing consecutive rounds of proliferation, SHM, CSR and affinity selection. Interactions with antigen-presenting 
FDCs and cytokine-secreting TFH cells, are essential for antibody maturation and terminal differentiation. The key 
proteins associated with the GC reaction, including transcription factors, enzymes and chemokine receptors, are 
indicated.   
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Those B cell clones that have acquired mutations that improve antibody affinity, are selected to 
differentiate into effector plasma and memory B cells126,127. Clones with inappropriate mutations are 
eliminated by apoptosis and are cleared by tangible body macrophages128,129. The mechanisms 
responsible for clonal selection remain poorly understood. The evidence to date suggests that B cell 
selection and differentiation is directed by a combination of signals, including the nature of the 
antigen, the affinity status of the B cell, the B cell intrinsic transcription program, the cytokine or 
cellular signals derived from the TFH cells and FDCs, as well as the temporal and spatial 
organisation of the B cell130,131. Indeed, in silico modeling concurs with this theory132, however, it 
remains to be directly established under physiological conditions.  
 
Nonetheless, the GC reaction yields plasma cells and memory B cells, and the characteristics of 
each terminally differentiated subset are presented here. GC-derived plasma cells are non-
proliferating, long-lived cells, that reside in the bone marrow for several months to years after 
challenge85,133,134. However, a proportion of these cells can also reside in the spleen for 
approximately 1 year134. Plasma cell differentiation peaks approximately 1 week after challenge, 
and rapidly decreases thereafter85,133. In contrast to plasma cells, memory B cells do not secrete 
antibody, rather they differentiate into antibody secreting cells upon reinfection, re-initiate the GC 
response and self-replenish135-137. Memory B cells appear within 3 days of immunisation, peak at 
day 21 and persist until at least day 56 after immunisation135. They can reside in both the spleen and 
bone marrow, until they are called upon during re-infection136. GC-derived memory B cells can be 
isotype switched, or they can retain IgM137,138. Of course, it is important to note that early TD 
memory B cells can also be produced independently of the GC28,81. These cells can be isotope 
switched, but are not mutated and are of low-affinity, and therefore suited to aiding the initial rapid 
response to infection. 
 
Molecularly, the differentiation of GC B cells is associated with the expression of transcription 
factors. The transcription factor Blimp-1, encoded by the Prdm1 gene, is essential for plasma cell 
differentiation, but not memory formation89,139. In fact, IRF4 expression induces Blimp-1 and AID 
expression and consequently drives plasma cell differentiation105,140,141. Blimp-1 represses B cell 
genes associated with proliferation, CSR, B cell phenotype and signalling, including Bcl-6, thereby 
favouring plasma cell differentiation88,102,142. Blimp-1 also induces XBP-1, a transcription factor 
required for plasma cell generation but not memory cell generation88,143,144. In addition, Pax5, 
although required for early B cell development, is repressed during plasma cell differentiation by 
Blimp-1145-147. Conversely, Bcl-6 not only supports GC formation, but represses Blimp-1 
expression and thereby inhibits plasma cell differentiation142. Despite the number of transcription 
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factors identified for plasma cell differentiation, no transcription factor has been identified that 
specifically instructs GC B cells to differentiate into memory B cells.  
 
1.5. Lymphocyte Migration 
The cellular events of the humoral response occur in specific microenvironments within secondary 
lymphoid organs. This spatial distribution enables cell-cell interactions, which are essential for the 
initiation and progression of the response. The organisation of lymphocytes in the humoral response 
must be both accurate and precise – lymphocytes must be at the right place at the right time for an 
efficient immune response to be generated. Cellular organisation is coordinated by a family of 
chemokine receptors that exert their function by binding chemotactic cytokines, known as 
chemokines.  
 
1.5.1. Chemokines and Chemokine Receptors 
Chemokines are small 8–12 kDa soluble proteins that direct lymphocyte migration by binding 
seven-transmembrane Gαi-protein coupled chemokine receptors148,149. Currently, 20 receptors and 
50 chemokines have been identified150-152. Chemokine receptors are made up of an extracellular N-
terminal, seven-transmembrane α-helical domain and an intracellular C-terminal domain that is 
coupled to pertussis toxin sensitive G-proteins (Fig. 6)150. Upon ligand binding, chemokine 
receptors undergo a conformational change that activates the G-proteins and triggers Janus Kinase 
(JAK)/ signal transducers and activators of transcription (STAT) signalling, resulting in calcium 
mobilisation and chemotaxis of lymphocytes153. Chemokine receptors direct lymphocyte migration 
by binding to chemokines expressed in what is thought to be a gradient in the surrounding 
environment. 
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Figure 1.5.1.1. The structure of chemokine receptors 
Chemokine receptors are seven transmembrane G-protein coupled receptors that bind chemokines. The binding of 
chemokines occurs at 3 key sites: (1) the carboxy-terminal α-helix, (2) the N loop region enabling initial receptor 
contact, and (3) the amino-terminus154. 
Reproduced from Moser and Willimann (2004)154. 
 
 
Chemokine receptors can be functionally separated into two broad groups – inflammatory and 
homeostatic. Inflammatory chemokine receptors mediate the recruitment of monocytes, neutrophils 
and NK cells to sites of infection, while homeostatic chemokines are constitutively expressed and 
function in recruiting B cells, T cells, and antigen presenting cells to secondary lymphoid organs. It 
is important to note that some receptors have both inflammatory and homeostatic functions. 
Chemokine receptors can be further subdivided based on the frequency and structural arrangement 
of cysteine groups in their amino terminus – C, CC, CXC, CX3C, where C is a cysteine group and 
X is an amino acid, and a similar nomenclature exists for chemokine ligands151. A current list of 
chemokine receptors and their ligands is provided in Table 1.5.1.1. Most chemokine-chemokine 
receptor interactions are not exclusive and this is particularly true for inflammatory chemokines, 
which are typically capable of recognising multiple receptors, thus providing versatility when 
responding to infection.  
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Table 1.5.1.1. Chemokine Receptors  
 
Classification Receptor Ligand/s Function 
C XCR1 XCL1 & 2 Inflammatory 
CC CCR1 CCL3, 5, 7, 14, 15, 16 & 23 Inflammatory 
CCR2 CCL2, 7, 8, 13 & 16 Inflammatory 
CCR3 CCL5, 7, 8, 11, 13, 15, 16, 24, 26 & 28 Inflammatory 
CCR4 CCL17 & 22 Homeostatic 
CCR5 CCL3, 4, 5, 8, 11, 14 &16 Inflammatory 
CCR6 CCL20 Homeostatic 
CCR7 CCL19 & 21 Homeostatic  
CCR8 CCL1 Homeostatic 
CCR9 CCL25 Homeostatic 
CCR10 CCL27 & 28 Homeostatic 
CXC CXCR1 CXCL6, 7 & 8 Inflammatory 
CXCR2 CXCL1, 2, 3, 5, 6, 7 & 8 Inflammatory 
CXCR3-A CXCL9, 10 & 11 Inflammatory 
CXCR3-B CXCL4, 9, 10 &11 Inflammatory 
CXCR4 CXCL12 Homeostatic 
CXCR5 CXCL13 Homeostatic 
CXCR6 CXCL16 Inflammatory 
CXCR7 CXCL12 Inflammatory 
CX3C CX3CR1 CX3CL1 Inflammatory 
Adapted from references: 151,152,155.  
  
      
1.5.2. Chemokine Receptors in Humoral Immunity 
Lymphocyte migration is imperative for the immune system to maintain homeostasis and generate 
immune responses upon infection. Lymphocytes are required to migrate from primary lymphoid 
organs, recirculate throughout the periphery and localise within microenvironments of secondary 
lymphoid organs. It is clear that the precise positioning of B cells in secondary lymphoid organs is 
determined by several chemokine receptors. The responsiveness of B cells to chemokines, which 
define various microenvironments, enables this precise localisation during the humoral response. 
This migration is essential as it allows B cells to receive appropriate cues that direct terminal 
differentiation.  
 
Currently, four major chemokine receptors contribute to B cell movement: CXCR5, CCR7, CXCR4 
and Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) (Fig. 1.5.2.1). B cell homing to 
follicles is dependent on the expression of CXCR5156. Upon activation, B cells upregulate CCR7, 
overpowering the CXCR5 signal to the B cell follicle, facilitating their migration to the T-B border, 
where they can interact with cognate Th cells (Fig. 1.5.2.1)52. After B cells receive T cell help, they 
are selected to differentiate into GC or EF B cells. For the formation of EF, B cells downregulate 
their expression of CXCR5 and CCR7, and upregulate their expression of EBI2, allowing their 
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migration to extrafollicular sites (Fig. 1.5.2.1)157,158. Conversely, the downregulation of EBI2 
enables GC formation157. Once in the GC, B cells express high levels of CXCR5 and CXCR4, 
allowing activated B cells to migrate between the CXCL12+ dark zone and CXCL13+ light zones of 
the GC (Fig. 1.5.2.1)95-97,159. After differentiation into plasma cells, B cells downregulate CXCR5 
and CCR7 expression, while simultaneously upregulating CXCR4 expression, so that plasma cells 
can migrate to the periphery to exert their effector functions160,161. However, the chemokine 
receptors responsible for T-B cell conjugate migration and the migration of precursor B cells 
remain to be defined. Furthermore, while a number of influential chemokine receptors are known, it 
is not known whether other chemokine receptors that have not yet been functionally defined, 
contribute to B cell movement in the humoral response. Thus, B cell movement in the humoral 
response remains to be fully elucidated.  
 
 
 
 
 
Figure 1.5.2.1. The chemokine receptor-directed positioning of B cells during the T 
cell-dependent humoral response 
At any one time, B cells are exposed to a variety of chemokines (dots) that are constitutively expressed in secondary 
lymphoid organs and act to define niches within these organs. Depending on the differentiation state of B cells, for 
instance whether B cells have been activated, or received T cell help, B cells can respond to chemokines through the 
modulation of chemokine receptor expression. The chemokine receptors and the modulation of their expression 
required for B cell localisation to the T-B border, extrafollicular foci and germinal centre is depicted.  
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1.6. The CC-chemokine receptor 6  
At the start of this project, the function of the chemokine receptor, CCR6, was unknown. It was 
clear that CCR6 had a characteristic expression profile on B cells differentiating in response to 
antigen, indicating that CCR6 may contribute to B cell organisation in the humoral immune 
response. An overview of CCR6, including its identification, cellular distribution and known 
interactions, are described below.   
 
1.6.1. The identification of CCR6 
CCR6, originally termed STRL22, was first identified in 1997162. Using a series of cloning and 
sequencing techniques, CCR6 was identified in human cells by its conserved chemokine receptor 
sequences that were shared by CXCR1, CXCR2, CXCR4, CCR7 and CXCR5162. The gene 
encoding CCR6 was mapped to human chromosome 6 and it was determined that multiple protein 
variants existed162. Furthermore, northern blot analysis of human tissue demonstrated that CCR6 
was expressed by lymphocytes in lymphoid tissue162.  
 
1.6.2. The ligand for CCR6 
Subsequently, three research groups simultaneously identified the ligand for CCR6. At the time, 
CCL20 was a novel chemokine without a specific chemokine receptor and consequently research 
efforts focused on identifying its receptor. Baba and colleagues transfected human cell lines with 
cloned chemokine receptors, including CCR6, and measured calcium mobilisation after the addition 
of CCL20 using a fluorescent calcium-indicator dye163. This demonstrated that CCR6 responded to 
CCL20 with high specificity and hence further investigation into CCR6 expression was undertaken. 
Northern blot analysis showed that human (h) CCR6 messenger ribonucleic acid (mRNA) was 
expressed in the spleen, lymph node and appendix, and at a lower level in the liver, intestine and 
testis163. CCR6 mRNA was also detected in peripheral blood leukocytes: specifically B cells, CD4+ 
T cells and CD8+ T cells, but not granulocytes, monocytes or NK cells163. This work suggested that 
CCR6 may be involved in lymphocyte trafficking within secondary lymphoid organs163. 
Meanwhile, Liao and co-workers had also identified CCL20 as the ligand for CCR6, by analysing 
calcium mobilisation in human cell lines transfected with CCR6, and PBMCs. This work showed 
that CCR6 was specific for CCL20, as CCL20 dependent migration was not inhibited by other 
chemokines164. Finally, Greaves and colleagues also reported on the identification of the CCR6-
CCL20 mediated migration of human CD34+-derived dendritic cells165. In addition, they confirmed 
that CCR6 was expressed in CD4+ and CD8+ T cells of the blood, as well as splenic B cells165. 
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However, when splenic B cells were activated with anti-CD40 and IL-4, CCR6 mRNA expression 
was found to be reduced165.  
 
Although CCR6 bound to CCL20 with high specificity, CCR6 was also reported to bind small 
antimicrobial peptides, known as β-defensins166. Antimicrobial peptides, such as the β-defensins, 
are produced in the innate response and act to recruit cells to sites of infection167-169. Briefly, β-
defensins are expressed by epithelial cells and function in the recruitment of CCR6+ dendritic cells, 
neutrophils, mast cells and T cells. However, this migration does not occur by a calcium flux, as it 
does in chemokine-chemokine receptor interactions, instead the β-defensins act purely as an 
inflammatory signal. Thus, it was clear that CCR6 was responsive to a single chemokine, CCL20163-
165,170. The hCCL20 protein was mapped to chromosome 2 and found to share only 20–28% 
homology with other chemokines170. Initially, CCL20 was largely detected in the liver, lung, and to 
a lesser extent in the thymus and intestine170. Subsequently, CCL20 was identified in other 
lymphoid tissues including the tonsils and appendix171. Furthermore, chemotaxis assays revealed 
CCL20 was chemotactic for lymphocytes isolated from human peripheral blood170. Overall, the 
evidence thus far indicated that CCR6 responded to the chemokine, CCL20, and that the CCR6-
CCL20 axis contributed to the migration of leukocytes.  
 
1.6.3. The function of CCR6 
To proceed with functional studies of CCR6, an alternative model to humans was required and 
hence, the murine (m) counterparts of hCCR6 and hCCL20 were cloned172. The mCCR6 gene 
encodes a 367 amino acid protein with several mRNA variants and shares 73.8% sequence 
homology with hCCR6172152,. Northern blot analysis revealed that mCCR6 mRNA was expressed in 
the spleen and lymph node172. Furthermore, quantitative real-time polymerase chain reaction (qRT-
PCR) analysis demonstrated that murine B cells from the spleen, lymph node and thymus expressed 
CCR6172. CCR6 expression was also detected in splenic dendritic cells, as well as CD4+ T cells 
from the spleen and lymph node, while mCCL20 was largely detected in the thymus, colon and 
small intestine172. In addition, mCCL20 was shown to induce calcium mobilisation in human cells 
transfected with mCCR6, in a dose-dependent manner172. Overall, the similarity observed between 
murine and human CCR6 demonstrated that Mus musculus was a suitable model to study the role of 
CCR6. From here, research efforts began to focus on examining the role of CCR6 in the mucosal, 
cutaneous and systemic immune systems.  
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CCR6 and Mucosal Immunity  
CCR6 has been implicated in many areas of the immune system including the mucosa and in 
particular, the intestine. The first reports that described the generation of CCR6 deficient mice, to 
study the function of CCR6, provided robust evidence for CCR6 as a regulator of intestinal 
immunity. Two groups independently generated homozygous null CCR6 mice173,174. These mice 
were healthy and had no gross abnormalities in the structure of organs and lymphoid tissue, nor in 
the frequency of major leukocyte populations, indicating that CCR6 was not required for leukocyte 
development173,174. However, CCR6 appeared necessary for the localisation of dendritic cells to 
Peyer’s Patches (PPs) via CCL20173,174. Following the examination of four independently derived 
CCR6-/- mice, using a more sensitive immunohistology technique than the previous studies, it was 
evident that a different chemokine receptor, CCR9, and not CCR6, was responsible for this 
dendritic cell localisation175. Despite this setback, research in this area continued to show that 
CCR6 contributed to intestinal immunity. Both CCR6 and CCL20 were found to be highly 
expressed in isolated lymphoid follicles (ILFs) of the intestine, collectively known as the 
gastrointestinal-associated lymphoid tissue (GALT)176. These sites are essential for antigen 
interaction and the initiation of adaptive immune responses. Furthermore, ILFs were reduced in 
CCR6-/- mice, and this corresponded with a reduction in the frequency of intestinal B cells176. This 
finding was confirmed in bone marrow reconstitution and adoptive transfer experiments, 
demonstrating that CCR6 was required for B cell migration in the intestine and was necessary for 
the establishment of ILFs176. In addition, reductions in the frequency of PPs B cells in the absence 
of CCR6, further supported a role for CCR6 in intenstinal B cell migration, particularly through 
antigen uptake into the GALT176-178. Despite no signs of inflammation, increases in the total 
lymphocyte population, particularly T cells, was reported in the intestinal mucosa of CCR6-/- mice 
173,174. Overall, it is clear that CCR6 contributes to the organisation of lymphoid tissue in the 
intestine.  
 
CCR6 and Cutaneous Immunity 
The function of CCR6 has also been examined during inflammation and diseases affecting the skin. 
While contact hypersensitivity responses between WT and CCR6-/- mice had been reported as 
normal, there was a reduced response to delayed type hypersensitivity in CCR6-/- mice, indicating a 
defect in CD4+ T cell activation or migration173,174. Also, CCR6 has been implicated in the 
development of graft versus-host disease, where host T cells selectively damage the skin and 
intestinal tissues179. Together, this suggests that CCR6 contributes to T cell migration in the skin. In 
addition, CCR6 has been implicated in the migration of dendritic cells and B cells in the skin, 
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potentially aiding antigen uptake, processing and presentation during inflammation180,181. 
Consequently, CCR6 contributes to leukocyte migration in cutaneous immune responses.	  	  
CCR6 and Systemic Immunity 
While CCR6 had been implicated in intestinal and cutaneous immunity, evidence of systemic 
alterations had also been documented. The development and use of CCR6.enhanced green 
Fluorescent Protein (eGFP) knock-in mice demonstrated that CCR6 is expressed in all mature B 
cells, splenic CD4+ T cells, CD8+ T cells and dendritic cells181. Interestingly, altered antibody 
responses were observed in the absence of CCR6. Specifically, CCR6-/- mice immunised with the 
protein carrier, keyhole limpet hemocyanin (KLH) generated increased IgM and decreased IgG3 
levels compared to WT mice174, while immunisation with the hapten, 2,4-dinitrophenol (DNP) 
conjugated to KLH, caused a reduction in IgG2b levels in CCR6-/- mice compared to WT mice173. 
Furthermore, more recent work has demonstrated that CCR6-/- mice produce more low-affinity than 
high-affinity antibody forming cells than WT mice, in response to TD antigen challenge182. In 
addition, preliminary evidence indicates that CCR6-/- mice establish more TD GC follicles than WT 
mice182. Overall, these studies indicate that CCR6 contributes to the efficient generation of humoral 
responses. Indeed, further work in this field implicated CCR6 in B cell differentiation and this 
evidence is described below. 
 
The research conducted into the CCR6-CCL20 axis during B cell differentiation is limited and 
conflicting. While CCR6 had been detected on freshly isolated human peripheral B cells, it was 
shown that these cells do not respond to CCL20 in calcium mobilisation assays183. In contrast, it has 
also been reported that human peripheral B cells do in fact respond to CCL20, but at a lower level 
compared to other chemokines184. Furthermore, this migration response remained low after 
stimulation with either Lipopolysaccharide (LPS) or anti-CD40/IL-4 and was correlated with a 
reduction in both CCR6 cell surface expression and mRNA levels184. In agreement with this, 
Krzysiek and colleagues also documented that CCR6 expression and responsiveness to CCL20 
decreased on human B cells, activated by crosslinking185. However, it was also reported that human 
peripheral B cells activated by cross-linking, show enhanced responses to CCL20186. It is important 
to note, that these studies used B cells isolated from peripheral blood, which were then activated in 
vitro. Therefore, these B cells are inherently different to follicular B cells, which are largely 
responsible for initiating humoral immune responses. When human tonsillar B cells were cultured 
without stimuli, CCR6 expression was increased, however this did not correlate with enhanced 
migration towards CCL20184,187. Overall, due to the contradictory nature of these studies, it was 
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clear that further investigation was needed to resolve the relationship between CCR6 expression and 
B cell activation.  
 
Several groups followed this line of inquiry and as such, have established the expression profile of 
CCR6 on B cells at different developmental stages. It is known that initial bone marrow progenitor 
B cells do not express CCR6, however CCR6 is expressed on naïve follicular B cells188. In addition, 
chemotaxis assays have demonstrated that CCL20 induces the migration of follicular B cells, and to 
a lesser extent, MZ B cells from the spleen, lymph node and PPs188. Another study has confirmed 
that CCR6 is expressed on follicular B cells and shown that only 20% of follicular B cells migrate 
in response to CCL20, suggesting that only a few subsets of B cells respond to CCL20189. This was 
furthered by studies examining tonsillar B cells via flow cytometry and qRT-PCR, which have 
demonstrated that CCR6 is expressed by naïve B cells, is highly expressed on memory B cells, and 
expressed at low levels on GC and in vitro differentiated plasma cells185-187. Furthermore, it has 
been shown that CCL20 induces the migration of naïve and memory B cells, which both express 
moderate to high levels of CCR6185,186. Finally, evidence that strongly supported the variation in 
CCR6 expression on B cells during differentiation arose from the transcriptional analysis of murine 
B cell subsets. This investigation demonstrated that CCR6 is expressed at a moderate level on naïve 
follicular B cells, that CCR6 expression is reduced on GC and plasma B cells, and that CCR6 is 
highly expressed on memory B cells (Fig. 1.6.3.1)190. More recently, CCR6 expression has been 
detected on precursor B cells, which arise after T-B cell interactions, prior to GC and EF 
differentiation (Fig. 1.6.3.1)73. However, it has yet to be determined whether CCR6 is expressed 
during B cell activation, T-B cell conjugate movement and EF development. Overall, the research 
to date has provided valuable insight into the characteristics of CCR6 expression and 
responsiveness to CCL20 in the B cell compartment. However, studies investigating the function of 
CCR6 are lacking. Further work is required to establish the purpose of modulating CCR6 
expression during B cell differentiation in the humoral response.  
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Figure 1.6.3.1. The expression profile of CCR6 on B cells during the T cell-dependent 
humoral response 
CCR6 is moderately expressed on naïve follicular B cells. Following TD antigen activation, CCR6 is expressed on 
precursor cells, at low levels on germinal centre (GC) and plasma B cells, and high levels on memory B cells. It is 
currently unknown whether CCR6 is expressed on activated B cells and extrafollicular foci (EF) B cells.  
 
 
1.7. Autoimmunity  
Models of humoral responses are extremely valuable in studying the mechanisms underlying the 
development of humoral immunity. However, considerable insight can also be gained from 
dysregulated immune responses, as is the case in autoimmunity. Autoimmunity is defined as a state 
of self-reactivity, where the immune system loses tolerance to self-antigens and mounts a response 
against the host. This is particularly devastating if B cells are affected. If B cells specific for host 
antigens are selected to survive and subsequently differentiate in the periphery, they can generate a 
targeted antibody response against the host. Under normal conditions, the immune system prevents 
the onset of autoimmunity through B cell survival decisions, where B cells are either selected to 
survive or are eliminated by apoptosis, based on the affinity status of their BCR during 
development in the bone marrow and in the periphery191,192. Given the incredible diversity of B cell 
clones produced through gene arrangement in the bone marrow, it is inevitable that B cells specific 
for host pathogens are also generated. The majority of these host specific B cells are normally 
eliminated and the few that enter the periphery are unlikely to encounter antigen and are 
unresponsive to antigen. Unfortunately though, auto-reactive B cells can escape elimination and 
can, consequently, cause autoimmune disease that can greatly vary in onset and severity.  
 
1.7.1. CCR6 and Autoimmunity  
It is interesting to consider the role of CCR6 in a dysregulated model of humoral immunity, given 
its role in mediating systemic lymphocyte migration and the excessive production of auto-reactive 
lymphocytes that occurs in autoimmune disease. In fact, CCR6 has been implicated in the 
pathogenesis of multiple autoimmune diseases, including Rheumatoid Arthritis (RA), Multiple 
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Sclerosis (MS) and of particular interest to this thesis, Systemic Lupus Erythematosus (SLE). 
Several studies have demonstrated associations between the expression of CCR6 at the gene, 
mRNA and surface level, with several autoimmune diseases. A comprehensive list of these 
associations has been compiled and is displayed in Table 1.7.1.1. This evidence provides 
unquestionable support that CCR6 contributes to the efficient generation of humoral immune 
responses.  
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Table 1.7.1.1. CCR6 autoimmune disease associations 
 
Disease Characteristics Model  Effect 
Ankylosing 
Spondylitis (AS) 
Inflammation 
of axial 
skeleton and 
sacroiliac joints 
Human Increased frequency of CCR6+ Th cells in blood during AS193 
Autoimmune 
Hepatitis (AIH) 
Liver damage Mouse  Dysregulated CCR6 dependent migration of splenic T cells to 
CCL20+ liver induces AIH194 
Discoid Lupus 
Erythematosus 
(DLE) 
Skin damage  Human CCR6+ dendritic cells identified in skin lesions of DLE patients and 
correlated with disease activity195 
Granulomatosis 
with Polyangitis 
(GPA) 
Inflammation 
of respiratory 
tract and 
vasculitis  
 Increased frequency of CCR6+ memory T cells196 
Multiple Sclerosis 
(MS)/ 
Experimental 
Autoimmune 
Encephalomyelitis 
(EAE) 
Central nervous 
system (CNS) 
inflammation 
Mouse  
 
 
CCR6+ cells including CD4+ T cells and dendritic cells, infiltrate the 
CNS, contributing to EAE severity197-201 
CCR6 and CCL20 expression increased in CNS during EAE202,203 
Increased CCL20 mRNA expression in CNS and lymph nodes 
correlates with EAE onset and severity204 
CCL20 expressed by astrocytes in the CNS during EAE and acts to 
recruit T cells205 
Sjögren’s 
Syndrome (SS) 
Inflammation 
of lacrimal and 
salivary glands 
Human Unchanged expression of CCR6 on B cells in SS206 
Increased frequency of circulating CCR6+ Th17 cells in SS207 
Psoriasis Chronic skin 
disease 
Human CCR6, CCL20 and β-defensin-2 expression increased in skin lesions 
during Psoriasis208,209 
Increased frequency of CCR6+ T cells in skin lesions compared to 
blood during Psoriasis210 
CCL20 expressed by keratinocytes and PBMCs209 
Memory T cells have increased CCR6 expression209 
Rheumatoid 
Arthritis (RA) 
Joint 
inflammation 
Human 
  
CCR6 gene polymorphisms, rs3093024, rs3093023, rs59466457, 
rs1571878, associated with RA susceptibility211-214 
CCR6+ mononuclear cells, including B cells and Th17 cells, are 
recruited to CCL20+ joints during RA215-218 
CCR6 and CCL20 expressed in bone tissue of RA patients219 
Increased CCR6 and CCL20 mRNA in RA synovial tissue220 
Reduced frequency of CCR6+ B cells in RA221 
Increased frequency of CCR6+ memory B cells in blood during RA220 
Unchanged CCR6 expression on CD3+ T cells during RA222 
Systemic Lupus 
Erythematosus 
(SLE) 
Systemic 
disease  
 
Human 
 
 
Positive correlation between CCR6 mRNA in PBMCs and SLE 
severity223 
Increased frequency of TFH cells and memory T cells correlates with 
SLE severity224,225 
Reduced CCR6 expression on circulatory T cells in SLE226 
No alteration in frequency of CCR6+ B cells and Th17 cells in 
SLE221,224 
Systemic Sclerosis 
(SSc) 
Systemic 
disease 
Human  CCR6 dinucleotide polymorphisms, rs3093023 & rs10946216, 
associated with SSc susceptibility227 
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1.7.2. CCR6 and SLE 
SLE is a complex autoimmune disease that affects multiple organs and is difficult to diagnose and 
subsequently treat due to its various clinical and immunological manifestations228. Symptoms can 
range from cutaneous rashes, hair weakness and ulcers, to joint synovitis or tenderness, haemolytic 
anaemia, as well as renal and neurological problems228. Immunologically, it can be characterised by 
leukopenia, auto-antibody production against nuclear proteins, DNA and phospholipids, and a 
reduction in complement proteins228. The auto-antibodies generated can form immune complexes 
that are then deposited in organs throughout the body, causing widespread inflammation and tissue 
damage229-231. SLE is also associated with a reduction in lymphocyte activity and impaired 
lymphocyte migration232,233. It is currently unknown as to how these immune defects arise. Whilst a 
number of cellular factors are known to contribute to the development of SLE, it appears that B 
cells play an essential role. The murine MRLlpr model displays an SLE-like disease characterised by 
increased antibody production, auto-reactive antibody production and inflammation. In this mouse 
model, B cells cause dysregulation in antigen presentation, lymphocyte interactions, proliferation, 
differentiation and antibody production234-238. Furthermore, studies in SLE patients have shown that 
B cells are in a hyperactive state, inducing higher calcium responses following activation and 
thereby contributing to disease pathogenesis239. In addition, reductions in the frequency of 
circulatory B cells have also been documented in SLE240, whereas increased populations of GC and 
memory B cells have been reported in the secondary lymphoid organs of SLE participants241. 
Collectively, it is clear that the B cell compartment is substantially altered during SLE. Although 
the precise mechanism underlying disease development is unknown, it has been proposed that the 
defective selection of auto-reactive B cells into the GC response, likely due to a breakdown in B 
cell tolerance during early development, is responsible for the abnormal B cell repertoire observed 
in SLE242-244. Currently, SLE therapies used to treat disease are targeted towards inhibiting the 
signalling, proliferation and differentiation of B cells, and T-B cell interactions245.  
 
Along with the alterations in the B cell compartment described above, SLE has also been associated 
with an altered chemokine receptor profile. Recently, there has been great interest in defining the 
contribution of chemokine receptors to disease, due to their pivotal role in lymphocyte organisation; 
however, few studies have examined CCR6 expression in SLE and most of these studies have 
examined CCR6 expression on T cells224,246-249. Studies examining the expression of CCR6 on B 
cells during SLE are beginning to emerge. In particular, one study has analysed several chemokine 
receptors, including CCR6, on B cell subsets in peripheral blood samples of SLE participants. 
Despite the limited number of participants, the study showed a trend of reducing CCR6+ B cell 
frequency in participants diagnosed with SLE, compared to controls221. Furthermore, a significantly 
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higher level of CCR6 mRNA has been detected in peripheral blood mononuclear cells (PBMCs) of 
SLE participants compared to controls and this correlated with disease progression223. In addition, a 
significant reduction in CXCR5+ plasma and memory B cells, as well as CXCR4+ naïve and 
memory B cells was also observed in SLE participants compared to controls221. This data indicates 
that CCR6 may contribute to the hyperactive B cell phenotype observed in SLE. Thus, further work 
is necessary to clearly elucidate whether CCR6 expression is associated with SLE and would 
indicate if chemokine receptors, including CCR6, can be used as biological markers of disease or 
therapeutic targets.   
 
1.8. Scope of Study  
Recently, interest in defining chemokine receptor mediated positioning of lymphocytes during the 
humoral response has intensified. Whilst the major chemokine receptors essential for the migration 
of B cells within the spleen have been identified, it is expected that other chemokine receptors 
contribute to this process. Such information is necessary to enhance our understanding of the 
initiation and progression of efficient humoral immune responses, and can be applied to 
vaccinations and immune system disorders. It is also important as it may lead to the development of 
diagnostic tools and pharmaceuticals to treat disease. Therefore, there is a need to fully comprehend 
the chemokine receptor driven cellular organisation of the humoral immune system. 
 
CCR6 is a strong candidate for B cell localisation in the humoral response for several reasons. First, 
the expression of CCR6 on B cells is modulated during their differentiation in response to TD 
antigens: CCR6 is expressed at moderate levels on naïve B cells, low levels on GC and plasma B 
cells, and high levels on memory B cells. Such a specific expression profile is consistent with the 
idea that CCR6 has a role in GC and EF B cell fate decisions. In addition, the altered GC formation 
and antibody generation detected in CCR6 deficient mice, suggests a substantial role for CCR6 in 
the efficient generation of humoral immune responses. Thus, the research to date indicates that 
CCR6 contributes to efficient B cell differentiation and antibody production. Consequently, I 
hypothesised that the expression of CCR6 on B cells is necessary for the efficient generation of TD 
humoral responses, specifically B cell fate decisions. To investigate this hypothesis, I aimed to: 
 
1) Define the expression of CCR6 during B cell activation 
2) Characterise the TD humoral immune response in the absence of CCR6 
3) Identify the potential molecular mechanisms that underlie B cell dysregulation in the absence 
of CCR6 and finally 
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4) Examine the relevance of CCR6 in the B cell-mediated autoimmune disease, Systemic Lupus 
Erythematosus 
 
To accomplish this, I have used a combination of gene deficient mouse models and clinical samples 
to examine the properties governing B cell differentiation during TD humoral responses. These 
protocols are described in the following chapter. In Chapter 3, I quantify CCR6 expression during 
TD B cell activation. In the next chapter, the effect of the distinct CCR6 expression profile is 
examined on B cell differentiation. Here, I demonstrate that CCR6 is required for efficient B cell 
differentiation in the early stages of humoral immunity. In Chapter 5, I investigate the potential 
cellular and molecular mechanisms that underlie CCR6 regulation of B cell differentiation. In 
Chapter 6, I examine whether there is an association between CCR6 expression on B cells and 
systemic autoimmune disease. The results arising from this work will demonstrate that CCR6 
contributes to efficient B cell differentiation in the TD humoral response, and this novel finding is 
critically discussed in the closing chapter. Overall, this is the first study to characterise the role of 
CCR6 in B cell differentiation, providing a compelling explanation as to how changes in CCR6 
expression may regulate B cell differentiation in the humoral response and ultimately, it provides 
great insight into the development of efficient humoral responses.  
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2.1. Animals 
Mice were purchased from The Jackson Laboratory (U.S.A.) and either transferred from James 
Cook University, Queensland (Australia) or imported directly to the University of Tasmania 
Cambridge Farm Facility. Mice were bred at this location before being transferred to our specific 
pathogen-free facility at the Menzies Institute for Medical Research, at the University of Tasmania. 
The MD4 x CCR6-eGFP mice were bred at University of Tasmania Cambridge Farm Facility. A 
complete list of animals used is provided in Table 2.1.1. Mice were used for the experiments 
described in this chapter, at 6–8 weeks of age, unless otherwise stated. All animal procedures were 
approved by the Animal Ethics Committee of the University of Tasmania (Ethics Number: A11694 
& A11626), in accordance with the Australian Code of Practice and Guidelines, set out by the 
National Health and Medical Research Council. 
 
Table 2.1.1: Strains of Mus musculus used 
 
Strain Common 
Name 
JAX® 
Stock Number 
Description 
C57BL/6J WT 000664 Wild-type 
B6.SJL-Ptprca Pepcb/BoyJ Ly5.1 002014 C57BL/6 congenic strain variant 
B6.PL-Thy1a/CyJ Thy1.1 000406 C57BL/6 congenic strain variant 
B6.129P2-Ccr6tm1Dgen/J CCR6-/- 005793 Targeted knock-out 
B6.129S6-Ccr6tm1(EGFP)Irw/J CCR6-eGFP 013061 Targeted eGFP knock-in that abolishes 
CCR6 function  
C57BL/6-Tg(IghelMD4)4Ccg/J MD4 002595 BCR (predominantly IgM & IgD) specific 
for HEL (transgene) 
B6.Cg-Tg(TcraTcrb)425Cbn/J OT-II 004194 CD4 TCR α- & β-chain is specific for 
OVA (transgene) 
B6(Cg)-Rag2tm1.1Cgn/J Rag 008449 Targeted knock-out that arrests B & T cell 
development in pro-stages 
B6.129P2(C)-Ccr7tm1Rfor/J CCR7-/- 006621 Targeted knock-out 
B6.129S2(Cg)-Cxcr5tm1Lipp/J CXCR5-/- 006659 Targeted knock-out 
B6Smn.C3-Faslgld/J gld 001021 Fas-ligand point mutation causing 
generalized lymphoproliferative disease 
(gld) 
C57BL/6-Tg(IghelMD4)4Ccg/J x  
B6.129S6-Ccr6tm1(EGFP)Irw/J 
MD4.CCR6-
eGFP 
- HEL-specific BCR & targeted eGFP 
knock-in that abolishes CCR6 function 
 
2.2. Participants  
All participants were recruited from Tasmania. A total of 14 participants diagnosed with SLE were 
recruited, including 7 from Launceston and 7 from Hobart. In addition, 20 healthy volunteers were 
recruited, including 5 from Hobart and 15 from Launceston. The inclusion criteria was a diagnosis, 
or not, of SLE and an age between 18–80 years. The details of each cohort are provided in Table 
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2.2.1. All participants provided informed and voluntary written consent prior to being included in 
this study. This study was approved by the Human Ethics Committee of the University of Tasmania 
(Ethics Number: H001067). Participants provided one blood sample of 9–18 mL for flow cytometry 
analysis.  
 
Table 2.2.1: Characteristics of Participants 
 
 Participants (n) Female/Male Ratio Age (yrs) 
Mean±SD 
Age at Diagnosis 
(yrs) 
Mean±SD 
Control 20 12/8 45.25 ± 15.17 - 
SLE 14 13/1 54.71 ± 15.62 40 ± 15.89 
Total 33    
 
 
 
2.3. Standard Solutions 
A list of frequently used solutions is provided in Table. 2.3.1. 
 
 
Table 2.3.1: Frequently used Solutions 
 
Solutions Components 
10 x Phosphate 
Buffered Saline 
(PBS) 
80 g NaCl (Sigma-Aldrich®, S5886) 
14.4 g Na2HPO4H20 (Sigma-Aldrich®, S5136) 
2.4 g KH2PO4 (Sigma-Aldrich®, P0662) 
2 g KCl (Sigma-Aldrich®, P9541) 
H20 to 1 L (pH 7.4 on dilution) 
FACS Buffer 100 mL 10 x PBS 
1 g Bovine Serum Albumin (BSA)  
2 mL 10 % Sodium Azide (Sigma-Aldrich®, S2002) 
H20 to 1 L 
Red Blood Cell 
(RBC) Lysis Buffer 
4.55 g NH4Cl (Sigma-Aldrich®: A0171) 
10 mL 1 M HEPES (Sigma-Aldrich®, H3375) 
H20 to 500 mL  
MACS Buffer 150 mL 10 x PBS  
7.5 g BSA 
3 mL 10 % Sodium Azide 
6 mL 0.5 M Ethylenediaminetetraacetic acid (EDTA) pH 8  
H20 to 1.5 L 
10 x Tris-Borate-
EDTA (TBE) 
108 g Tris (hydroxymethyl)aminomethane (Sigma-Aldrich®, T87602) 
55 g Boric Acid (Sigma-Aldrich®, B6768) 
40 mL 0.5 M EDTA pH 8 
H20 to 1 L 
Carbonate Buffer 4.2 g NaHCO3 (Sigma-Aldrich®, S6014) 
1.78 g Na2CO3 (Sigma-Aldrich®, 223484) 
H20 to 500 mL (pH 9.5) 
Conjugation Buffer 0.35 M Mannitol (Sigma-Aldrich®, M4125) 
0.1 M NaCl 
H20 to 500 mL 
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2.4. Antigens and Immunisations 
Several antigens were used to induce a humoral immune response in mice. The hapten, 4-hydroxy-
3-nitrophenyl acetyl (NP), coupled to the protein carrier, KLH, at a conjugation ratio of 23–27 
(Biosearch Technologies, N-5060-25) was prepared by precipitation with 10 % alum (Sigma-
Aldrich®, 237086-100G) and Dulbecco's Modified Eagle's medium (DMEM) (Life Technologies™, 
11960-044) containing 1 M HEPES (Sigma-Aldrich®, H3375-100G), at a ratio of 1:2:1 (v/v/v). The 
pH was adjusted to 6–7 and the antigen was washed 4 times in sterile 1 x Phosphate Buffered Saline 
(PBS) for 10 minutes at 4 °C and 1500 rpm, using the Allegra® X15R centrifuge (Beckman 
Coulter, U.S.A.). Mice were then intraperitoneally (i.p.) immunised with 50–100 µg of alum 
precipitated NP-KLH in sterile 1 x PBS.  
 
Alternatively, mice received 108 sheep red blood cells (SRBCs) (IMVS, SHBA0100) via i.p. 
immunisation or 108 hen egg lysozyme (HEL) (Sigma-Aldrich®, A5503) conjugated SRBCs 
subcutaneously (s.c.) in the thigh. For the preparation of HEL-SBRCs, 5 mL of SRBCs was washed 
with sterile 1 x PBS and resuspended in conjugation buffer with 250 µg of HEL. It was then 
incubated on ice, on a laboratory rocker for 10 minutes. Next, 50 mg of 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDCI) (Sigma-Aldrich®, E7750) was added and the antigen 
was incubated for a further 30  minutes. The antigen was then washed in sterile 1 x PBS until cell 
lysis had stopped and finally, resuspended in sterile 1 x PBS for immunisations.  
 
2.5. Flow Cytometry and Cell Sorting 
Mouse cell suspensions were prepared by isolating and homogenising the spleen or inguinal lymph 
nodes in FACS Buffer. Cells were collected after centrifuging at 1500 rpm for 5 minutes at 4  °C. 
The red blood cells (RBCs) were removed by resuspending the samples in 10 mL of RBC Lysis 
Buffer and incubating at 37 °C for 10 minutes. Lysed samples were then washed in FACS Buffer. 
For the analysis of murine PBMC, blood was collected into tubes containing 50 µL of the anti-
coagulant, ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich®, FDS) and the lymphocytes 
were subsequently isolated using Histopaque 1083 (Sigma-Aldrich®, 10831), as per the 
manufacturer’s instructions. 
 
To detect specific cell subsets, 1.5 x 106 cells were stained with 50 µL of antibodies for 25 minutes 
on ice. Antibodies used to detect B cells, chemokine receptors and T cells are detailed in Tables 
2.5.1, 2.5.2, and 2.5.3 respectively. The secondary antibodies used are listed in Table 2.5.4. For 
CCR6 DyLight™ 488, purified CCR6 (R&D) was labeled using the DyLight™ 488 Microscale 
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antibody labeling kit (THERMO Scientific™, 53025). To detect extrafollicular B cells, HEL 
(Sigma-Aldrich®, A5503) was labeled with DyLight™ 650 using the DyLight™ 650 Microscale 
antibody labeling kit (THERMO Scientific™, 84536). Samples were washed in 2 mL of FACS 
Buffer as per the centrifuge settings above. Where purified antibodies were used, samples were 
blocked with 10 % rat serum (Sigma-Aldrich®, R9759) prior to the addition of directly labeled 
antibodies, to prevent non-specific background. For intracellular staining, the Forkhead box P3 
(FOXP3) Fix/Perm Buffer Set was used as per the manufacturer’s instructions (BioLegend®, 
421403).  
 
Table 2.5.1: Antibodies used to detect murine B cells  
 
Antibody Working 
Dilution 
Clone Manufacturer Catalogue 
Number 
B220 (CD45R) APC Cy™7 1/200 RA3-6B2 BD 552094 
CD38 PerCP-eFluor® 710 1/200 90 eBioscience 46-0381-82 
GL7 eFluor® 450 1/100 GL-7 eBioscience 48-5902-82 
CD95 PE-Cy™7 1/200 Jo2 BD 557653 
IgMb FITC 1/200 AF6-78 BD 553520 
CD73 PE-Cy™7 1/400 TY/11.8 eBioscience 25-0731 
IgD APC 1/200 11-26 eBioscience 17-5993 
CD138 PE 1/200 281-2 BD 553714 
CD21/35 FITC 1/200 7G6 BD 553818 
CD23 Biotin 1/200 B3B4 BD 553137 
Ig λ Biotin 1/200 R11-153 BD 553431 
Purified Ig λ1, λ2, λ3 light chain 1/200 R26-46 BD 553432 
 
 
Table 2.5.2: Antibodies used to detect chemokine receptors in murine samples  
 
Antibody Working 
Dilution 
Clone Manufacturer Catalogue 
Number 
CCR6 PE 1/100 29-247 BioLegend® 129-804 
Purified CCR6 1/1000 140706 R&D MAB590 
Purified CXCR5 1/100 2G8 BD 551961 
Purified CXCR4 1/200 2B11 BD 551852 
CCR7 supernatant 1/2 4B12.2 - - 
 
 
Table 2.5.3: Antibodies used to detect murine T cells  
 
Antibody Working 
Dilution 
Clone Manufacturer Catalogue 
Number 
PD-1 PE 1/100 J43 eBioscience 12-9985-81 
TCRαβ PB 1/200 H57-597 Life Technologies™ HM3628 
CD4 PerCP-Cy™5.5 1/400 RM4-5 BD 550954 
CD8a APC-Cy™7 1/200 53-6.7 BD 557654 
CD44 PeCy™7 1/400 IM7 BioLegend® 103029 
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Table 2.5.4: Secondary antibodies used for flow cytometry in murine samples 
  
Antibody Working 
Dilution 
Clone Manufacturer Catalogue 
Number 
Streptavidin V500 1/200 - BD 561419 
Donkey α-Rat IgG Alexa Fluor® 647 1/200 - Jackson 
ImmunoResearch 
Laboratories, Inc. 
712-606-153 
 
Goat α-Rat IgG Alexa Fluor® 488 1/200 - Life Technologies™ A-11006 
 
 
Human PBMCs were isolated from blood samples using Histopaque (Sigma-Aldrich®, 10771), as 
per the manufacturer’s instructions. Cells were stained with antibodies to detect B and T cells, as 
described in Tables 2.5.5 and 2.5.6.  
 
Table 2.5.5: Antibodies used to detect human B cells by flow cytometry 
 
 
Table 2.5.6: Antibodies used to detect human T cells by flow cytometry  
 
 
All samples were filtered through 48 µm nylon mesh (Sefar, 03-50/31) prior to being acquired on 
the CyAn™ ADP Flow Cytometer (Beckman Coulter, U.S.A.) and the MoFlo® Astrios™ cell sorter 
(Beckman Coulter, U.S.A.). Flow cytometry data was analysed with FlowJo version 9 (Tree Star 
Inc., U.S.A.) for Macintosh. Cell sorting was carried out by Ms. Jocelyn Darby. 
Antibodies Working 
Dilution 
Clone Manufacturer Catalogue 
Number 
CCR6 PE 1/40 11A9 BD 559562 
CD27 PE-CF594 1/40 M-T271 BD 562297 
CD19 Alexa Fluor® 488 1/100 HIB19 BD 557697 
CD38 APC 1/5 HIT2 BD 555462 
IgD BV421 1/100 IA6-2 BD 562518 
CD95 PE-Cy™7 1/20 DX2 BD 561633 
Antibodies Working 
Dilution 
Clone Manufacturer Catalogue 
Number 
CCR7 PE-CF594 1/20 150503 BD 562381 
CXCR5 BV421 1/20 RF8B2 BD 562747 
PD-1 Alexa Fluor® 647 1/20 EH12.1 BD 560838 
CD4 PerCP-Cy™5.5 1/10 L200 BD 552838 
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2.6. Immunofluorescence 
Secondary lymphoid organs from mice, including the spleen, were frozen in Tissue-Tek® O.C.T. 
(ProSciTech, IA018) using liquid nitrogen vapour. The Leica CM1850 cryostat (Leica Biosystems, 
Germany) was used to prepare 10 µm cross-sections which were fixed to Flex IHC microscope 
slides (Dako, K8020) with Acetone (Sigma-Aldrich®, 270725) for 10 minutes at -20 °C. A PAP pen 
(Sigma-Aldrich®, Z672548) was used to create a hydrophobic barrier around sections and the slides 
were allowed to air-dry prior to being blocked with 1 x PBS and 1 % Bovine Serum Albumin 
(BSA) for 15 minutes at 4 °C. Slides were placed in a humidifying chamber and stained for 25 
minutes at room temperature with 100 µL of antibodies. The primary and secondary antibodies used 
for immunofluorescence are listed in Tables 2.6.1 and 2.6.2 respectively. Sections were washed 
thoroughly in 1 x PBS and 0.1 % BSA in-between stains. Coverslips (Dako, C5704) were fixed to 
slides using polyvinyl alcohol mounting medium with DABCO® (Sigma-Aldrich®, 10981). To 
quantify GC follicles, stained sections were visualised with the Leica DM LB2 Microscope (Leica 
Biosystems, Germany) using the 5 x air objective. All other images were acquired with the LSM 
510 Meta Confocal Microscope (Carl Zeiss, Germany) using the Plan-Apochromat 20 x NA 0.75 
air objective. Images were processed using ImageJ version 1.45s (ImageJ, U.S.A.).  
 
Table 2.6.1: Primary antibodies used for immunofluorescence  
 
Antibodies Application Working 
Dilution 
Clone Manufacturer Catalogue 
Number 
PNA Biotin IH 1/300 - Vector Laboratories B-1075 
B220 Biotin IH 1/300 RA3-6B2 BioLegend® 103204 
CD4 purified IH 1/200 RM4-5 BD 553043 
B220 purified IH 1/300 RA3-6B2 BD 553084 
 
 
Table 2.6.2: Secondary antibodies used for immunofluorescence  
 
Antibodies Application Working 
Dilution 
Clone Manufacturer Catalogue 
Number 
Streptavidin Alexa Fluor® 
594 
IH 1/300 - Life Technologies™ S-11227 
Goat α-Rat IgG Alexa 
Fluor® 633 
IH 1/300 - Life Technologies™ A-21094 
Goat α-Rat IgG Alexa 
Fluor® 488 
IH 1/300 - Life Technologies™ A-11006 
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For the examination of T-B cell conjugates, splenocytes were first labelled with flow cytometry 
antibodies and then fixed for 30 minutes in 0.2 % (v/v) Paraformaldehyde (Sigma-Aldrich®, 
158127). Forward scatter parameters were used to isolate T-B cell conjugates using the MoFlo® 
Astrios™ cell sorter. Sorted conjugates were then air-dried onto Flex IHC microscope slides for 
visualisation with the confocal microscope.  
 
2.7. Magnetic Cell Separation  
Anti-CD43 (Ly-48) MACS® MicroBeads (Miltenyi Biotec, 130-049-801) were used to purify B 
cells from splenocytes by depletion, with the aid of the AutoMACS Pro Separator (Miltenyi Biotec, 
Germany) as per the manufacturer’s instructions. B cells were subsequently used for adoptive 
transfer, tissue culture or quantitative (q) RT-PCR. 
 
2.8. Tissue culture 
B cells were cultured at 106 cells/well in 200 µL of Gibco® RPMI-1640 medium (Life 
Technologies™, 21870-092) supplemented with 5 mL of Gibco® 
Penicillin/Streptomycin/Glutamine (Life Technologies™, 10378-016) and 10 % (v/v) Gibco® fetal 
calf serum (FCS) (Life Technologies™, 10099141), at 37 °C and 5 % CO2. To examine CCR6 
expression, B cells were stimulated with 5 µg/ mL of HEL for 24 hours and analysed by flow 
cytometry at 2, 4, 8, 12 and 24 hours after the addition of HEL.  
 
2.9. Adoptive Transfers  
For mixed adoptive transfers, 107 naïve B cells from either CCR6-/- or WT mice were transferred 
into recipient Rag mice, along with either naïve WT or CCR6-/- splenocytes containing an 
equivalent number of B cells, as approximated by flow cytometry. The donor cells were allowed to 
settle for 3 days before the recipient mice were challenged with NP-KLH. The response was 
subsequently analysed 5 days later by flow cytometry and immunofluorescence.   	  	  
2.10. Quantitative Real-Time Polymerase Chain Reaction  
For samples containing 1000 cells, RNA was extracted using an in-house lysis buffer containing 
1 µL of 10 % (v/v) Igepal® (Sigma-Aldrich®, 1000862047), 2 µL of Oligo-dT (GeneWorks), 
CHAPTER 2 
MATERIALS AND METHODS 
 
 
J. BANNAN 
THE ROLE OF CCR6 IN B CELL DIFFERENTIATION DURING THE HUMORAL IMMUNE RESPONSE 
 
42 
0.4 µL of 0.1 M dithiothreitol (DTT) (Invitrogen, Y00147), 1 µL of rRNASEOUT™ (Invitrogen, 
100000840), 2 µL of 1 x PBS and Gibco® UltraPure™ distilled H20 (Life Technologies™, 10977-
015) to 11 uL. Alternatively, RNA was extracted from samples containing 1000 cells using the 
iScript™ RT-qPCR Sample Preparation Reagent (BIO-RAD, 170-8898), as specified.  
 
For samples containing 106 cells, pellets were re-suspended in TRIzol® Reagent (Life 
Technologies™, 15596-018) and RNA was isolated according to the manufacturer’s instructions. 
Complimentary DNA (cDNA) was synthesised using the QuantiTect® Reverse Transcription Kit 
(Qiagen, 205313). The primers (GeneWorks) detailed in Table 2.10.1 were used to amplify 2 µL of 
cDNA via the SensiFAST™ SYBR No-ROX Kit (Bioline, 98005). Gene expression was analysed 
using the Rotor-Gene qRT-PCR cycler (Qiagen, Germany). Data was displayed as the difference in 
cycle threshold (CT) between the gene of interest and the reference gene, 18S ribosomal RNA 
(rRNA).   
 
 Table 2.10.1: Primers used for quantitative Real-time Polymerase Chain Reaction 
 	  
2.11. Preparation for Next Generation Sequencing  
RNA was extracted from samples containing 1000 cells using the iScript™ RT-qPCR Sample 
Preparation Reagent as per the manufacturer’s instructions. The RNA was subsequently precipitated 
by incubating on ice for 30 minutes in 0.3 M Sodium Acetate (Sigma-Aldrich®, S2889), 2 x (v/v) of 
 Sequence (5’-3’)  
Gene Forward Reverse Product 
(bp) 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 151 
Bcl-6 CTGCAATGGAGCATGTTGT CGGCTGTTCAGGAACTCTTC 106 
IL-21 TGAAAGCCTGTGGAAGTGCAAACC AGCAGATTCATCACAGGACACCCA 108 
CCR6 TGTCCTCACCCTACCGTTCTG TACAGGCCAGGAGCAT 131 
CXCR5 CGACATCAGACAGTGACCAGCC GTCCTGTAGGGGAATCTCCGTG 151 
AID TGCTACGTGGTGAAGAGGAG TCCCAGTCTGAGATGTAGCG 119 
EBI2 CAGCTTTACCCACTCGGATA AAGAAGCGGTCTATGCTCAA 148 
Id2 TCAGCCTGCATCACCAGAGA CTGCAAGGACAGGATGCTGATA 92 
IRF4 CTGAGTGGCTGTATGCCAGA ATCAGCAATGGGAAAGTTCG 194 
CCL20 ATAGGATCCACTCCTGGAGCTGAGAATGG ATAGGATCCTTACATCTTCTTGACTCTT
AGGCTGA 
328 
CCR6 CCTCACATTCTTAGGACTGGAGC GGCAATCAGAGCTCTCGGA 151 
CCR7 CCAGCAAGCAGCTCAACATT GCCGATGAAGGCATACAAGA 92 
Pax5 CAGACCACAGAGTATTCAGCCATG AGGGACTTCCAGAAAATTCACTCC 259 
Blimp-1 TCTGTTCAAGCCGAGGCATCC TCTTGGGAACTGTGTCATTAG 163 
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Absolute Ethanol (Sigma-Aldrich®, 459844) and 20 µg of Glycogen (Life Technologies™, 
AM9510). The precipitated RNA pellet was collected after centrifuging for 20 minutes, 4 °C at 
maximum speed and washed in 70 % ethanol for 3  minutes, 4 °C at maximum speed. The pellet 
was then air-dried before being resuspended in 20  µL of Gibco® UltraPure™ distilled H20. All 
precipitated RNA was used to synthesise cDNA, as previously described. Of this cDNA, 3 µL was 
used as the template to amplify the variable region of the Ig heavy chain in the J558 region by PCR.  
 
The PCR reaction consisted of 5 x Green GoTaq® Reaction Buffer (Promega, M7911), 25 mM 
MgCl2 (Promega, 83511), 10 mM deoxynucleotide triphosphates (dNTPs) (Bioline, BIO-39025), 
20 µM each of both the forward and reverse sequencing primers, GoTaq® hot start polymerase 
(Promega, M5005), and Gibco® Ultrapure H20 to 25 µL. The primers were provided by Professor 
Thomas Winkler’s laboratory. The forward primer, 5’- CGTATCGCCTCCCTCGCGCCATCAG- 
MID-GRGCCTGGGRCTTCAGTGAAG-3’ binds the variable Ig region, whilst the reverse 
primers, 5’-RCTCAGGGAARTARCCYTTGAC-3’ and 5’-GTGCTGGGCAGGAAGTCCCG-3’ 
bind the constant γ or µ region respectively. The various MID sequences located on the forward 
primer, used to identify distinct samples, are listed in Table 2.11.1. This protocol required 
optimisation and as such, alternate reverse primers were generated: IgM Rv 5’-
TATGCGCCTTGCCAGCCCGCTCAGGTGCTGGGCAGGAAGTCCCG-3’ and IgG Rv 5’-
CTATGCGCCTTGCCAGCCCGCTCAGRCTCAGGGAARTARCCYTTGAC-3’.  
 
The PCR was incubated in the Veriti thermal cycler (Applied Biosystems®, U.S.A.) under the 
following conditions: 95 °C for 5 minutes, 40 cycles of 95 °C for 30 seconds, 54 °C for 30 seconds 
and 72 °C for 1 minute, followed by 72 °C for 7 minutes and 4 °C for ∞. The samples were then 
analysed on a 1 % agarose (Bioline, BIO-41025) gel containing GelRed™ (Biotium, 41003), in 1 x 
Tris-Borate-EDTA (TBE) buffer. The DNA was extracted using the Wizard SV® Gel & PCR 
Clean-up System (Promega, A9282). The concentration of DNA was determined using the Qubit 
2.0 Fluorometer (Life Technologies™, U.S.A.). For analysis, 200 ng of DNA was precipitated as 
previously described and sent as a dried pellet to Dr. Andreas Hiergeist in Germany for 454 
sequencing using the GS Junior system (Roche: Switzerland). 
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Table 2.11.1: Next Generation MID Sequences 
 
 
 
 
 
 
 
 
2.12. Serum Isolation 
Blood was collected from the tail vein of mice. To isolate the serum, samples were incubated at 
37 °C for 30 minutes, followed by 30 minutes at 4 °c, and then centrifuged for 5 minutes at 1500 
rpm in the microcentrifuge (Thermo Scientific, U.S.A.). Serum was stored at -20 °C until it was 
analysed by enzyme-linked immunosorbent assay (ELISA).   
 
2.13. Enzyme-linked immunosorbent assay 
To detect NP-specific antibodies in mouse serum, 96 well round-bottom plates (Sarstedt, 82.1582) 
were coated with 5 µg/ mL NP-BSA with a conjugation ratio >20 (Fisher Biotec, N-5050H-10) in 
carbonate buffer overnight at 4 °C. The plate was then washed with 1 x PBS and 0.05 % Tween 
(Sigma-Aldrich®, P1379) and subsequently blocked in 1 x PBS and 1 % BSA (Sigma-Aldrich®, 
A7906) for 1 hour at 4 °C. Following washing, serum was diluted 1/1000 and incubated in the plate 
at ambient temperature for 2 hours. If necessary, samples were diluted further. Afterwards, the plate 
was washed and incubated with biotinylated IgM, IgG1b or IgG2ab for 1 hour. NP-specific 
antibodies were detected with streptavidin bound Horseradish Peroxidase (HRP), which was 
incubated for 30 minutes. Details of the antibodies used for the ELISA are shown in Table 2.13.1. 
TMB substrate (Sigma-Aldrich®, T0440) was used to develop the HRP. Once the standards had 
developed, 2N Sulfuric Acid (Sigma-Aldrich®, 320501) was added to stop the reaction. The plate 
was washed between antibody labeling steps and substrate addition. The light absorbance was 
measured at 450 nm on the Spectra Max Plus384 plate reader (Molecular Devices, U.S.A.). The 
MID Name Sequence (5’-3’) 
2 ACGCTCGACA 
3 AGACGCACTC 
4 AGCACTGTAG 
5 ATCAGACACG 
6 ATATCGCGAG 
7 CGTGTCTCTA 
8 CTCGCGTGTC 
9 TCTCTATGCG 
10 TGATACGTCT 
11 CATAGTAGTG 
14 TCACGTACTA 
15 CGTCTAGTAC 
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standard curve was generated by combining and subsequently diluting serum collected at Days 7 
and 21 post alum-precipitated NP-KLH immunised WT mice.  
 
Table 2.13.1: Antibodies used for Enzyme-linked Immunosorbent Assay 
Antibodies Application Working 
Dilution 
Clone Manufacturer Catalogue 
Number 
IgM Biotin ELISA 1/1000 R6-60.2 BD 553406 
IgG1b Biotin ELISA 1/2500 B68-2 BD 553533 
IgG2ab Biotin ELISA 1/5000 5.7 BD 553504 
Streptavidin HRP ELISA 1/1000 - BD 554066 
 
 
2.14. Statistical Analysis 
All data are expressed as the mean ± standard error of the mean (SEM). Data were analysed using 
GraphPad Prism 5.0a (GraphPad Software Inc., U.S.A.). Comparisons between two groups were 
performed using the non-parametric Mann-Whitney two-tail t-test. Comparisons between 3 or more 
groups were performed using the Kruskal-Wallis One-way analysis of variance (ANOVA). A p-
value of ≤ 0.05 was considered significant.  
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The overall purpose of this thesis was to investigate the function of CCR6 in the humoral immune 
response. The first part of this work involved determining whether CCR6 is expressed during B cell 
activation. Previous reports have demonstrated a unique expression profile for CCR6 during B cell 
differentiation. Specifically, it is known that CCR6 is expressed on naïve B cells, downregulated on 
GC and plasma cells, and upregulated on memory B cells190. The fact that CCR6 is expressed by 
naïve and effector B cells suggests that CCR6 expression is altered during B cell activation. 
However, this has yet to be investigated. Previous unpublished observations from the Körner 
laboratory have indicated that CCR6 is upregulated on B cells within 24 hours of stimulation in 
vitro, in response to both B cell specific (HEL) and generic (anti-CD40) stimuli (Fromm and 
Körner, unpublished results). Furthermore, chemotaxis assays from the same laboratory indicate 
that B cells activated with the Toll-like receptor ligand, LPS, display enhanced migration towards 
CCL20, when compared to naïve B cells (Fromm and Körner, unpublished results). However, the 
precise expression of CCR6 on B cells after antigen-specific activation remains to be established. 
Therefore, I set out to determine the cellular expression of CCR6 during TD B cell activation.   
 
3.1. CCR6 expression is upregulated upon T cell-dependent B cell activation in 
vitro 
To quantify CCR6 expression on the surface of B cells, an appropriate antibody that specifically 
detected CCR6 by flow cytometry had to be selected. Three antibodies were tested: monoclonal 
CCR6 (R&D) purified from hybridoma supernatant and detected with anti-rat Alexa Fluor® 647 
(Jackson), purified CCR6 (R&D) conjugated to DyLight 488 and CCR6 PE (BD). These antibodies 
were used to examine CCR6 expression on splenic B cells from WT and CCR6-/- mice challenged 
for 5 days with NP-KLH –  a standard immunogen used to study TD humoral immunity. CCR6 PE 
and purified CCR6 were found to be the most appropriate antibodies as they clearly distinguished 
CCR6 expression on WT B cells from CCR6-/- B cells (Fig. 3.1.1). CCR6 DyLight 488 provided a 
weak signal that could not be clearly separated from background (Fig. 3.1.1).   
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Figure 3.1.1. Optimisation of CCR6 detection on B cells 
WT (blue) and CCR6-/- (red) mice were i.p. immunised with 50µg of NP-KLH for 5 days. The mean fluorescence 
intensity of CCR6 expression was quantified by flow cytometry on splenic B220+ cells using purified CCR6 detected 
with anti-rat Alexa Fluor® 647, CCR6 conjugated to DyLight™ 488 and CCR6 PE (n=1).   
 
 
Following the identification of suitable antibodies to detect CCR6, I defined the kinetics of CCR6 
expression during TD B cell activation in vitro using flow cytometry. Naïve B cells were isolated 
from HEL-Ig transgenic MD4 mice using anti-CD43 MicroBeads and activated in vitro for 24 hours 
with the antigen HEL. Throughout this time, CCR6 expression was regularly examined on B cells, 
as was their expression of CD38 and GL7 – two cell surface markers used to identify differentiated 
B cell subsets23,24,28. Naïve B cells were CD38+ GL7lo CCR6+ (Fig. 3.1.2a). After 8 hours of 
activation, as demonstrated by the significant upregulation of CD69 on the surface of B cells, a 
significant increase in CCR6 expression was observed, which corresponded with significant 
increases in both CD38 and GL7 expression (Fig. 3.1.2a, b). In vivo, CD38+ GL7+ B cells define 
precursor B cells that directly arise after B cell activation and T cell help28,73. The results from this 
study suggest that B cells encounter antigen, upregulate CCR6 surface expression during activation 
and maintain this expression as CD38+ GL7+ precursor B cells.  
 
When CCR6 expression was examined at the mRNA level using qRT-PCR, the upregulation of 
CCR6 surface expression did not correspond with an increase in CCR6 mRNA. In fact, CCR6 
mRNA expression was significantly reduced 8 hours after activation (Fig. 3.1.2c). It should be 
noted that the primers used to quantify CCR6 mRNA expression were validated in WT and CCR6-/- 
mice. Also, the mRNA quantification of 18S and other chemokine receptors in the same samples, 
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provides an intrinsic control for the quality of the RNA. Thus, the most likely explanation for the 
discrepancy between surface and mRNA expression is that the upregulation of CCR6 mRNA is 
transient, while the increased surface expression of CCR6 8 hours after activation is the result of an 
accumulation of CCR6 on the surface over time. It is also possible that post-transcriptional and 
post-translational mechanisms contribute to this increased surface expression of CCR6. 
Furthermore, it has been shown that the downregulation of CCR6 from the cell surface depends on 
the presence of its ligand, CCL20189, which these B cells did not have access to in vitro.  
 
Subsequently, CCR6 mRNA expression was quantified at an earlier time point in an attempt to 
capture this transient response. However, CCR6 mRNA expression remained low 2 hours after 
activation (Fig. 3.1.2c). Consequently, it is likely that CCR6 mRNA expression peaks quickly after 
activation and begins to decline soon thereafter, prior to 2 hours after activation, and therefore is not 
captured by this experiment. Alternatively, it is possible that the increased CCR6 surface expression 
and reduced mRNA expression may occur simultaneously, facilitating both the current and 
imminent needs of the B cell.  
 
As the chemokine receptors, CXCR5, CCR7, CXCR4 and EBI2, are known to coordinate B cell 
positioning during the humoral response52,159,188, their expression was also analysed on MD4 B cells 
during activation in vitro. As expected, activated B cells upregulated CXCR5, CXCR4 and CCR7 
expression on the cell surface (Fig. 3.1.2a, b). In contrast to surface expression though, CXCR5 
mRNA was significantly decreased in activated B cells at both 2 and 8 hours after activation (Fig. 
3.1.2c). CXCR4 mRNA expression was significantly upregulated 2 hours after activation, before a 
strong reduction was observed 6 hours later (Fig. 3.1.2c). Interestingly, the upregulation of CCR7 
surface expression correlated with a significant upregulation in CCR7 mRNA 8 hours after 
activation (Fig. 3.1.2c). This is different to the mRNA levels observed for CCR6, CXCR5 and 
CXCR4, and may be due to the fact that high sustained CCR7 expression is required by B cells 
immediately after activation in vivo, for interaction with Th cells52. While EBI2 surface expression 
could not be examined, EBI2 mRNA expression was, and a significant decrease in EBI2 mRNA 
was detected in MD4 B cells 8 hours after activation (Fig. 3.1.2c).  
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Figure 3.1.2. CCR6 expression during T cell-dependent B cell activation in vitro 
B cells were isolated from MD4 mice using anti-CD43 MicroBeads and stimulated in vitro for 8 hours with 5µg/mL of 
HEL. The B cell surface expression of CD69, CD38, GL7, CCR6, CXCR5, CXCR4 and CCR7 was monitored by flow 
cytometry. Representative images of surface protein expression on unstimulated and activated B cells are shown (a).  
The mean fluorescence intensities were quantified in unstimulated B cells and B cells cultured with HEL for 8 hours 
(activated) (b). The relative gene expression of CCR6, CXCR5, CXCR4, CCR7 and EBI2 was quantified by qRT-PCR 
in unstimulated and activated B cells at 2 and 8 hours following antigen challenge (c). Figure represents data collected 
from 2 independent experiments (n=8 mice).  
Mann – Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01; ***significant at p<0.001 
 
 
Next I examined B cell activation in the absence of CCR6. Unactivated MD4.CCR6-/- B cells had a 
significantly higher expression of CD69 compared to MD4 B cells. However, this did not appear to 
enhance their activation or differentiation into CD38+ GL7+ B cells, when compared to MD4 B cells 
(Fig. 3.1.3). In fact, MD4.CCR6-/- B cells tended to have significant reductions in CD38 expression 
compared to MD4 B cells following stimulation (Fig. 3.1.3). This was also true for GL7 expression, 
but was only significant 2 hours after activation (Fig. 3.1.3). In addition, significant reductions in 
CXCR5, CXCR4 and CCR7 surface expression were detected after activation in MD4.CCR6-/- B 
cells compared to MD4 B cells (Fig. 3.1.3), suggesting a possible connection between the 
CHAPTER 3 
CCR6 EXPRESSION ON ACTIVATED B CELLS DURING THE HUMORAL RESPONSE 
J. BANNAN 
THE ROLE OF CCR6 IN B CELL DIFFERENTIATION DURING THE HUMORAL IMMUNE RESPONSE  
51 
chemokine receptors. Overall, MD4.CCR6-/- B cells displayed similar trends to MD4 B cells, in that 
they too had increased expression levels of the chemokine receptors, as well as CD69, CD38 and 
GL7, after activation with HEL (Fig. 3.1.3). 
 
 
 
Fig. 3.1.3. In vitro T cell-dependent B cell activation in the absence of CCR6  
B cells were isolated from MD4 and MD4.CCR6-/- mice using anti-CD43 MicroBeads and cultured in vitro for 24 hours 
with 5ug/ml of HEL. Throughout this period, the mean fluorescent intensity of CD69, CD38, GL7, CXCR5, CXCR4, 
CCR7 and CCR6 expression, was quantified by flow cytometry. Figure represents data collected from 2 independent 
experiments (n=8 mice/genotype).  
Mann – Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01; ***significant at p<0.001 
 
 
3.2. CCR6 is expressed by T cell-dependent activated B cells in vivo 
To validate the finding that CCR6 is upregulated on activated B cells in vitro, CCR6 expression was 
analysed on B cell subsets in vivo. WT mice were immunised with NP-KLH and the splenic B cell 
population was examined seven days later by flow cytometry, at the peak of the humoral response. 
Rare antigen-specific responding B cells were easily identified from the remaining peripheral B cell 
population using anti-λ Ig antibodies, as NP specifically induces λ-IgL antibody production250,251. 
As mentioned previously, CD38 and GL7 expression identifies peripheral B cells. Specifically, five 
distinct subsets can be identified: CD38+ GL7- naïve B cells, CD38+ GL7+ precursor B cells, CD38- 
GL7+ GC B cells, CD38- GL7- plasma cells and CD38hi GL7- memory B cells23,24,28. The gating 
strategy used to identify these subsets is displayed in Fig. 3.2.1a. Briefly, lymphocytes and singlets 
were selected based on the forward and side scatter properties of the cells. Form here, λ+ B cells 
were selected and separated into the five B cell subsets based on their expression of CD38 and GL7. 
Using this strategy, CCR6 expression was quantified on each B cell subset, as shown in Fig. 3.2.1b. 
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This analysis revealed that naïve B cells expressed a moderate level of CCR6 (Fig. 3.2.1b, c). The 
GC B cells had a significantly lower expression of CCR6 compared to both naïve B cells and 
memory B cells (Fig. 3.2.1b, c). Plasma cells were also found to express low to moderate levels of 
CCR6 (Fig. 3.2.1b, c). This expression profile concurs with that previously documented in the 
literature185,186,190. Interestingly, CCR6 expression was significantly higher on precursor B cells than 
on GC and plasma cells (Fig. 3.2.1b, c). The high expression of CCR6 on precursor B cells, which 
arise after naïve B cells become activated, supports the previous in vitro finding that CCR6 is 
upregulated on activated B cells. 
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Figure 3.2.1. CCR6 is highly expressed by CD38+ GL7+ precursor B cells in vivo  
WT mice were i.p. immunised with 100µg of NP-KLH for 7 days. Responding B cells were identified by their 
expression of λ-Ig and delineated based on their expression of CD38 and GL7: 1) CD38- GL7- plasma cells, 2) CD38+ 
GL7- naïve B cells, 3) CD38hi GL7- memory B cells, 4) CD38+ GL7+ precursor B cells and 5) CD38- GL7+ GC B cells 
(a). Representative images of CCR6 expression on B cell subsets are displayed (b). The mean fluorescence intensity of 
CCR6 expression on each B cell subset was quantified by flow cytometry (c). Figure represents data collected from 2 
independent experiments (n=9 mice/genotype).  
Kruskal – Wallis one-way ANOVA, *significant at p<0.05; **significant at p<0.01; ***significant at 0.001 
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Having observed that CCR6 is expressed by CD38+ GL7+ precursor B cells in vivo, I next examined 
whether CCR6 is expressed by B cells during interactions with Th cells. To achieve this, a 
combination of cell sorting and immunofluorescence was used. To visualise CCR6 expression, a 
CCR6.eGFP knock-in mouse was used, which expresses GFP where CCR6 would normally be 
expressed. Mice were immunised for six days with SRBC, a potent inducer of TD humoral immune 
responses. T-B cell conjugates were then isolated using forward scatter properties, along with B220 
and CD4 expression. Despite the low frequency of conjugates present in vivo during a normal 
humoral response, it was possible to isolate intact conjugates after mild fixation using the MoFlo® 
Astrios™ cell sorter. Once sorted, conjugates were examined for GFP expression using the confocal 
microscope. GFP expression was observed on the B cell of T-B cell conjugates, as predicted, but 
also, surprisingly, on the T cell of T-B cell conjugates (Fig. 3.2.2). The fact that CCR6 is expressed 
by T-B cell conjugates suggests that CCR6 has a broader function than simply B cell activity. 
However, it is important to note that not all observed conjugates expressed GFP, indicating that 
CCR6 is not an absolute requirement for T-B cell conjugate formation and the subsequent 
differentiation of B cells. In further support of this, is the previous finding that CCR6-/- B cells are 
still capable of becoming activated and upregulating their expression of CD38 and GL7 in vitro.  
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Figure 3.2.2. CCR6 is expressed by T-B cell conjugates in vivo 
CCR6-eGFP mice were i.p. immunised with SRBC. T-B cell conjugates were isolated 6 days later using the MoFlo® 
Astrios™ cell sorter. Conjugates were selected using the forward scatter parameters, as well as B220 and CD4 
expression. Prior to sorting, samples were fixed in 2% formaldehyde for 30 minutes. Purified conjugates were air-dried 
onto slides and imaged using the confocal microscope (n=1). Images show 3 distinct T-B cell conjugates. 
Objective magnification: top panel 40x, bottom panel 20x; Scale bars are 10µm. 
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To investigate the formation of T-B cell conjugates in the absence of CCR6, WT and CCR6-/- mice 
were immunised with NP-KLH for 42 days and T-B cell conjugates were quantified by flow 
cytometry throughout this period. As before, T-B cell conjugates were identified using forward 
scatter parameters, B220 and CD4 expression (Fig. 3.2.3a). This analysis demonstrated that T-B 
cell conjugates are still formed in the CCR6-/- mice (Fig. 3.2.3a, b). In fact, at days 14 and 21 post 
antigen challenge, CCR6-/- mice had a significantly higher frequency of T-B conjugates than WT 
mice (Fig. 3.2.3b). However, for the remaining response, the CCR6-/- mice produced an equivalent 
number of T-B cell conjugates to WT mice (Fig. 3.2.3b). Overall, these results demonstrate that 
CCR6 is not essential for T-B cell conjugate formation, but may contribute to B cell differentiation 
in the early humoral response. 
 
 
 
 
 
Fig. 3.2.3. Quantification of T-B cell conjugates in vivo 
WT and CCR6-/- mice were i.p. immunised with 100ug of NP-KLH for 42 days. Flow cytometry was used to examine 
T-B cell conjugates, which were identified by their forward scatter parameters, as well as B220 and CD4 expression (a). 
The frequency of T-B cell conjugates was quantified at days 5, 7, 10, 14, 21 and 42 following challenge. Figure 
represents data collected from 1 experiment (n=4 mice/genotype).  
Mann – Whitney two-tail t-test, *significant at p<0.05 
 
 
3.3. Concluding Remarks 
In this chapter I have quantified CCR6 expression on activated B cells. Initially, an in vitro model 
was employed to directly investigate the phenotype of naïve B cells as they underwent activation. 
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This model established that CCR6 is upregulated on activated B cells. Further investigation in vivo 
demonstrated that CCR6 is highly expressed on precursor B cells, which arise from CCR6+ naïve B 
cells and appear prior to CCR6lo GC B cells. Moreover, CCR6 expression was detected on T-B cell 
conjugates. However, to directly demonstrate that CCR6 is upregulated in vivo, it will be necessary 
to isolate and transfer antigen-specific naïve B cells into recipient mice, which are then immunised 
with TD antigens. In this way, CCR6 expression can be analysed on activated cells derived from the 
naïve donor cells. While a similar experiment has already been carried out182, the authors 
transferred whole splenocytes and not naïve B cells directly, thus they did not exclude activated or 
differentiated B cell subsets already present in the donor population. In addition, regular 
examination of the B cell population is needed, so that the activated B cells can be identified as they 
appear in response to antigen challenge. This improved model would also be useful to visualise the 
localisation of B cells deficient in CCR6, as well as the migration of T-B cell conjugates. Such 
insights would be useful to assess the impact of CCR6 on B cell migration. Overall the data 
presented within this chapter demonstrates that CCR6 is upregulated on follicular B cells upon 
antigen activation continues to be expressed as B cells interact with Th cells and is maximal on 
precursor B cells, prior to their differentiation into GCs and EF. Taken together, this data suggests 
that CCR6 may aid B cell migration during their activation, while B cell fate decisions are made. 
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The next step in addressing the role of CCR6 in the humoral response was to characterise B cell 
differentiation in the absence of CCR6. As demonstrated in the previous chapter, activated B cells 
express high levels of CCR6, suggesting an important role for the chemokine receptor in the 
subsequent differentiation of B cells. It was therefore expected that if CCR6 is required for B cell 
differentiation, then B cell differentiation would be halted, or at least reduced in the absence of 
CCR6. To determine this, a TD humoral response was induced in CCR6-/- mice using NP-KLH. As 
noted earlier, NP-KLH induces a TD humoral response characterised by the production of λ-
specific B cells. In addition to this, the NP-KLH induced model of humoral immunity is a valuable 
study model, as the spatial and temporal organisation of B cells in this TD response have been 
defined53,77,252, and consequently provide an excellent framework for this study.  
 
4.1. CCR6 counterbalances excessive splenic Germinal Centre formation 
The development of GCs is considered the hallmark feature of the humoral response because of 
their prominent appearance and specialised antibody maturation capacity. Therefore, GCs are a 
good indicator of the functionality of the humoral response. As such, I began analysing splenic B 
cell differentiation by quantifying the GC response in both CCR6-/- and WT mice immunised with 
NP-KLH.  
 
Initially, the frequency of GC B cells was determined by flow cytometry. Antigen-specific GC B 
cells were identified by their expression of CD38 and GL7, as shown in Fig. 4.1.1a. WT GC B cells 
were detectable throughout the primary immune response, from days 3–42 post antigen challenge 
(Fig. 4.1.1a, b). The beginning of the GC response was detected at day 3 with approximately 0.3% 
of λ+ B cells, it peaked by day 7 with approximately 8% of λ+ B cells and gradually declined by day 
42 to approximately 1% of λ+ B cells. This GC B cell kinetic correlates with the TD GC response 
described previously53,77. However, substantial alterations were detected early in the GC response 
of CCR6-/- mice. A significantly higher frequency of GC B cells was observed in CCR6-/- mice at 
days 3 and 5 post antigen challenge, compared to WT mice (Fig. 4.1.1a, b). This increase was only 
short-lived, as there were similar quantities of GC B cells between CCR6-/- and WT mice for the 
remaining response, except at day 21, where the CCR6-/- mice appeared to have fewer GC B cells 
than WT mice (Fig. 4.1.1a, b). Furthermore, when all antigen-specific B cells were examined, the 
increased frequency of GC B cells detected in CCR6-/- mice at day 5, corresponded with a 
significant increase in the frequency of all antigen-specific B cells (Fig. 4.1.1c). In addition, the 
total antigen-specific B cell population was observed to increase at day 3 and decrease at day 21 in 
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the CCR6-/- mice compared to the WT mice, correlating with the increased frequency of GC B cells 
observed in the CCR6-/- mice (Fig. 4.1.1ac).  
 
 
 
 
Figure 4.1.1. The T cell-dependent Germinal kinetics in the absence of CCR6 
WT and CCR6-/- mice were i.p. immunised with 50–100µg of NP-KLH for 42 days. Representative images of the GC 
population (CD38- GL7+), indicated by the gate, are displaced (a). The frequencies of λ-specific GC B cells (b) and total 
λ-specific B cells (c) were quantified 3, 5, 7, 10, 14, 21 and 42 days after antigen challenge. Data is indicative of 1–2 
independent experiments (Day 3 n=8 WT mice, 6 CCR6-/- mice; Day 5 n=5 mice/genotype; Day 7, 21 & 42 n=9 
mice/genotype; Day 10 n=8 WT mice, 9 CCR6-/- mice; Day 14 n=4 mice/genotype).  
Mann-Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01 
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To determine whether the increased frequency of early GC B cells in the CCR6-/- mice results in an 
overall increase in the number of GC follicles established, splenic GC follicles were quantified 
during the humoral response using immunofluorescence. Two antibodies were used to identify GC 
follicles: B220 and PNA. PNA is a protein specifically expressed by GC B cells, such that GC 
follicles are identified by a bright PNA cluster encapsulated by a B220+ border91,253. Quantification 
of GC follicles revealed that the CCR6-/- mice had significantly more follicles at days 3 and 5 
following antigen challenge than WT mice (Fig. 4.1.2a). The CCR6-/- GC follicle response then 
peaked at day 7 and declined as per normal (Fig. 4.1.2a). During this time, the frequency of GC 
follicles between CCR6-/- and WT mice were similar. Representative images of the GC follicle 
response in the absence of CCR6 are displayed in Fig. 4.1.2b. Overall, the frequency of CCR6-/- GC 
B cells correlates with the number of CCR6-/- GC follicles formed, demonstrating that the increased 
population of GC B cells results in more GC B cells seeding follicles and consequently more GC 
follicles being established. The increased GC response observed at days 3 and 5 post antigen 
challenge in the CCR6-/- mice, suggests that the cause of dysregulation occurs early, during the 
initiation of the humoral response. As the GC response in CCR6-/- mice peaks at day 7 as per 
normal, it seems that more B cells are initially recruited into the GC B cell differentiation pathway. 
Furthermore, the CCR6-/- GC response is not reduced beyond the WT GC response after day 5, 
indicating firstly that there is not a constant supply of B cells differentiating into GC B cells and 
secondly, that the early GCs do not persist for an extended period of time. Consequently, CCR6 
appears necessary for initial B cell activation and selection in the humoral response.  
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Figure 4.1.2. The frequency of splenic Germinal Centre follicles during the T cell-
dependent humoral response in the absence of CCR6 
Spleen sections of WT and CCR6-/- mice immunised with 50–100µg of NP-KLH, were examined for GC follicles at 3, 
5, 7, 10, 14, 21 and 42 days following antigen challenge. GC follicles were identified as B220+ PNA+ clusters and 
quantified in 1 spleen cross-section/mouse (a). Representative images of the GC follicle response in WT and CCR6-/- 
mice are shown (b). Arrows indicate GC follicles. Data was collected from 1–2 independent experiments (Day 3 & 21 
n=4 WT mice, 3 CCR6-/- mice; Day 5, 14 & 42 n=4 WT mice, 4 CCR6-/- mice; Day 7 & 10 n=5 WT mice, 5 CCR6-/- 
mice).  
Mann-Whitney two-tail t-test, *significant at p<0.05 
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4.2. CCR6 regulates efficient effector B cell differentiation 
After establishing that the GC response was increased in CCR6-/- mice, the frequency of other B 
cell subsets including naïve, precursor, memory and plasma cells, were also examined in these 
mice. Again, CCR6-/- and WT mice were immunised with NP-KLH for 42 days and the λ-specific B 
cell subsets identified by CD38 and GL7 expression, were quantified by flow cytometry. The gating 
strategy employed to quantify these distinct B cell subsets is displayed in Fig. 4.2.1a. As the loss of 
CCR6 triggers GC expansion in the early stages of the humoral immune response, I examined 
whether this was due to an initial increase in activated B cells, and therefore a reduction in the naïve 
B cell population. Throughout the course of the humoral response, the naïve B cell population 
(CD38+ GL7-) generally appeared reduced in the CCR6-/- mice compared to the WT mice (Fig. 
4.2.1b). The frequency of naïve B cells was significantly reduced in CCR6-/- mice at days 3, 5 and 
14 post antigen challenge compared to WT mice (Fig. 4.2.1b). This result correlates with the 
increased GC response observed at days 3 and 5 in the CCR6-/- mice and implies that more B cells 
are being recruited into the humoral response in CCR6-/- mice than in WT mice. The increased 
population of activated B cells would potentially account for the increased GC response, however 
these B cells would also have to be selected to differentiate into GC B cells. Given the reduction in 
naïve B cells, it was hypothesised that the frequency of precursor B cells that have just been 
activated, would also increase. Interestingly, when the frequency of the precursor B cell population 
was examined, a similar quantity of precursor B cells (CD38+ GL7+) was detected between CCR6-/- 
and WT mice throughout the humoral response (Fig. 4.2.1c). Though their existence has only 
recently been described and their complete function remains to be established, this population does 
arise before GC formation, and is thought to be capable of differentiating directly into GC and EF B 
cells28,73. The precursor stage is quick and it is possible that no difference in the frequency of 
precursor cells is detected, as B cells are quickly entering and leaving this stage.  
 
After examining the B cell populations responsible for initiating the humoral response, which 
appear prior to GC B cells, I next investigated whether the absence of CCR6 affected the outcome 
of the humoral response by quantifying the plasma and memory B cell populations. The plasma cell 
population (CD38- GL7-) was detected 3 days after antigen challenge in both CCR6-/- and WT mice 
(Fig. 4.2.1d). It then increased rapidly to day 5 and plateaued until day 14, where the frequency 
dropped off at day 21, only to rise again by day 42 (Fig. 4.2.1d). Throughout the humoral response 
though, the CCR6-/- mice generated a similar frequency of plasma cells to WT mice (Fig. 4.2.1d). 
However, it is important to note that it is unclear whether these plasma cells are derived from the 
GC or EF, as there are no distinguishing markers available.  
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Next, memory B cells were examined. Memory B cells are thought to share a similar CD38+ GL7- 
phenotype to naïve B cells. However in this study, I identified a discrete CD38hi GL7- population, 
for the first time, believed to be memory B cells. This population was significantly increased in 
CCR6-/- mice compared to WT mice at 3, 5 and 10 days following antigen challenge (Fig. 4.2.1e). 
Of course, it is possible that the memory B cell population may have a bimodal expression of 
CD38. However, further analysis of this population based on the expression of IgM and IgD, 
supported the notion that the CD38hi GL7- B cells were part of the memory B cell population. The 
CD38hi GL7- population expressed high levels of IgM, while IgD expression was similar to that of 
the CD38+ GL7- naïve B cells (Fig. 4.2.2a, b). Also, the expression level of both IgM and IgD was 
higher on the CD38hi GL7- cells, compared to the GC and plasma B cells (Fig. 4.2.2a). In contrast, 
IgM expression appeared similar between the GC and naive B cells, while IgD expression was 
higher on the naïve cells than on the GC B cells, consistent with a naïve phenotype (Fig. 4.2.2a). In 
agreement with these observations is the existence of IgMhi memory B cells28. Furthermore, the 
temporal and cellular kinetics of the naïve and memory B cell population lends further support to 
their delineation. Both the naïve (CD38+ GL7-) and memory (CD38hi GL7- ) B cell populations are 
present 3 days after NP-KLH immunisation in WT mice, although the memory B cell population is 
substantially smaller than the naïve subset, as would be expected (Fig. 4.2.1b, e). Overall, it appears 
that the increased early GC response observed in the absence of CCR6 is due to an increase in 
activated B cells and results in an increased early memory B cell response.  
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Figure 4.2.1. Effector B cell differentiation during the T cell-dependent humoral 
immune response in the absence of CCR6 
WT and CCR6-/- mice were immunised with 50-100µg of NP-KLH and the splenic B cell subsets were examined 3–42 
days following challenge by flow cytometry. B cell populations were identified by their expression of CD38 and GL7, 
and representative images of WT and CCR6-/- mice at day 5 are shown (a): 1) CD38- GL7- plasma B cells, 2) CD38+ 
GL7- naïve B cells, 3) CD38hi GL7- memory B cells, 4) CD38+ GL7+ precursor B cells and 5) CD38- GL7+ GC B cells. 
The frequencies of naive (b), precursor (c), plasma (d) and memory (e) B cells were quantified. Data was collated from 
1–2 independent experiments (Day 3 n=8 WT mice, 6 CCR6-/- mice; Day 5 n=5 mice/genotype; Day 7, 21 & 42 n=9 
mice/genotype; Day 10 n=8 WT mice, 9 CCR6-/- mice; Day 14 n=4 mice/genotype). 
Mann-Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01; ***significant at p<0.001 
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Figure 4.2.2. Characterisation of the CD38hi GL7- B cell population in the T cell-
dependent humoral response 
WT mice were immunised with 100µg of NP-KLH and the splenic CD38hi GL7- (memory) and CD38+ GL7- (naïve) B 
cells were examined by flow cytometry at 5, 7, 10 and 14 days after immunisation. The representative image indicates 
the expression of IgM and IgD on 1) CD38- GL7- plasma cells, 2) CD38+ GL7- naïve B cells, 3) CD38hi GL7- memory 
B cells and 5) CD38- GL7+ GC B cells (a). CD38+ GL7+ precursor B cells are also indicated in the gating strategy (a). 
The mean fluorescence intensity of IgM (b) and IgD (c) expression was quantified on naïve and memory B cells. Figure 
represents data collected from 1 experiment (Day 5, 7 & 14 n=4 mice/genotype; Day 10 n=3 mice/genotype). 
Mann-Whitney two-tail t-test, *significant at p<0.05 
 	  
4.3. CCR6 contributes to humoral responses in multiple secondary lymphoid 
organs 
Having established that the absence of CCR6 causes B cell dysregulation in TD humoral responses 
in the spleen, I wanted to determine if this alteration is systemic, that is, if it also occurs in other 
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secondary lymphoid organs. As such, B cell differentiation was analysed in the draining lymph 
node of CCR6-/- and WT mice. Mice were subcutaneously immunised with SRBC, to allow lymph 
node B cells to directly respond to antigen, based on their proximity to the site of immunisation. 
Responding lymph node B cells were then examined six days after immunisation, which represents 
the peak of the humoral response. The frequency of B cells was quantified by flow cytometry using 
antibodies against CD38 and GL7. However, the response measured is not antigen specific, as it is 
not possible to identify SRBC specific B cells. The gating strategy used to examine B cells in the 
lymph node is shown in Fig. 4.3.1a.  
 
Initially, the frequency of the entire B cell population was quantified. In the CCR6-/- mice, the B 
cell population appeared increased compared to WT mice (Fig. 4.3.1b). A significant increase in the 
frequency of GC B cells (CD38- GL7+) was detected in CCR6-/- mice compared to WT mice (Fig. 
4.3.1c) and this finding parallels the GC response observed in the spleen. Also, the naïve B cells 
(CD38+ GL7-) were significantly reduced in the CCR6-/- mice compared to the WT mice, again 
correlating with the splenic B cell response (Fig. 4.3.1d). Interestingly, the frequency of precursor B 
cells (CD38+ GL7+) was found to be significantly higher in the CCR6-/- mice than in the WT mice 
(Fig. 4.3.1e). This finding differs to that in the spleen and is perhaps a result of the higher 
sensitivity in detecting this population in the lymph node, due to the lower frequency of B cells that 
reside in this organ. Furthermore, the prominent memory B cell population (CD38hi GL7-), 
previously detected in the spleen, could not be detected in the lymph node and the reason for this is 
unknown (Fig. 4.3.1a). Finally, a similar frequency of plasma cells (CD38- GL7-) was observed 
between CCR6-/- and WT mice (Fig. 4.3.1f). Overall, the results obtained from the draining lymph 
node strengthen the conclusion that CCR6 plays a role in the regulation of B cell differentiation in 
the early humoral response. It is clear that the absence of CCR6 causes B cell dysregulation, such 
that more naïve B cells become activated and are subsequently selected to differentiate into GC B 
cells. Therefore, this work demonstrates that the absence of CCR6 affects the ability of follicular B 
cells to generate an efficient systemic humoral response.  
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Figure 4.3.1. The T cell-dependent humoral response of lymph node B cells 
WT and CCR6-/- mice were s.c. immunised with SRBCs for 7 days. The draining lymph node B cell subsets, delineated 
by CD38 and GL7 were quantified by flow cytometry: 1) CD38- GL7- plasma cells, 2) CD38+ GL7- naïve B cells, 3) 
CD38+ GL7+ precursor B cells, 4) CD38- GL7+ GC B cells (a). The frequency of all B cells (b), GC B cells (c), naive B 
cells (d) precursor B cells (e) and plasma cells (f) were quantified. Figure represents data generated from 1 experiment 
(n=5 WT mice, 4 CCR6-/- mice).  
Mann-Whitney two-tail t-test, *significant at p<0.05 
 
 
4.4 CCR6 expression is linked to the formation of Extrafollicular Foci 
Given that the GC B cell differentiation pathway is increased in the absence of CCR6, I wanted to 
determine whether the EF pathway was also affected in the CCR6-/- mice. In considering that the 
plasma cell population was not altered in the absence of CCR6, it was expected that EF B cell 
differentiation occurred normally. However, a previous report has shown that CCR6-/- mice have a 
higher frequency of low-affinity antibody forming cells182.  As EF are the major producers of low-
affinity plasma cells, an increase in the extrafollicular response would potentially account for this 
published finding.  
 
To evaluate the influence of CCR6 on EF development, the antigen-specific HEL-Ig transgenic 
MD4 mice and MD4.CCR6-/- mice were immunised with HEL-SRBC. The extrafollicular B cell 
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population, identified as B220lo cells that produce antibodies against HEL, was quantified by flow 
cytometry six days later, as shown in Fig. 4.4.1a. This analysis revealed a significant reduction in 
the frequency of extrafollicular B cells in the CCR6-/- mice compared to the WT mice (Fig. 4.4.1a, 
b). This suggests firstly that CCR6 is expressed by EF B cells, as its loss results in a reduction of 
this population and secondly, that CCR6 expression by B cells destined to differentiate into EF, 
may direct their migration to extrafollicular sites. Overall, the reduced EF response and increased 
GC response observed in the absence of CCR6 is perplexing, as it is unclear whether the alterations 
in EF and GC differentiation are separate events, or whether they are linked. It is possible that the 
excessive GC response may actually compensate for the impaired EF response in the absence of 
CCR6.  
 
 
 
 
 
Figure 4.4.1. CCR6 deficiency impairs the Extrafollicular response 
The frequency of splenic EF B cells was analysed by flow cytometry in MD4 and MD4.CCR6-/- mice, 6 days after i.p. 
immunisation with HEL-SRBC. Representative flow cytometry images show the EF (B220lo intracellular HEL+) 
population, as indicated by the gate (a). The frequency of B cells was quantified by flow cytometry (b). Data was 
compiled from 2 independent experiments (n= 7 MD4 mice, 8 MD4.CCR6-/- mice). 
Mann-Whitney two-tail t-test, **significant at p<0.01 
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4.5. CCR6 influences Marginal Zone B cells during T cell-dependent humoral 
responses 
Having assessed the consequences of CCR6 deficiency on the follicular B cell subset in TD 
humoral responses, the influence of CCR6 on MZ B cells was subsequently examined. Although 
MZ B cells are primarily involved in innate and TI immune responses254,255, they are also capable of 
contributing to TD humoral responses. For instance, MZ B cells have been shown to aid cognate 
CD4+ T cell activation and contribute to the maintenance of FDC antigen levels256. For this reason, 
the response of MZ B cells in the CCR6-/- mice was investigated, in the NP-KLH induced humoral 
response. The frequency of MZ B cells was quantified by flow cytometry between days 5–42, using 
antibodies against CD21 and CD23. The MZ B cell population was identified by their high CD21 
and low CD23 expression (Fig. 4.5.1a)257,258. A significant reduction in the frequency of MZ B cells 
was detected 21 days following antigen challenge in the CCR6-/- mice compared to the WT mice 
(Fig. 4.5.1b). There also appeared to be an increase in the frequency of MZ B cells in CCR6-/- mice 
10 days after antigen challenge compared to WT mice, however this was not significant due to the 
varying responses in individual mice. Similar frequencies of MZ B cells were observed between 
CCR6-/- and WT mice for the remaining response. Therefore, the findings from this work suggest 
that MZ B cells do not contribute to the induction of the humoral response, but rather play a greater 
role in the later stages of the responses, potentially in the cessation of the GC response.   
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Figure 4.5.1. The contribution of CCR6 to Marginal Zone B cell differentiation in the 
T cell-dependent humoral response 
WT and CCR6-/- mice were immunised with 100µg of NP-KLH and the splenic MZ B cell population was quantified by 
flow cytometry 5, 7, 10, 14, 21 and 42 days following immunisation. Representative flow cytometry images indicate the 
CD21hi CD23lo MZ B cell population in WT and CCR6-/- mice at day 21 (a). The frequency of MZ B cells was 
quantified (b). Data was collected from 1 experiment (Day 5, 21 &42 n=4 WT mice, 4 CCR6-/- mice; Day 7 n=4 WT 
mice, 3 CCR6-/- mice; Day 10 n=3 WT mice, 4 CCR6-/- mice; Day 14 n=5 WT mice, 4 CCR6-/- mice). 
Mann-Whitney two-tail t-test, *significant at p<0.05 
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4.6. Concluding Remarks 
In summary, I have directly examined the temporal kinetics of B cell differentiation in the absence 
of CCR6. The major TD antigen used to induce humoral immunity was NP-KLH. This model of 
humoral immunity was advantageous as it was possible to identify the expansion of NP-specific λ-
Ig B cells. The λ+ B cell population could be subdivided into five distinct subsets, based on the 
expression level of CD38 and GL7: naïve (CD38+ GL7-), precursor (CD38+ GL7+), GC (CD38- 
GL7+), plasma (CD38- GL7-) and memory (CD38hi GL7-) B cells. The cell surface phenotype of 
these subsets is consistent with the literature. For example, GL7 is not expressed by the follicular B 
cell subsets, except following activation, in which it is upregulated on precursor and GC B 
cells28,259,260. In addition, CD38 is expressed on naïve B cells and precursor B cells, downregulated 
on GC B cells, absent from plasma cells and upregulated on memory B cells24,28,261,262. Furthermore, 
the upregulation of both CD38 and GL7 on activated B cells concurs with the in vitro findings 
documented in Chapter 3. Subsequent analysis of the CD38hi GL7- memory B cells confirmed its 
identity, corresponding with the previously reported existence of IgMhi memory B cells98,137,138.  
 
The B cell response of WT mice to NP has been well defined26-28,50,53,77,85,135. Briefly, naïve B cells 
become activated and subsequently interact with Th cells within 2 days of antigen challenge. B cells 
then enter a precursor stage at day 3, which is quickly followed by GC differentiation. The GC B 
cell response peaks at day 7, declines and persists until at least day 16. Meanwhile the EF response 
is initiated early, peaks by day 8 and dissipates by day 14. During this time, plasma and memory B 
cells are generated, peaking approximately 1 week and 21 days after antigen challenge, 
respectively. Hence, these studies have provided an excellent reference for TD B cell kinetics. In 
this study, I detected GC B cells 3 days after antigen challenge. The GC B cell population peaked at 
day 7, gradually declined by day 21 and persisted at low levels, as observed at day 42. This 
correlated with a reduction in the naïve B cells and the appearance of memory and plasma cells. 
The memory B cells remained at a similar level for the course of the response, while the plasma 
cells increased at day 6, and declined at day 21 before rising again at day 42. Also, a high frequency 
of precursor B cells was observed at day 3 and 7, before declining and plateauing for the remaining 
response. Thus, the results from this study correlate with the literature.  
 
The best method available to quantify the extrafollicular response is to examine the B220lo cells that 
produce HEL-specific antibodies. In doing this, the EF B cell population was found to be 
significantly reduced in the absence of CCR6. However, it would also be valuable to examine the 
EF response in the SWHEL mouse model, which differs from the MD4 model used here, in that it is 
capable of B cell isotype switching78,263. The investigation of the EF B cell response to HEL–
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SRBCs, a potent inducer of TD responses, has been published previously75. This study has provided 
valuable insight at the peak of the response in CCR6 deficient mice compared to WT mice. It used 
unimmunised mice as reference points, and as such mice without SRBCs were not included in this 
study. It would be appropriate in future studies though, to document the initiation and progression 
of SRBC-mediated responses, including experiments without SRBCs.  
 
Although MZ B cells are involved in innate-like immune responses254,255, they have also been 
implicated in TD immune responses. Indeed in NP studies, it has been proposed that MZ B cells 
share a similar function to follicular B cells, in that they too are responsible for the early generation 
of antibody forming cells, particularly plasma cells, IgM+ memory B cells, and GC B cells264. 
Whilst the potential dysregulation of the MZ B cell compartment in the CCR6-/- mice could account 
for the increased production of IgMhi memory B cells and the increased GC B cell response, a 
consistent MZ B cell population was observed for most of the humoral response in CCR6-/- and WT 
mice, effectively ruling out this possibility. However, there was a significant decrease in MZ B cells 
21 days following antigen challenge in the CCR6-/- mice, which corresponded with a reduction in 
GC B cells at day 21 in the CCR6-/- mice. It has previously been established that MZ B cells migrate 
to the B cell follicle to deliver antigen to FDCs, thereby supporting the GC response265-267. This 
published data, in combination with the results of this investigation, indicate that the CCR6-/- mice 
may effectively maintain antigen supply to the GC via the MZ B cells, until its cessation at day 21, 
at which point both a decrease in MZ  and GC B cells is detected.  
 
Overall, this chapter has demonstrated that CCR6 performs a substantial role in regulating B cell 
differentiation during the initial stages of the humoral immune response. The absence of CCR6 
appears to inhibit EF development, which may be overcome by excessive GC formation. 
Furthermore, this results in an increased early memory response, while the plasma cell response 
appears unaffected. The functional significance of this dysregulation will be investigated in the next 
chapter.  
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In this chapter, I report on the biological consequences of CCR6 impairment, particularly in regards 
to the heightened GC response, and shed light onto the potential mechanisms underlying the B cell 
dysregulation observed in the CCR6-/- mice. Understanding the CCR6 mediated regulation of B cell 
differentiation is crucial, as it will enhance our knowledge of the mechanisms underlying efficient 
humoral responses and conversely, how humoral responses can be manipulated for therapeutic 
applications.  
 
5.1. CCR6 contributes to the Germinal Centre reaction 
Considering the substantial increase in the early GC response of CCR6-/- mice, the quality of the 
GC reaction was evaluated. As there is a clear structure-function relationship between B cell 
positioning in secondary lymphoid organs and the function of B cells, the structure of GC follicles 
was examined in the absence of CCR6. Within GC follicles, B cells are positioned in the light or 
dark zone depending on their expression of CXCR5 and CXCR4159. This spatial division enables 
SHM and affinity selection to occur in discrete specialised microenvironments. Specifically, clonal 
expansion and SHM of B cells occurs in the dark zone, whilst affinity selection occurs in the light 
zone95-97.  
 
The structure of GC follicles in CCR6-/- and WT mice was assessed by immunofluorescence five 
days following NP-KLH challenge. The structure of GCs was examined using antibodies against 
IgD, PNA and CD35. These antibodies were selected, as IgD identifies B cell follicles but not GC B 
cells23,91, PNA identifies GC B cells91,253 and CD35 identifies FDCs located in the light zone268. 
Upon examination of spleen sections, no gross abnormalities were observed in the GC follicles 
between CCR6-/- and WT mice (Fig. 5.1.1). Consistent with the findings in the previous chapter, 
noticeably more GC follicles were observed in CCR6-/- mice than WT mice (Fig. 5.1.1). In addition, 
both the size of the GC follicles and the size of the light zone within the GC were comparable 
between CCR6-/- and WT mice (Fig. 5.1.5). However, the PNA+ dark zone appeared more 
prominent in the CCR6-/- mice than the WT mice (Fig. 5.1.5). This would suggest that the WT mice 
are in the early stages of GC follicle establishment.  
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Figure 5.1.1. The structure of Germinal Centre follicles in the CCR6 deficient 
humoral response 
CCR6-/- and WT mice were immunised with 100µg of NP-KLH for 5 days. Spleen sections were stained with antibodies 
against IgD, PNA and CD35. GC follicles were identified as IgD- PNA+ CD35+. Samples were imaged using the 
confocal microscope (n=3 mice/genotype). Images indicate (GC) germinal centres, (B) B cell follicles, (T) T cell zones 
and (S) Sinus.   
Objective magnification: 10x; Scale bars are 100µm 
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Having observed that the structure of GC follicles in CCR6-/- mice is largely intact, the antibody 
maturation and differentiation capacity of CCR6-/- GC B cells was analysed at the molecular level. 
Specifically, qRT-PCR was used to examine the expression of the chemokine receptors that 
contribute to GC organisation, as well as the transcription factors and enzymes that direct the GC 
reaction. GC B cells were isolated from CCR6-/- and WT mice that had been immunised with NP-
KLH for 5 days, using the MoFlo® Astrios™ cell sorter. All samples were normalised by cell 
number and gene expression was analysed using the relative ΔCT method, which compares 
physiological changes in gene expression at the mRNA level relative to a reference gene. 
 
Initially, the transcription factor Bcl-6 was examined, which is essential for GC formation102. A 
significant increase in Bcl-6 expression was detected in CCR6-/- GC B cells compared to WT GC B 
cells (Fig. 5.1.2). This increase was not due to an increase in the frequency of GC B cells, as all 
samples were normalised by cell number. Thus, Bcl-6 expression is inherently higher in CCR6-/- GC 
B cells. As Bcl-6 is essential for GC formation and proliferation, it offers an explanation for the 
increased GC response observed in the CCR6-/- mice in Chapter 4. The next protein examined was 
inhibitor of DNA-binding 2 (Id2). Id2 is a protein that negatively regulates splenic B cell 
differentiation and in the GC, suppresses AID activity and therefore SHM35,269,270. Interestingly, a 
significant increase in the mRNA expression of Id2 was also detected in the CCR6-/- GC B cells 
compared to the WT GC B cells (Fig.5.1.2). Hence, it was possible that the increased Id2 
expression was inhibiting AID expression and consequently SHM, potentially accounting for the 
increased frequency of low-affinity antibody-forming cells documented in CCR6-/- mice182. 
However, when AID expression was examined, it was not downregulated in CCR6-/- GC B cells, 
but expressed at a similar level to GC B cells in WT mice (Fig. 5.1.2). This indicates that SHM is 
not impaired in CCR6-/- mice. Therefore, I investigated whether terminal B cell differentiation was 
affected, by examining the expression of Blimp-1 and IRF4. These proteins are transcription factors 
that are essential for plasma cell, but not memory B cell, differentiation139. Again, both the CCR6-/- 
and WT GC B cells produced similar levels of Blimp-1 and IRF4 mRNA, illustrating that terminal 
differentiation into plasma cells is not affected by CCR6 expression (Fig. 5.1.2). This finding 
concurs with the similar frequency of plasma cells observed between CCR6-/- and WT mice in 
Chapter 4. In addition, Pax5 expression was analysed. Pax5 is required for B cell lineage 
commitment and GC formation, while its downregulation facilitates plasma cell 
differentiation145,147,271,272. Thus, it was possible that Pax5 may contribute to the increased GC 
response detected in CCR6-/- mice. However this was not the case, as equivalent levels of Pax5 
expression were detected between CCR6-/- and WT GC B cells (Fig. 5.1.2). Finally, the expression 
of the chemokine receptors: CXCR5, CXCR4, CCR7 and EBI2 were examined, due to their pivotal 
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role in B cell positioning during the humoral response. Specifically, CXCR5 and CXCR4 are 
essential for B cell positioning within the light and dark zones of the GC, while the downregulation 
of CCR7 and EBI2, is required for B cells to migrate in a CXCR5-dependent manner to the B cell 
follicle52,156,158,159. Consequently, I wanted to rule out the possibility that chemokine receptors other 
than CCR6 were responsible for the increased GC seeding in CCR6-/- mice. This analysis showed 
no significant variation in the expression of CXCR5, CXCR4, CCR7 or EBI2, between CCR6-/- and 
WT GC B cells (Fig. 5.1.2). Therefore, CCR6-/- GC B cells do not have any alterations in the 
chemokine receptors that play pivotal roles in the GC response.  
 
 
 
Figure 5.1.2. The molecular characteristics of CCR6 deficient Germinal Centre B 
cells 
WT and CCR6-/- mice were i.p. immunised with 100µg of NP-KLH for 5 days. 1000 GC B cells, identified as λ + CD38- 
GL7+ B cells, were isolated using the MoFlo® Astrios™ cell sorter. RNA was extracted and cDNA subsequently 
synthesised. Gene expression of Bcl-6, Id2, AID, Blimp-1, IRF4, Pax5, CXCR5, CXCR4, CCR7 and EBI2, relative to 
18S, was analysed by qRT-PCR. Data is displayed as ΔCt and represents 3 independent experiments (n=9 WT mice, 11 
CCR6-/- mice; except for Blimp-1 where n=8 mice/genotype, and CXCR5 & CXCR4 where n=9 WT mice, 10 CCR6-/- 
mice). 
Mann-Whitney two-tail t-test, *significant at p<0.05 
 
 
In continuing with the analysis of the GC response, the TFH cell and FDC populations were also 
examined in the CCR6-/- mice. The TFH cells are crucial in supporting the GC reaction as they 
secrete proteins that support B cell proliferation and the affinity selection of B cells. As such, the 
TFH cells of CCR6-/- and WT mice immunised with NP-KLH for five days were isolated and 
prepared for qRT-PCR analysis. The TFH cells were isolated using the MoFlo® Astrios™ cell 
sorter, based on their high expression of CXCR5 and PD-1119,273,274. Three populations of T cells 
were identified: CXCR5- PD-1- non-TFH cells, CXCR5int PD-1int intermediate TFH cells and 
CXCR5hi PD-1hi TFH cells. Intermediate TFH cells must upregulate CXCR5 and PD-1 to become TFH 
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cells274-276. As per the analysis of GC B cells, all TFH cell samples were normalised by cell number 
and the samples prepared for qRT-PCR.  
 
Initially, CCR6 and CCL20 expression was quantified in WT TFH cell subsets. Given that CCR6 
expression was detected on the surface of T cells in T-B cell conjugates in Chapter 3, CCR6 mRNA 
expression was examined on TFH cell subsets in WT mice by qRT-PCR. This analysis showed that 
all three populations: non-TFH cells, intermediate TFH cells and TFH cells, expressed similar levels of 
CCR6 mRNA (Fig. 5.1.3a). The possibility that T cells were responsible for CCL20 production 
arose, as T cells are known to produce cytokines that support B cell differentiation. Hence, CCL20 
expression was examined on the TFH cell subsets of WT mice. A significantly higher amount of 
CCL20 mRNA was detected in the intermediate TFH cells, compared to the TFH cells (Fig. 5.1.3b). 
This is interesting as the TFH cells are thought to arise from precursor T cells at the T-B border, 
which are in the process of upregulating CXCR5 and PD-1 expression51. Thus, the finding that 
intermediate TFH cells produce CCL20 indicates that CCL20 may act in an autocrine manner to 
retain T cells at the T-B border, and potentially also retain activated B cells, which upregulate 
CCR6 expression, as demonstrated in Chapter 3, and localise to the T-B border.  
 
Next, the expression of proteins associated with the differentiation and function of TFH cells were 
examined. Given that IL-21 production by TFH cells is fundamental for TFH cell commitment 
through an autocrine mechanism277, and consequently GC formation, B cell differentiation and 
antibody production277-279, IL-21 expression was examined in CCR6-/- and WT mice. A significantly 
higher amount of IL-21 mRNA was detected in CCR6-/- TFH cells than in WT TFH cells (Fig. 5.1.3c). 
However, this increase in IL-21 expression did not induce significant increases in Bcl-6 nor CXCR5 
expression (Fig. 5.1.3c), proteins that are essential for TFH cell development and the GC 
response119,273,275,280. Nonetheless, it has been demonstrated that IL-21 secreted by TFH cells also 
acts directly on GC B cells, through Bcl-6 and thereby controls GC formation and terminal B cell 
differentiation121,122,279. Therefore, it is highly likely that the increased IL-21 production by TFH 
cells in the CCR6-/- mice, directly induces the increased Bcl-6 expression of GC B cells and is 
consequently responsible for the increased early GC response observed in these mice. When IL-21 
was examined in intermediate TFH cells, precursor to TFH cells, IL-21 expression was found to be 
similar between CCR6-/- and WT mice (Fig. 5.1.3d, e). 
 
As mentioned earlier, no significant variation in CXCR5 expression was detected in CCR6-/- TFH 
cells compared to WT TFH cells, and this was also true for CCR7 (Fig. 5.1.3c). Both of these 
chemokine receptors are required for TFH cell localisation to the GC274,281, and therefore the results 
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indicate no impairment in the localisation of TFH cells to GC follicles. Likewise, there was no 
significant variation in either CXCR5 or CCR7 expression between CCR6-/- and WT intermediate 
TFH cells and non-TFH cells (Fig. 5.1.3c, d, e). In addition, FoxP3 expression was quantified in TFH 
cells. FoxP3 expression was quantified, as it is expressed by follicular regulatory T cells (TFR) in 
the GC, which phenotypically resemble the TFH cells, but are instead responsible for suppressing the 
GC response282. As predicted, there was no significant variation in FoxP3 expression between 
CCR6-/- and WT TFH cell subsets, demonstrating that the increased GC response was not due to a 
loss in TFR cells (Fig. 5.1.3c). Finally, there was no significant variation in the expression of FoxP3 
or Bcl-6 in the intermediate TFH cells and TFH cells, between CCR6-/- and WT mice (Fig. 5.1.3d, e).  
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Fig. 5.1.3. The molecular characteristics of CCR6 deficient T Follicular Helper cells 
WT and CCR6-/- mice were i.p. immunised with 100µg of NP-KLH for 5 days. 1000 cells from the TFH cell subsets: 
CXCR5hi PD-1hi TFH cells, CXCR5int PD-1int intermediate TFH cells and CXCR5- PD-1-  non-TFH cells, were isolated 
using the MoFlo® Astrios™ cell sorter. RNA was extracted and cDNA synthesised. The gene expression of CCR6 (a) 
and CCL20 (b) was quantified in TFH cell subsets of WT mice. Also, the gene expression of IL-21, CCR7, CXCR5, 
FoxP3 and Bcl-6 was quantified in TFH cells (c), intermediate TFH cells (d) and non-TFH cells (e). Figure represents data 
collected from 2 independent experiments (n=6 mice/genotype). Inefficient reactions were excluded.  
Mann-Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01 
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In addition to examining the molecular characteristics of TFH cells, the TFH cell response was also 
examined by flow cytometry. WT and CCR6-/- mice were immunised with NP-KLH and the TFH 
cells were quantified 5–42 days after antigen challenge. As mentioned earlier, TFH cells are 
identified by their high expression of CXCR5 and PD-1. The gating strategy used to detect TFH cells 
is displayed in Fig. 5.1.4a. The WT TFH cell response peaked at day 7, as did the GC response, 
before declining (Fig. 5.1.4b). It was hypothesised that the increased GC response observed in 
CCR6-/- mice at day 5, would be associated with an increased frequency of TFH cells. However, the 
CCR6-/- mice had a similar frequency of TFH cells compared to WT mice, 5 days after antigen 
challenge (Fig. 5.1.4.b). While there was no change in the frequency of TFH cells between CCR6-/- 
and WT mice, the GC response is still increased in CCR6-/- mice, and thus, the TFH cell population 
is reduced compared to WT mice. This finding suggests that at this time point, CCR6-/- GC follicles 
are either under more stringent selection pressure due to the lower number of TFH cells, or the 
reduced number of TFH cells may directly impair B cell affinity selection. Surprisingly, a significant 
increase in the frequency of TFH cells was observed in CCR6-/- mice at days 10 and 42 after antigen 
challenge, compared to WT mice (Fig. 5.1.4a), and perhaps reflects a delayed response to the 
increased early GC B cell population. Next, I examined the intermediate TFH cell population, which 
is thought to be the precursor of TFH cells. Similar to the TFH cells, the intermediate TFH cell 
population peaked at day 7 before declining (Fig. 5.1.4c). During this time, the frequency of 
intermediate TFH cells was generally similar between CCR6-/- and WT mice (Fig. 5.1.4c). However, 
a significant reduction in the frequency of intermediate TFH cells was detected at day 21, and a 
significant increase was also detected at day 42 following antigen challenge, in the CCR6-/- mice 
compared to the WT mice (Fig. 5.1.4c). The frequency of non-TFH cells was also similar between 
CCR6-/- and WT mice, except at day 21, where a significant increase was detected (Fig. 5.1.4d). 
The reasons for these late stage alterations in the TFH cell compartment are unknown and probably 
reflect the effects of GC cessation in the absence of CCR6. Overall, these results suggest that the 
unchanged TFH cell population in the CCR6-/- mice, which have an increased GC response, may 
impair the affinity selection of B cells.  
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Fig. 5.1.4 The T Follicular Helper cell kinetics of the T cell-dependent humoral 
response in the absence of CCR6 
WT and CCR6-/- mice were i.p. immunised with 100µg of NP-KLH and the TFH cell subsets were quantified by flow 
cytometry at days 5, 7, 10, 14, 21 and 42 after antigen challenge. The compartment was separated into three subsets 
based on their expression of CXCR5 and PD-1: 1) CXCR5- PD-1-  non-TFH cells, 2) CXCR5int PD-1int intermediate TFH 
cells and 3) CXCR5hi PD-1hi TFH cells, and representative images of WT and CCR6-/- mice at day 10 are displayed (a). 
The frequency of TFH cells (b), intermediate TFH cells (c) and non-TFH cells (d) were quantified in WT and CCR6-/- 
mice. Figure represents data collected from 1 experiment (n=4 mice/genotype). 
Mann-Whitney two-tail t-test, *significant at p<0.05 
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Having completed the analysis of the TFH cells, the FDC compartment was examined. The FDC 
network is essential to the GC reaction, as it provides a source of antigen for the GC B cells 
required for affinity selection, as well as signals that support the GC reaction112,283,284. A 
preliminary flow cytometry study was carried out, where WT and CCR6-/- mice were immunised 
with NP-KLH and the frequency of the FDC population was quantified 5–42 days following 
antigen challenge. The FDCs were identified by their forward and side scatter parameters, as well as 
their distinct CD21/35 expression268. The gating strategy used to quantify the FDC population is 
displayed in Fig. 5.1.5a. Although the frequency of FDCs appeared to be decreased at day 5 and 
increased at day 10 in the CCR6-/- mice compared to the WT mice, no significant variation was 
detected. Similar to the cellular kinetics of the TFH cells in the CCR6-/- mice, the increased GC cell 
response and largely unchanged FDC response indicates that affinity selection may be impaired in 
the absence of CCR6. However, whether the impaired affinity selection of CCR6-/- mice has a long-
term impact on the humoral response is unknown. Consequently, the reduced TFH cell and FDC 
populations in the CCR6-/- mice may account for the increased generation of low-affinity antibody 
forming cells documented in the CCR6-/- mice182.  
 
 
 
Fig. 5.1.5. The Follicular Dendritic cell kinetics of the CCR6 deficient T cell-
dependent humoral response 
WT and CCR6-/- mice were i.p. immunised with 100µg of NP-KLH for 42 days. The FDCs were identified by flow 
cytometry as CD21/35+ monocytes (a). The frequency of FDCs was quantified in WT and CCR6-/- mice at 5, 7, 10, 14, 
21 and 42 days after challenge (b). Figure represents data collected from 1 experiment (n=4 mice/genotype). 
Mann-Whitney two-tail t-test 
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Having found no substantial variation in the quality of the GC response, I examined whether the 
end product – antibody production – was affected by the absence of CCR6. Thus far, there has been 
no evidence to suggest alterations in antibody generation in the CCR6-/- mice. Therefore, it was 
hypothesised that there would be little, if any, variation in antibody production between CCR6-/- and 
WT mice. Antibody production was quantified in the serum of CCR6-/- and WT mice challenged 
with NP-KLH for 42 day. IgM and IgG production was analysed by ELISA, as IgM is the BCR and 
thus the first antibody to be produced in the response, and IgG appears later, after B cells undergo 
CSR. As expected, IgM production occurred first, between days 7–21 following antigen challenge 
(Fig. 5.1.6). This was followed by IgG2ab production between days 7–42, and IgG1b production 
between days 14–42 after antigen challenge (Fig. 5.1.6). An equivalent production of IgM was 
observed between CCR6-/- and WT mice, following antigen challenge (Fig. 5.1.6). Similarly, 
IgG2ab and IgG1b production was similar between CCR6-/- and WT mice, throughout the course of 
the humoral response (Fig. 5.1.6). Overall, this data suggests that antibody production is not altered 
in the absence of CCR6.  
 
 
 
 
Figure 5.1.6. T cell-dependent antibody production in the absence of CCR6 
WT and CCR6-/- mice were i.p. immunised with 50–100µg of NP-KLH. Serum was isolated from blood collected from 
unimmunised mice (day 0) and immunised mice at days 3, 7, 14, 21, 28, 33 and 42 after antigen challenge. The 
concentrations of NP-specific IgM, IgG2ab and IgG1b levels were quantified by ELISA, using a standard curve 
generated from serum collected from WT mice at day 7 and 21 following immunisation. Figure represents data 
collected from 1 experiment (IgM, IgG1b & IgG2ab Day 0, 7, 14 & 21 n=5 mice/genotype; IgM, IgG1b & IgG2ab Day 3, 
and IgG1b Day 28 n=5 WT mice, 4 CCR6-/- mice; IgM & IgG2ab Day 21 n=5 mice/genotype; IgM & IgG2ab Day 42 
n=3 WT mice, 5 CCR6-/- mice; IgM Day 33 n=4 WT mice, 5 CCR6-/- mice; IgG1b Day 33 n=4 WT mice, 3 CCR6-/- 
mice; IgG1b Day 42 n=3 mice/genotype; IgG2ab Day 33 n=4 mice/genotype).  
Mann-Whitney two-tail t-test 
 
 
To conclusively reconcile the increased frequency of low-affinity antibody forming cells previously 
documented in the CCR6-/- mice182, which are likely to be a defect in the affinity selection due to a 
reduction in the TFH cell and FDC compartment,  I wanted to examine the frequency of mutations 
introduced into CCR6-/- GC B cells during SHM. To achieve this, a sequencing method developed 
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by Professor Thomas Winkler’s laboratory, was implemented. This method allows the 
quantification of point mutations in the variable region of NP-specific IgM and IgG genes. 
Specifically, the rate of mutation in IgM and IgG GC B cells from CCR6-/- and WT mice challenged 
with NP-KLH for 5 days, could be quantified. However, this protocol first had to be optimised for 
the low-frequency population of GC B cells, as it had been originally designed for use with the NP-
Ig specific B cell enriched transgenic B1-8 mouse strain. Briefly, this protocol involved sorting B 
cells, isolating RNA and synthesising cDNA for subsequent amplification and sequencing. The 
primers developed by the Winkler laboratory were used to specifically amplify the variable region 
of NP-specific IgM and IgG genes.  
 
Initially, the primers used to isolate IgM and IgG were tested in the WT splenic B cell population 
using an annealing temperature gradient. The primers for both IgM and IgG appeared stable over a 
range of annealing temperatures and consequently, an annealing temperature of 58 °C was selected 
for the remaining optimisation (Fig. 5.1.7a). Next, the sensitivity of the primers was tested by 
serially diluting 1.4 µg of WT splenic cDNA. This was necessary, as it would only be possible to 
isolate 1000 GC B cells from mice, due to the low frequency of this population and the time 
constraints in cell sorting. This analysis revealed that the sequencing primers for IgM were quite 
sensitive, with the product being detected in 0.14 ng of splenic cDNA, whilst IgG was less so, as it 
could only be detected in samples containing 14.7 ng of splenic cDNA (Fig. 5.1.7b). Subsequently, 
the IgM and IgG primers were tested on 1000 splenic B cells that were isolated using anti-CD43 
MicroBeads. Sample preparation of 1000 B cells was tested in two ways. RNA was either isolated 
using the NP-40 lysis buffer or the iScript™ RT-qPCR sample preparation reagent, prior to cDNA 
synthesis. The primers were also tested on samples containing RNA isolated from 10 000 splenic B 
cells using the iScript™ RT-qPCR sample preparation reagent. Whilst the PCR was successful, as 
indicated by the 18S product for all three samples, only IgM could be detected in samples 
containing 1000 cells (Fig. 5.1.7c). Thus, I proceeded to prepare GC samples for IgM sequencing 
only.  
 
After immunising 5x CCR6-/- and 5x WT mice with NP-KLH for five days, 1000 GC B cells were 
isolated using the MoFlo® Astrios™ cell sorter. Samples were prepared by isolating RNA using the 
iScript™ RT-qPCR sample preparation reagent, synthesising cDNA and amplifying the NP-specific 
IgM variable sequences. A representative image of WT and CCR6-/- GC B cell samples prepared for 
sequencing is displayed in Fig. 5.1.7d. All products were then purified and precipitated, before 
being sent to Germany for sequencing by Dr. Andreas Hiergeist. Unfortunately, the samples could 
not be analysed as the reverse primer was not compatible with the sequencing machine.  
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Figure 5.1.7. Preparation of antigen-specific Germinal Centre B cells for 
Immunoglobulin Sequencing 
Naïve splenic cDNA was used to test IgM and IgG primers at annealing temperatures of 52 °C, 55 °C, 58 °C, 60 °C, 62 
°C and 65 °C (left to right) (a). 1.4µg of splenic cDNA was serially diluted 8 times at a ratio of 1:10 to test the 
sensitivity of the IgM (top panel) and IgG (bottom panel) primers (b). The first well contains undiluted cDNA and the 
last well located after ladder is a no template control. The IgM and IgG primers were then tested on 3 small populations 
of splenic B cells: 2 wells of 1000 naïve B cells in which RNA was extracted using firstly an in-house NP-40 lysis 
buffer or secondly the iScript™ RT-qPCR sample preparation reagent, followed by 1 well of 10 000 naïve B cells in 
which RNA was extracted using the iScript™ RT-qPCR sample preparation reagent (left to right) (c). 18S positive 
controls and no template controls are indicated. WT and CCR6-/- mice were i.p. immunised with 100µg of NP-KLH for 
5 days. 1000 GC B cells were isolated by their λ+ CD38- GL7+ expression, using the MoFlo® Astrios™ cell sorter. 
RNA was isolated using the iScript™ RT-qPCR sample preparation reagent and cDNA synthesised. NP-specific IgM 
cDNA was amplified. Representative images of IgM in GC B cell samples from three WT (1–3) and three CCR6-/- (4–
6) mice are shown (d). The 18S positive controls (top panel), as well as IgM and 18S no template controls for each 
sample (bottom panel) are displayed (right panel).  
 
 
In an effort to resolve this, new IgM and IgG reverse primers were designed and tested as before. 
Again, the primers for IgM and IgG appeared stable over various annealing temperatures and 
concentrations (Fig. 5.1.8a). However, both the IgM and IgG primers were even less sensitive than 
the previous set and as a result, IgM and IgG could not be detected in B cell samples containing 
1000 cells (Fig. 5.1.8b). A final avenue to solve this issue would be to design and test nested 
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primers for IgM and IgG. However, considering the sensitivity of the primers, it would be more 
appropriate to use the B1-8 mouse model, which is enriched for NP-specific B cells, and 
subsequently backcross it with the CCR6-/- mice. In this way, antigen-specific enriched WT and 
CCR6-/- GC B cells could be examined. 
 
 
 
Figure 5.1.8. Optimisation of the sample preparation protocol for antigen-specific 
Immunoglobulin Sequencing 
Naïve splenic cDNA was used to test the new IgM (left panel) and IgG (right panel) reverse primers, with the original 
forward primers, at annealing temperatures of 53 °C, 55 °C, 58 °C, 60 °C, 62 °C and 65 °C (left to right), at two 
difference concentrations; 20 µM and 50 µM (a). The no template controls and the positive 18S control are indicated. 
1.4µg of splenic cDNA was then serially diluted 5 times at a ratio of 1:10 to test the sensitivity of the IgM (left panel) 
and IgG (right panel) primers, beginning with undiluted cDNA (b). Following the five samples of diluted cDNA, 3 
samples of 1000 B cells were tested: 1000 naïve splenic B cells, and 2 samples of 1000 GC B cells (λ+ CD38- GL7+) 
that were isolated from WT mice immunised for 5 days with 100µg of NP-KLH, using the MoFlo® Astrios™ cell 
sorter. The 18S positive controls for the naïve splenic B cells and the 2 samples of GC B cells are shown in right panel. 
The no template controls for IgM (left panel), IgG and 18S (right panel) are indicated.  
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5.2. The effects of CCR6 are not intrinsic to B cells 
After analysing the quality of the GC reaction in the CCR6-/- mice, I next examined how B cell 
differentiation becomes dysregulated in these mice, with an emphasis on the contribution of 
chemokine receptors. Whilst I have established that Bcl-6 expression is increased in CCR6-/- GC B 
cells and is likely a result of increased TFH cell-secreted IL-21, the direct cause for these alterations 
has yet to be determined. It is currently unclear whether the intrinsic loss of CCR6 on B cells alone 
is responsible for the dysregulated B cell response, or if in fact the loss of CCR6 on other 
leukocytes, contributes to this dysregulation. It is also unknown as to whether other chemokine 
receptors responsible for B cell positioning, also influence the B cell dysregulation in the CCR6-/- 
mice.  
 
In order to determine whether CCR6 regulates the humoral immune response exclusively via B 
cells, an adoptive transfer system was employed. Mixtures of naïve CCR6-/- and WT splenocytes 
were transferred into recipient Rag mice, which lack mature B and T cell subsets. These mice were 
then immunised with NP-KLH. In this way, I created the precise environment that B cells 
underwent differentiation in, in response to antigen challenge. For instance, naïve CCR6-/- B cells 
were transferred in combination with WT splenocytes. Thus CCR6-/- B cells differentiated in a WT 
environment. Also, naïve WT B cells were mixed with CCR6-/- splenocytes, such that WT B cells 
differentiated in a CCR6-/- environment. It is important to note that the WT and CCR6-/- B cells 
were always at an equivalent ratio in each recipient mouse, such that the CCR6-/- and WT B cells 
were in direct competition with each other. For controls, recipient mice received either WT or 
CCR6-/- splenocytes, consisting of the same total number of donor naïve B cells present in the 
mixtures. The splenic GC response was then analysed five days after immunisation by flow 
cytometry, using antibodies against CD38 and GL7. Representative images of the GC response in 
the reconstituted Rag mice are displayed in Fig. 5.2.1a. A significant increase in the frequency of 
GC B cells was detected in the recipient mice that received a mixture of WT B cells and CCR6-/- 
splenocytes, compared to the recipient mice that received WT splenocytes (Fig. 5.2.1b). This differs 
to the recipient mice that received CCR6-/- B cells and WT splenocytes, which generated a similar 
frequency of GC B cells as the recipient mice that received WT splenocytes (Fig. 5.2.1b). This 
result indicates that CCR6 activity is not intrinsic to B cells and in fact other cells within the spleen, 
such as T cells and dendritic cells, are contributing to the excessive early GC response documented 
in the CCR6-/- mice in Chapter 4. This finding is consistent with the CCR6 expression documented 
in Th cells during T-B cell interactions in Chapter 3, and the altered TFH cell and FDC 
compartments reported earlier in this chapter.  
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In addition to GC formation, the contribution of WT and CCR6-/- B cells to the GC response was 
also assessed. This was accomplished by making use of the congenic markers that distinguish the 
WT and CCR6-/- mice. For this study, the WT mice used were Ly5.1 mice, thus their splenocytes 
can be detected using an anti-CD45.1 antibody, whereas the CCR6-/- cells can be identified using an 
anti-CD45.2 antibody. However, the CD45.2 antibody will also detect Rag cells, as they too express 
CD45.2. The expression of CD45.1 and CD45.2 on GC B cells was quantified by flow cytometry. 
As expected, CD45.1+ B cells predominated in the GC response when recipient mice received only 
WT cells (Fig. 5.2.1c, d). A comparably lower frequency of CD45.2+ B cells was also detected in 
these mice, however they were not transferred from CCR6-/- mice, and therefore reflect the 
recipients’ population (Fig. 5.2.1c). It is possible that these recipient cells do respond to antigen 
challenge and undergo differentiation into GC B cells, as they too have been provided with a donor 
environment. Similarly, CD45.2+ CCR6-/- B cells predominated in the GC response when recipient 
mice received only CCR6-/- cells (Fig. 5.2.1c, d). Upon transferring mixtures of WT and CCR6-/- 
cells into recipient mice, CD45.2+ CCR6-/- B cells appeared to outcompete their CD45.1+ WT 
counterparts in both mixtures, forming the majority of GC B cells (Fig. 5.2.1c). On closer 
inspection however, there was no difference in the contribution of WT and CCR6-/- B cells, as 
approximately 20% of these CD45.2+ cells are likely recipient B cells rather than CCR6-/- B cells 
(Fig. 5.2.1c, d). Thus, CCR6-/- B cells are not preferentially recruited into the GC response and 
contribute equally with WT B cells. This demonstrates that the increased GC response observed in 
the CCR6-/- mice is most likely due to the loss of CCR6 on leukocytes other than B cells.  
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Figure 5.2.1. The contribution of CCR6 deficient leukocytes to Germinal Centre 
formation in the T cell-dependent humoral response 
Splenic CD43- naïve B cells were isolated from Ly5.1 (WT) and CCR6-/- splenocytes using the AutoMACS Pro 
Separator. WT B cells were combined with CCR6-/- splenocytes, such that each donor contributed 50% of the total 
number (2x107) of donor B cells, and were subsequently transferred into naïve recipient Rag mice. Similarly, CCR6-/- B 
cells and WT splenocytes were transferred into Rag mice. As controls, recipient Rag mice received either WT or CCR6-
/- splenocytes containing a total of 2x107 donor B cells. All recipient mice were i.p. immunised with 50µg of NP-KLH 3 
days after cell transfer. The CD38- GL7+ GC response was analysed by flow cytometry 5 days later. Representative flow 
cytometry images of the GC B cell response in Rag mice are displayed (a). The frequency of GC B cells (b) and the 
contribution of CD45.1+ WT and CD45.2+ CCR6-/- cells (c) were quantified. Spleen sections of Rag mice were stained 
with antibodies against B220, CD45.1 and PNA to visualise the GC response. Representative images of GC follicles are 
displayed (d). Data was collated from 2 independent experiments (n=6 recipient mice/transfer group, except for CCR6-/- 
B cells + WT spleen where n=5).  
Mann-Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01 
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5.3. CCR6 deficiency results in an altered chemokine receptor expression 
I next investigated whether the absence of CCR6 in the CCR6-/- mice affected the expression level 
of other chemokine receptors, perhaps influencing B cell differentiation in these mice. To determine 
this, I immunised WT and CCR6-/- mice with NP-KLH for seven days. The expression of CXCR5, 
CCR7, CXCR4 and CCR6 was quantified on λ+ B cells using flow cytometry and representative 
images are displayed in Fig. 5.3.1a. Initially chemokine receptor expression was quantified on all λ+ 
B cells. As expected, the CCR6-/- mice were negative for CCR6 (Fig. 5.3.1b). The expression of 
CXCR5 and CCR7 on all λ+ B cells from CCR6-/- mice was consistent with that of WT mice (Fig. 
5.3.1b). However, CXCR4 expression was significantly increased on CCR6-/- λ+ B cells compared 
to WT λ+ B cells (Fig. 5.3.1b). Next, precursor and GC B cells were examined for chemokine 
receptor expression, as alterations in chemokine receptor expression on these cells may contribute 
to the increased GC response observed in the CCR6-/- mice in Chapter 4. A significant increase in 
CCR7 expression was detected on CCR6-/- precursor B cells compared to WT precursor B cells 
(Fig.5.3.1c). CCR7 is required for localisation to the T-B border and thus may facilitate rapid T-B 
cell conjugate movement and precursor localisation in the CCR6-/- mice. In theory, this may 
facilitate the excessive early expansion of the GC response in the absence of CCR6. In terms of 
CXCR5 and CXCR4 expression, similar levels were detected on precursor B cells between CCR6-/- 
and WT mice (Fig.5.3.1c). There was also no significant variation in CXCR5, CCR7 or CXCR4 
expression on GC B cells in CCR6-/- mice compared to WT mice (Fig. 5.3.1d). As expected, the GC 
B cell population did not express CCR6 (Fig. 5.3.1d). Overall, CCR7 may play an important role in 
T-B cell interactions and B cell differentiation during the TD humoral response in the absence of 
CCR6.  
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Figure 5.3.1. The chemokine receptor expression profile of CCR6 deficient B cells in 
the T cell-dependent humoral response 
WT and CCR6-/- mice were i.p. immunised with 100µg of NP-KLH for 7 days. The expression of CCR6, CCR7, 
CXCR5 and CXCR4 was analysed by flow cytometry on all λ+ B cells, λ+ CD38+ GL7+ precursor B cells and λ+ CD38- 
GL7+ GC B cells, and representative images are shown (a). The mean fluorescent intensities of each chemokine receptor 
was quantified on all λ+ B cells (b), precursor B cells (c) and GC B cells (d). Data was collected from 2 independent 
experiments (n=8 mice/genotype, except for CCR6 & CXCR5 stains where n=4 mice/genotype).   
Mann-Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01 
 
 
To determine whether other chemokine receptors have a similar effect to CCR6 on TD B cell 
differentiation, chemokine receptor deficient mouse strains were immunised with NP-KLH for 
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seven days. B cell differentiation was quantified in CXCR5-/-, CCR7-/-, CCR6-/- and WT mice by 
flow cytometry, using antibodies against CD38 and GL7. Representative images of B cell subsets in 
chemokine receptor deficient mouse strains are shown in Fig. 5.3.2a. As CXCR5, and CCR7 are 
known to play a major role during B cell differentiation and GC formation52,156,281, their absence 
was thought to result in a reduction of this population and indeed, this was the case. A significant 
decrease in the GC B cell population was detected in CXCR5-/- mice as expected, but also in the 
CCR7-/- mice (Fig. 5.3.2b). This finding was surprising but not altogether unexpected, considering 
the vital role that CCR7 plays in TD humoral responses. Furthermore, the reduction in GC B cells 
observed in CCR7-/- mice correlated with a significant decrease in the total number of λ+ B cells 
(Fig. 5.3.2c). Consistent with the findings in Chapter 4, there was not a higher frequency of GC B 
cells in the CCR6-/- mice compared to the WT mice, seven days after antigen challenge (Fig. 
5.3.2b). Also, the frequency of all naïve and precursor B cells between CXCR5-/-, CCR7-/-, CCR6-/- 
and WT mice were similar (Fig. 5.3.2d, e). This was also true for the frequency of plasma cells and 
memory B cells between chemokine receptor deficient mouse strains and WT mice (Fig. 5.3.2f, g). 
Overall, this analysis shows that alterations in GC formation do occur in other chemokine receptor 
deficient strains of mice, indicating just how crucial chemokine receptors are to the regulation of 
the humoral response.   
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Figure 5.3.2. The influence of CXCR5 and CCR7 on T cell-dependent Germinal Centre 
B cell formation  
The GC B cell response was analysed by flow cytometry in WT, CCR6-/-, CCR7-/- and CXCR5-/- mice, 7 days after i.p. 
immunisation with 100µg of NP-KLH. B cell differentiation was examined using antibodies against CD38 and GL7: 1) 
CD38- GL7- plasma cells, 2) CD38+ GL7- naïve B cells, 3) CD38hi GL7- memory B cells, 4) CD38+ GL7+ precursor B 
cells and 5) CD38- GL7+ GC B cells (a). The frequency of GC B cells (b), all λ+ B cells (c), naïve B cells (d), precursor 
B cells (e), plasma cells (f), and memory B cells (g) were quantified. Data was collected from 2 independent 
experiments (n=8 mice/genotype).  
Mann-Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01 
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5.4. Concluding Remarks 
This chapter has provided several insights into the mechanisms responsible for the B cell 
dysregulation observed in the absence of CCR6. Specifically, this chapter has examined the 
structural, molecular and cellular mechanisms underlying the GC response in CCR6-/- mice.  
 
As part of this investigation, antibody production was analysed by ELISA. While this analysis 
showed that antibody production was not affected in the CCR6-/- mice, it was not possible to 
discriminate between low-affinity and high-affinity antibodies. This information would provide a 
valuable addition to the assessment of the quality of the response. It has already been shown that 
more low-affinity antibody forming cells are produced in CCR6-/- mice compared to WT mice, 
seven days after antigen challenge182, though, it remains to be determined whether this translates 
into the production of more low-affinity antibodies. Furthermore, it will be interesting to determine 
not only the phenotype of these antibody forming cells, that is whether they are memory or plasma 
cells, but also whether these cells are derived from the GC or EF. A complete time course of the 
frequency of antibody forming cells is also necessary, particularly in the early stage of the humoral 
response, so that it can be correlated with the results reported here.  
 
Taking into account the reduced EF response observed in the CCR6-/- mice, and the fact that MZ B 
cell differentiation remains largely intact in these mice, it is likely that the increased low-affinity 
antibody response documented in the literature is derived from the GC. In an attempt to examine the 
quality of GC-derived antibodies or at least the frequency of mutations introduced through SHM, I 
set out to examine mutations in the variable region of IgM and IgG in GC B cells from CCR6-/- and 
WT mice, using a sequencing technique developed by Professor Thomas Winkler’s laboratory. 
Unfortunately, this was not successful due to the low-frequency of GC B cells. This approach will 
require a larger population of NP-specific B cells, which can be obtained when using the B1-8 
mouse model. Overall, this information will provide a greater understanding as to how CCR6 
ultimately affects the antibody response.  
 
Despite examining the mechanisms of the GC response in this chapter, it is imperative that future 
work examines the quality of the extrafollicular response as well, so that the impairment of this 
population in CCR6-/- mice can be adequately explained. Though, it is clear that this will be 
challenging until our understanding of the molecular mechanisms underlying the extrafollicular 
reaction is enhanced.  
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To determine whether the dysregulated B cell response observed in CCR6-/- mice was due solely to 
the loss of CCR6 on B cells, or the collective loss of CCR6 on all leukocytes, an adoptive transfer 
model was implemented. In this model, recipient mice, which lacked mature B and T cells, were 
reconstituted with mixtures of CCR6-/- and WT splenocytes, and challenged with NP-KLH. This 
investigation demonstrated that the B cell dysregulation observed in the CCR6-/- mice was not 
intrinsic to B cells, but instead due to the loss of CCR6 on multiple leukocytes. This work indicates 
that CCR6 may act more globally, by directing the migration of leukocytes to specific niches in 
secondary lymphoid organs during the course of the humoral response. For instance, CCR6 may 
direct the migration of both B and T cells to the T-B border, or may also play a role in retaining B 
cells, T cells and dendritic cells in the GC. Thus, future work should determine precisely what other 
leukocytes express CCR6 and where this expression is required.  
 
It would also be interesting to determine whether CXCR5, CCR7, CXCR4 and EBI2, chemokine 
receptors known to direct lymphocyte movement in the humoral response, are capable of re-
establishing the humoral response in the CCR6-/- mice. Such a mechanism would explain the 
transient nature of B cell dysregulation in the CCR6-/- mice. While an increase in CCR7 expression 
was detected on precursor B cells deficient in CCR6, potentially enabling enhanced migration to the 
T-B border and as a downstream effect, selection into the GC differentiation pathway, substantial 
variations in chemokine receptor expression would potentially facilitate excessive GC formation. 
The most appropriate method to examine this would be to generate mice deficient for multiple 
chemokine receptors, or create further adoptive transfer chimeras using chemokine receptor 
deficient mice.  
 
An unexpected finding arising from this study was the severely impaired GC B cell response 
observed in the CCR7-/- mice. While CCR7 is involved in B cell migration during activation, 
particularly during the localisation of B cells to the T-B border to form conjugates with Th 
cells52,158, a subsequent role for CCR7 in GC formation has not previously been established. Follow 
up studies on this work could lead to interesting insights regarding the combined expression of 
chemokine receptors in GC formation.  
 
In summary, the data presented within this chapter start to uncover the mechanisms underlying 
CCR6 deficient B cell differentiation in the humoral response. Specifically, I have demonstrated 
that the increased early GC response observed in the CCR6-/- mice can be attributed to the increased 
expression of Bcl-6, which is due to the increased production of TFH cell-derived IL-21. In addition, 
the transiently increased GC response does not appear to affect antibody production. However, 
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affinity selection of GC-derived B cells appears to be impaired, as a result of a reduction in both the 
TFH cell and FDC compartments in the GCs of CCR6-/- mice. Finally, the dysregulation of B cell 
differentiation observed in the absence of CCR6, is not solely due to the loss of CCR6 expression 
on B cells, but is a result of the loss of CCR6 expression on multiple leukocytes.  
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In the past three chapters, I have established that CCR6 is upregulated on B cells upon activation 
during the humoral response and that CCR6 expression contributes to the efficient differentiation of 
GC and EF B cells. Specifically, I have demonstrated that the loss of CCR6 is associated with 
excessive GC formation. As such, I wanted to determine whether CCR6 expression was associated 
with B cell-mediated autoimmune diseases. SLE is one such disease. SLE causes widespread 
inflammation through the deposit of autoreactive antibodies and it is quite difficult to diagnose and 
subsequently treat due to its heterogeneity. Consequently, this disease model offered the 
opportunity to explore the potential for a diagnostic biomarker. This work would also provide a 
greater understanding of the human lymphocyte subsets, as well as the dysregulation of the immune 
system in disease.  
 
The aim of this chapter was to correlate the GC and TFH cell subsets in disease with CCR6 
expression using a mouse and human model of SLE. The FasLgld or generalised lymphoproliferative 
disease (gld) mouse model develops a spontaneous systemic autoimmune disease characterised by 
enlarged secondary lymphoid organs and increased proportions of B and T cells. The accumulation 
of autoreactive lymphocytes is a result of a point mutation in the FasL gene, which encodes a 
protein that induces apoptosis by binding the Fas receptor. This mouse exhibits similar 
immunological characteristics observed in SLE and is therefore a good model of autoimmunity. 
Given the observation that the absence of CCR6 is associated with excessive GC formation, I 
proposed that in a dysregulated immune response, where excessive GC proliferation occurs, CCR6 
expression would be reduced. To establish this, CCR6 expression was quantified on B and T cell 
populations using flow cytometry. The first part of this chapter presents findings obtained from the 
gld mouse model, while the second half details the findings obtained in the study of SLE.  
 
6.1. CCR6 expression is dysregulated in FasLgld mice 
As naïve gld mice spontaneously develop systemic autoimmunity, they were examined at 13 weeks 
of age when disease was evident. For controls, age-matched naïve WT mice were used. 
Lymphocytes were examined in the spleen, lymph nodes and blood of gld and WT mice.  
 
Initially, CCR6 expression was quantified on all B cells in the spleen, lymph node and blood, 
between gld and WT mice. Representative images of CCR6 and B220 expression between gld and 
WT mice are displayed in Fig. 6.1.1a. Similar frequencies of B cells were detected between gld and 
WT mice (Fig. 6.1.1b). However, there were significant reductions in the frequencies of B cells that 
expressed CCR6, in the spleen, lymph node and blood of gld mice compared to WT mice (Fig. 
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6.1.1.c). Furthermore, of those B cells expressing CCR6, CCR6 expression was increased in gld 
mice, and was significantly so in the lymph node (Fig. 6.1.1d).  
 
 
 
Figure 6.1.1. The CCR6+ B cell compartment in murine systemic autoimmunity 
The B cell compartment of the spleen, inguinal lymph node and blood, in WT and gld mice aged 13-15 weeks, was 
analysed by flow cytometry. The expression of CCR6 on B cells was analysed and representative images are displayed 
(a). The frequency of all B cells (b) and CCR6+ B cells (c), along with the mean fluorescence intensity of CCR6 
expression on the CCR6+ B cells (d) was quantified. Figure consists of data obtained from 2 independent experiments 
(n=8 mice/genotype). 
Mann-Whitney two-tail t-test, *significant at p<0.05; ***significant at 0.001 
 
 
To determine which B cells upregulated CCR6 expression in gld mice, B cell subsets delineated by 
CD38 and GL7 expression were examined in the spleen, lymph node and blood. The gating strategy 
used is depicted in Fig. 6.1.2a. A significantly higher frequency of GC B cells (CD38- GL7+) was 
detected in the spleen, lymph node and blood of gld mice compared to WT mice (Fig. 6.1.2b). This 
correlated with a significant increase in the frequency of plasma cells (CD38- GL7-) in the spleen, 
lymph node and blood, and precursor B cells (CD38+ GL7+) in the spleen and lymph node, of gld 
mice compared to WT mice (Fig. 6.1.2b). A significantly reduced frequency of naïve B cells 
(CD38+ GL7-) was also detected in the spleen, lymph node and blood of gld mice compared to WT 
mice (Fig. 6.1.2b). In addition, the frequency of memory B cells (CD38hi GL7-) was significantly 
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increased in the lymph node and blood of gld mice compared to WT mice (Fig. 6.1.2b). These 
fluctuations in B cell frequency are consistent with our current understanding of humoral responses, 
whereby naïve B cells become activated, exit the naïve B cell population and enter the precursor 
stage, differentiating into GC B cells and subsequently, plasma and memory B cells.   
 
Consistent with the increased CCR6 expression observed on the whole B cell population in gld 
mice, CCR6 expression was also increased on B cell subsets in gld mice compared to WT mice. 
Specifically, CCR6 expression was significantly higher on memory B cells (CD38hi GL7-) of the 
spleen, lymph node and blood in gld mice than WT mice (Fig. 6.1.2c). CCR6 expression was also 
significantly increased on naïve B cells (CD38+ GL7-) in the lymph node and precursor B cells 
(CD38+ GL7+) in the spleen and lymph node, in gld mice compared to WT mice (Fig. 6.1.2c). 
Interestingly, CCR6 expression was significantly reduced in the plasma cells (CD38- GL7-) of the 
lymph node from gld mice compared to WT mice (Fig. 6.1.2c). Importantly, the increased CCR6 
expression observed in gld mice does not reflect an increase in the frequency of these populations. 
The upregulation of CCR6 on B cells contradicts the initial hypothesis and suggests that CCR6 
expression on B cells may contribute to the pathophysiology of systemic autoimmunity.  
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Figure 6.1.2. The characteristics of CCR6 expression during B cell differentiation in 
murine systemic autoimmunity 
CCR6 expression was analysed by flow cytometry in naïve FasLgld and WT mice aged 13-15 
weeks. B cell subsets were identified by CD38 and GL7 expression: 1) CD38- GL7- plasma cells, 2) 
CD38+ GL7- naïve B cells, 3) CD38hi GL7- memory B cells, 4) CD38+ GL7+ precursor B cells and 
5) CD38- GL7+ GC B cells, and representative images of WT and FasLgld mice are shown (a). The 
frequency of B cell subsets (b) and mean fluorescence intensity of CCR6 on each B cell subset (c) 
was quantified in the spleen, inguinal lymph node and blood. Figure represents data obtained from 2 
independent experiments (n=8 mice/genotype). 
Mann-Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01; ***significant at 
0.001 
 
 
Given the B cell alterations established in the gld mice, I next investigated whether TFH cells were 
also increased during disease. As mentioned previously, murine TFH cells are identified by their 
high expression of both CXCR5 and PD-1 on CD4+ T cells274,281,285. The gating strategy used to 
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identify TFH cells is displayed in Fig. 6.1.3a. A significantly larger proportion of TFH cells 
(CXCR5hi PD-1hi) was detected in the spleen, lymph node and blood of gld mice compared to WT 
mice (Fig. 6.1.3b). This coincided with a significantly larger proportion of intermediate TFH cells 
(CXCR5int PD-1int) in the gld mice compared to the WT mice (Fig. 6.1.3b). In addition, there was a 
significant reduction in the frequency of non-TFH cells (CXCR5- PD-1-) in gld mice compared to 
WT mice (Fig. 6.1.3b). A significant reduction in the frequency of lymph node CD4+ T cells was 
also observed in the gld mice compared to WT mice (Fig. 6.1.3b). Therefore, it appears that more 
non-TFH cells are recruited into TFH cell differentiation, resulting in the large intermediate and 
genuine TFH cell populations observed in the gld mice.  
 
Following the analysis of T cell frequency in gld mice, each subset was then examined for CCR6 
expression. The expression of CCR6 was significantly upregulated on all CD4+ T cells and non-TFH 
cells from the spleen, lymph node and blood of gld mice compared to WT mice (Fig. 6.1.3c, d). 
However, CCR6 expression was significantly reduced on intermediate TFH cells in the gld mice 
compared to the WT mice (Fig. 6.1.3c, d). Also, there was no significant variation in the levels of 
CCR6 expression on TFH cells in the spleen, lymph node and blood between gld and WT mice (Fig. 
6.1.3c, d). Again, alterations in CCR6 expression were not a result of alterations in T cell 
frequency. Overall, this data provides further evidence that CCR6 contributes to TFH cell 
differentiation in humoral responses and may contribute to the pathophysiology of systemic 
autoimmunity.  
 
Consequently, excessive GC and TFH cell differentiation in the FasLgld mouse model is associated 
with increased CCR6 expression on naïve, memory and precursor B cells, and reduced CCR6 
expression on intermediate TFH cells. These results indicate that CCR6 could potentially be used as 
a biomarker to detect lymphocyte dysregulation, and therefore autoimmune disease. 
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Figure 6.1.3. The expression of CCR6 on T Follicular Helper cells in murine systemic 
autoimmunity 
The TFH cell compartment was analysed by flow cytometry in naïve WT and FasLgld mice, aged 13-15 weeks. Subsets 
of TFH cells were distinguished by their expression of CXCR5 and PD-1: 1) CXCR5- PD-1- non-TFH cells, 2) CXCR5int 
PD-1int intermediate TFH cells and 3) CXCR5hi PD-1hi TFH cells, and representative images of WT and FasLgld mice are 
displayed (a). The frequencies of T cell subsets (b) and mean fluorescence intensity of CCR6 expression on each T cell 
subset (c) was quantified in the spleen, inguinal lymph node and blood. Representative images of CCR6 expression in 
TFH cell subsets of WT and gld mice are displayed (d). Figure represents data collected from 1 experiment (Spleen n=8 
WT mice, 4 FasLgld mice; Lymph node & Blood n= 4mice/genotype). 
Mann-Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01 
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6.2. Prominent CCR6 expression identifies SLE 
Having gained promising results from the gld mouse model, I examined whether CCR6 expression 
was also altered in humans during SLE. While a previous study has broadly examined the 
frequency of CCR6+ B cells in SLE221, it was limited as the authors did not discriminate between B 
cell subsets and it had few participants. Therefore, I conducted a small preliminary study in 
Tasmania, in collaboration with Dr. Murray Adams. Participants were recruited into the study based 
on whether or not they had a diagnosis of SLE and were between the ages of 18–80 years.  
 
Participants provided a sample of blood, from which leukocytes were isolated for flow cytometry 
analysis. The frequency and mean fluorescence intensity of CCR6 expression was quantified on B 
and T cell populations in participants diagnosed with SLE and healthy controls. The CD19+ B cell 
population in humans can be delineated into 6 subsets using antibodies against CD38 and IgD: 
CD38low/int IgD+ naïve B cells, CD38+ IgD+ Pre-GC B cells, CD38low/int IgD- memory B cells and 
CD38+ IgD- B cells represent both GC and plasma cells 286. GC B cells were separated from plasma 
cells based on their expression of CD27286. The gating strategy employed to identify these subsets is 
displayed in Fig. 6.2.1a. CCR6 expression was quantified on each of these subsets and 
representative images are shown in Fig. 6.2.1b. The frequency of all CD19+ and CCR6+ CD19+ 
cells in SLE participants, appeared slightly elevated, but were not significantly different to control 
participants (Fig. 6.2.1c). Interestingly, a significant reduction in the frequency of Pre-GC B cells 
was detected in SLE participants compared to controls (Fig. 6.2.1c). The reduction in Pre-GC B 
cells during SLE could be attributed to increased GC seeding in secondary lymphoid organs, 
resulting in fewer circulatory B cells. The GC population also appeared reduced in participants 
diagnosed with SLE, although this was not significant (Fig. 6.2.1c). There was also no significant 
alterations in the plasma and memory B cell populations between SLE and control participants (Fig. 
6.2.1c).  
 
It is perplexing that pre-GC and GC B cells can be detected in the blood, given that they inherently 
reside within secondary lymphoid organs. It is possible that these circulatory populations represent 
distinct populations with migratory capabilities that share similar characteristics to genuine pre-GC 
and GC B cells. Such populations would allow the expansion of the B cell response to multiple 
secondary lymphoid organs. To clarify this, analysis of secondary lymphoid organs would provide a 
better indication of the B cell compartment, however these are less accessible in humans.  
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Figure 6.2.1. The expression of CCR6 in the circulating B cell population during 
Systemic Lupus Erythematosus 
Human peripheral CD19+ B cell subsets: memory B cells (1&2), GC/plasma cell (PC) (3), Pre-GC cells (4) and memory 
B cells (5&6), were identified by flow cytometry according to their expression of CD38 and IgD (a). The GC subset 
was distinguished from PCs based on their expression of CD27. Representative images of CCR6 expression on CD19+, 
naïve, Pre-GC, GC/PC and memory B cells, in SLE and control participants are shown (b). The frequency of all CD19+, 
CCR6+ CD19+ naïve, Pre-GC, GC, PC and memory B cells were quantified in SLE and control participants (c). The 
mean fluorescence intensity of CCR6 expression was quantified in each B cell subset between SLE and control 
participants (d). (n= 19 SLE, 14 Controls). 
Mann-Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01 
CHAPTER 6 
THE EXPRESSION PROFILE OF CCR6 IN SYSTEMIC LUPUS ERYTHEMATOSUS 
 
 
J. BANNAN 
THE ROLE OF CCR6 IN B CELL DIFFERENTIATION DURING THE HUMORAL IMMUNE RESPONSE 
  
108 
Following the quantification of B cell frequency, CCR6 expression was examined. A significant 
increase in CCR6 expression was detected on all CD19+ B cells in SLE participants compared to 
control participants (Fig. 6.2.1d). When individual B cell subsets were examined, the naïve and 
memory B cells were found to have a significantly higher expression of CCR6 in SLE participants 
than control participants (Fig. 6.2.1d). In addition, the Pre-GC, GC and plasma B cells appeared to 
have a higher expression of CCR6 in SLE participants compared to control participants (Fig. 
6.2.1d). The increase in CCR6 expression on these B cells during SLE reflects the overall increase 
in CCR6 expression observed on the CD19+ B cell population. Although contrary to initial 
expectations, the findings from the mouse and human model of SLE concur with each other and 
demonstrate that CCR6 expression is increased on naïve and memory circulatory B cells during 
SLE. This finding shows that CCR6 can be used as a biomarker of disease, due to its pronounced 
expression during SLE.   
 
Having analysed the B cell compartment in SLE, I next examined the TFH cell population. Human 
TFH cells are more difficult to identify than mouse, due to the lack of consistency in defining TFH 
cells in the clinical field. While initial studies defined TFH cells by high CXCR5 expression on 
CD4+ T cells119,273, others have reported on TFH cells as CXCR5+ ICOS+ CD4+ T cells287,288, 
CXCR5+ PD-1+ CD4+ T cells289, CXCR5+ CCR7- CD4+ T cells290 and CXCR5+ PD-1+ CCR7- CD4+ 
T cells276,291. Again, it has been questioned whether these circulatory TFH cells are in fact genuine. 
For instance, while the circulatory TFH cells represent the TFH cells in secondary lymphoid organs, it 
has been suggested that they act as memory cells, descendants of TFH cells that are capable of 
differentiating into fully-fledged TFH224,276,292. Consequently, I chose to define the human 
circulatory TFH cell population as CXCR5+ PD-1+ CCR7- CD4+ T cells and this gating strategy is 
presented in Fig. 6.2.2a. This classification allows the accurate detection of circulatory TFH cells 
and is comparable to the literature. When the T cell population was examined, a significant increase 
in the frequency of circulating TFH cells was detected in SLE participants compared to control 
participants (Fig. 6.2.2b). However, the frequency of all lymphocytes, CD4+ T cells and CXCR5+ 
CD4+ T cells, were similar between SLE and control participants (Fig. 6.2.2b).  
 
 
CHAPTER 6 
THE EXPRESSION PROFILE OF CCR6 IN SYSTEMIC LUPUS ERYTHEMATOSUS 
 
 
J. BANNAN 
THE ROLE OF CCR6 IN B CELL DIFFERENTIATION DURING THE HUMORAL IMMUNE RESPONSE 
  
109 
 
 
Figure 6.2.2. The expression of CCR6 on the circulating T Follicular Helper cell 
population in Systemic Lupus Erythematosus 
Human peripheral TFH cells were identified by flow cytometry as CXCR5+ CD4+ PD-1+ CCR7- cells and representative 
images of SLE and control participants are shown (a). The frequency of all lymphocytes, CD4+ cells, CXCR5+ CD4+ 
cells and TFH cells were quantified in SLE and control participants (b). The mean fluorescence intensity of CCR6 
expression was quantified on each T cell subset in participants diagnosed with SLE and controls (c). Representative 
images of CCR6 expression in the T cell subsets are displayed (d). (n= 13 SLE, 16 Controls).  
Mann-Whitney two-tail t-test, *significant at p<0.05; **significant at p<0.01 
 
 
Next, CCR6 expression was quantified on T cell subsets during SLE. Interestingly, CCR6 
expression was significantly reduced on all lymphocytes, CD4+ T cells and TFH cells in SLE 
participants compared to control participants (Fig. 6.2.2c, d). There also appeared to be a reduction 
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in CCR6 expression on intermediate TFH cells in SLE participants compared to control participants 
(Fig. 6.2.2c, d). This decrease in CCR6 expression on human TFH cells, is similar to that of the 
intermediate TFH cells observed in gld mice and also highlights the potential of CCR6 to be used as 
a marker of systemic autoimmune diseases.  
 
While the results obtained from this clinical study of SLE are original, significant and interesting, it 
is important to consider their relationship to a normal heterogeneous population. Participants from 
this study were sampled from the local state population and the data generated is not normally 
distributed, as was determined by graphical inspection. Hence, the Mann-Whitney t-test was 
selected for statistical analysis. Due to the small samples size in this study, it is possible that the 
data does not display a normal distribution, whereas a large population would accurately show 
whether the population is normally distributed or not. Thus, a retrospective power analysis was 
carried out based on the effect sizes (mean and standard deviation) observed here for CCR6 
expression on B and T cell subsets. The exposure rate for B and T cell analysis was 42.42 % and 
44.82 % respectively. This revealed that the current study had approximately 20% power for CCR6 
expression on B cells and approximately 50% power for CCR6 expression on T cells (Table 6.2.1). 
In clinical studies, it is widely agreed that a power of 80% is an acceptable probability of detecting 
statistically significant effects, that is, variations with a p-value <0.05. It is clear that the current 
study is underpowered, and such a small population would be more likely to produce both type-1 
(false positive) and type-II (false negative) errors, thereby placing the reliability of the observed 
effects into question. To rectify this, this study should be repeated with a larger cohort so that 
greater sensitivity can be provided to detect effects of the magnitude depicted here. It is also 
necessary to consider the age and gender of participants in this study. While age and gender are 
associated with SLE293-296, preliminary analysis in this study indicates that age and gender is not 
associated with chemokine receptor expression, or lymphocyte frequency in SLE. It has also been 
documented that chemokine receptor expression is not associated with age or gender in SLE221. 
However, it is possible that chemokine receptor expression and lymphocyte frequency is associated 
with disease severity. This concurs with published literature showing that chemokine expression 
and circulatory B cell frequency is correlated with SLE disease activity297-300. The current study did 
not have ethics approval to document a detailed medical history, including disease activity or 
severity, secondary inflammations and all treatments in participants diagnosed with SLE. As such, 
the possibility that these factors have contributed to chemokine receptor expression and lymphocyte 
frequency cannot be excluded and would need to be investigated in future studies. While this study 
was restricted, its purpose was as a preliminary investigation into CCR6 expression during 
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autoimmune disease, the results of which justify the need for a further large-scale study in the 
future.  
 
Table 6.2.1. Statistical power of Systemic Lupus Erythematosus study 
 
CCR6 Expression Current 
Power 
Sample size required for 
80% Power 
CD19+ B cells 20 % 210  (121 Controls & 89 SLE) 
Pre-GC B cells 19 % 216  (124 Controls & 92 SLE) 
GC/PC B cells 19 % 220  (127 Controls & 93 SLE) 
Total Memory B cells 37 % 98    (56 Controls & 42 SLE) 
Total Naïve B cells 20 % 204  (117 Controls & 87 SLE) 
Lymphocytes 29 % 113  (62 Controls & 51 SLE) 
CD4+ T cells 53 % 54    (30 Controls & 24 SLE) 
CXCR5+ CD4+ T cells 59 % 48    (26 Controls & 22 SLE) 
CXCR5+ PD-1+ CCR7lo CD4+ T cells  66 % 41    (23 Controls & 18 SLE) 
 
 
6.3. Concluding Remarks 
Throughout this chapter, I have examined CCR6 expression on B and T cell subsets in a mouse and 
human model of systemic autoimmunity. One important aspect to consider in this study is the 
validity of the mouse model of autoimmunity. Mouse models are extremely useful tools to 
investigate disease susceptibility, mechanisms of disease, and therapeutic strategies, because they 
offer greater sample accessibility than humans. Currently, several different mouse models are used 
in SLE research301. I have made use of the FasLgld strain, which has a mutation in the FasL gene, 
causing the spontaneous development of systemic autoimmune disease. It is similar to that of the 
MRLlpr mouse model, which has a mutation in the lpr gene. The gld mouse and other such strains, 
are considered SLE-like models as they present with similar immunological attributes that 
characterise SLE. Specifically, the gld mouse model exhibits lymphadenopathy and autoantibody 
production.  
 
To correlate the results obtained between mice and humans, I analysed lymphocytes in the blood 
and secondary lymphoid organs during systemic autoimmune disease. In the gld mice, significant 
increases in the precursor, GC, plasma cell and memory B cells, along with a significant decrease in 
naïve B cells, were detected when compared to WT mice. Also, CCR6 expression was significantly 
increased on naïve and memory B cells in gld mice compared to WT mice. These alterations in the 
B cell compartment of gld mice correlated with a significant reduction in non-TFH cells and 
significant increases in the intermediate TFH and TFH cell populations. Furthermore, CCR6 
expression was significantly increased on all CD4+ T cells and non-TFH cells, and it was 
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significantly reduced on intermediate TFH cells. Thus, the effector B and T cell populations of gld 
mice were generally increased during systemic autoimmunity, and while CCR6 expression trends 
were different between B and T cells, significant variations were detected during systemic 
autoimmunity. Finally, the systemic lymphoproliferation reported here in the gld mice, is consistent 
with the literature302. 
 
In the study of SLE, I identified human B cell subsets as CD38lo/int IgD+ naïve cells, CD38hi IgD+ 
pre-GC B cells, CD38hi IgD- CD27+ GC B cells, CD38hi IgD- CD27+ plasma cells and CD38low/int 
IgD- memory B cells. This is consistent with previously published work286. In addition, human T 
cells were detected based on CXCR5, CCR7, PD-1 and CD3 expression, and this profile was also 
consistent with previously published reports303. During SLE, the increased CCR6 expression on 
naïve and memory B cells, and the reduced CCR6 expression on all CD4+ T cells and TFH cells, 
reflected the trends of CCR6 expression observed in the murine model of systemic autoimmunity. 
In terms of population frequency, a significant increase in TFH cells was observed during SLE, 
correlating with the murine model, however, a significant decrease in Pre-GC B cells was detected 
during SLE, differing to the data collected in gld mice. Whilst there is variability in the data 
between the human and murine models of systemic autoimmunity, attributed to both species and 
disease differences, it is reassuring to observe similar alterations in the population frequency and 
CCR6 expression between both models.  
 
This study provided invaluable insights into autoimmunity, however, it was restricted by the low 
number of participants. Statistical significance was achieved as the characteristics examined were 
not normally distributed, allowing a non-parametric t-test to be used for analysis. Furthermore, the 
number of participants in this study is similar to other published reports in this field, including the 
publication by Henneken and colleagues (2005), which examined the frequency of CCR6+ B cells 
during SLE. Together, these studies provide strong evidence demonstrating a role for CCR6 in the 
pathophysiology of SLE.  
 
In summary, the findings established in the FasLgld mouse model were applied to a clinical study of 
SLE, which demonstrated that SLE participants can be distinguished from healthy controls by 1) the 
increased CCR6 expression on the total circulatory B cell population, reflecting the upregulated 
CCR6 expression on naïve and memory B cells and 2) the reduced expression of CCR6 on the 
circulatory TFH cell population. These prominent alterations highlight the potential for the 
development of a biomarker that targets CCR6 expression. Such a marker would be beneficial, as it 
would identify SLE, and in theory other autoimmune diseases that feature B cell dysregulation. 
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However, a larger follow up study with a more clinically defined cohort is needed before this 
application can be advocated. Overall, these findings are important for not only autoimmune 
disease, but they also provide insight into the mechanisms of protective antibody responses 
generated during disease and vaccination. 
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Given the distinct expression of CCR6 during TD B cell differentiation documented in the 
literature, it was surprising that very little was known regarding the function of this chemokine 
receptor. Thus, in considering the fundamental role that chemokine receptors, more broadly, have in 
positioning lymphocytes, I set out to determine this unknown. I hypothesised that CCR6 contributes 
to B cell differentiation in the humoral immune response. In this thesis, I have provided a direct 
quantitative assessment of the role of CCR6 during B cell differentiation. As briefly discussed in 
the previous four results chapters, this work has revealed a number of previously unreported 
features of TD humoral responses. Furthermore, three findings, the principal findings of this thesis, 
have emerged: 
1) CCR6 is upregulated upon follicular B cell activation  
2) CCR6 contributes to efficient GC and EF B cell differentiation 
3) CCR6 is associated with SLE  
These findings and their implications are discussed below in the context of the current literature in 
the field.  
 
7.1. CCR6 is upregulated upon follicular B cell activation  
B cell positioning in secondary lymphoid organs is largely determined by CXCR5 and CCR752,158. 
Though CCR6 has been implicated as an additional receptor in this process, its expression and 
migratory capacity has not been fully defined. In this study, I investigated the ability of antigen-
specific B cells to induce CCR6 expression during activation. HEL activation of MD4 B cells in 
vitro for 24 hrs, significantly increased the intensity of CCR6 expression on the cell surface. CCR6 
expression was maximal 8 hrs after stimulation. However, the cell surface expression of CCR6 after 
B cell activation did not correlate with the mRNA expression of CCR6. In fact, CCR6 mRNA 
levels were significantly reduced following antigen-specific activation. It was possible that an early 
transient increase in CCR6 mRNA could have occurred, such that 8 hrs post activation was too late 
to observe an increase in mRNA. Thus, transcripts were examined early after activation. Again, 
CCR6 mRNA was significantly reduced 2 hrs after B cell activation. These results differ from 
studies using human peripheral blood and tonsillar B cells activated ex vivo184-186. For instance, Liao 
and colleagues (2002) activated human B cells through IgM cross-linking for 3 days and reported 
no change in either surface expression or mRNA levels of CCR6. This discrepancy is likely due to 
the difference in the method used to activate B cells and of course, species variation between 
studies. It is generally accepted though, that cell surface expression does not always reflect 
transcript levels and in this case, it is possible that upon activation, B cells may export their 
intracellular supply of CCR6 to the cell surface and simultaneously downregulate CCR6 gene 
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expression, offering an explanation for the increased surface expression of CCR6 and decreased 
levels of CCR6 mRNA.  
 
When CCR6 expression was examined on antigen-specific B cell subsets defined by CD38 and 
GL7 expression in vivo, a distinct pattern was observed. Naïve and memory B cells were found to 
have a moderate expression of CCR6 and this expression was reduced on GC B cells and to a lesser 
extent plasma cells. This expression profile is consistent with published studies in both mice188,190 
and humans185-187. In accordance with the previous in vitro findings of this study, CCR6 expression 
was significantly increased on precursor B cells in vivo, which appear following activation, prior to 
GC differentiation. This confirms the physiological relevance of the in vitro model of B cell 
activation and is in agreement with a recent publication, documenting the appearance of CCR6hi 
CD95+ GL7+ IgD+ B cells, prior to GC formation73. Additionally, this study has revealed that CCR6 
is expressed on T-B cell conjugate pairs ex vivo. However, it is clear that CCR6 is not an absolute 
requirement for T-B cell interactions, as CCR6-/- mice are still capable of efficiently forming T-B 
cell conjugates. Overall, these results suggest that CCR6 is involved in the early B cell events of the 
humoral response.  
 
The question that remains is how does CCR6 affect B cells? Taking into account that CCR6 
belongs to a family of G-protein coupled chemokine receptors, well known for guiding migration, 
and that CCR6-dependent migration of follicular B cells has been previously reported188,189, it is 
likely that CCR6 directs activated B cell movement. Specifically, CCR6 expression may be 
required for the migration of naïve, memory and precursor B cells around secondary lymphoid 
organs, but must be downregulated on B cells for entry into the GC. Furthermore, this study has 
demonstrated that CCL20 is produced by TFH cell precursors, which are known to differentiate at 
the T-B border. The intermediate TFH cell-secreted CCL20 may provide a signal that retains CCR6+ 
B and T cells at the T-B border. In line with this, CCL20 has been shown as chemotactic for human 
lymphocytes164,170. However, studies documenting CCL20 expression are lacking. Furthermore, the 
CCR6-CCL20 dependent migration of antigen-specific activated B cells has not been investigated 
and will need to be directly established. Alternatively, other cells within secondary lymphoid could 
also express CCL20.  
 
Interestingly, CCR6 shares a similar expression profile on B cells, to another chemokine receptor, 
EBI2, which is known to contribute to B cell movement. EBI2 is expressed at high levels in naïve B 
cells and is transiently upregulated following B cell activation and during T cell help304,305. EBI2 
expression is downregulated on GC B cells, but maintained on plasma cells304. In fact, it has been 
CHAPTER 7 
DISCUSSION AND CONCLUSION 
 
 
J. BANNAN 
THE ROLE OF CCR6 IN B CELL DIFFERENTIATION DURING THE HUMORAL IMMUNE RESPONSE 
  
 117 
demonstrated that EBI2 expression on activated B cells is essential for B cells to migrate to 
extrafollicular sites to establish EF, whereas its downregulation allows B cells to migrate inside the 
B cell follicle to establish GC follicles157,158. Furthermore, EBI2 contributes to the CXCR5- and 
CCR7-dependent B cell organisation at the T-B cell border305. Thus, it is plausible to speculate a 
similar role for CCR6. CCR6 expression may aid B cell localisation to the T-B cell border and the 
migration of precursor B cells at the edge of B cell follicles, prior to B cell fate decisions. This role 
would be consistent with a model of balanced responsiveness by B cells, originally proposed by 
Reif and colleagues (2002). In this model, B cells alter their chemokine receptor expression in 
response to antigen, by integrating the various chemokine signals that spatially define secondary 
lymphoid organs. In this way, B cells are able to constantly re-position themselves as necessary. It 
is likely that this model extends further then the migration effects of CXCR5 and CCR7, such that 
B cells are also influenced by CXCR4 and EBI2. Given the distinct expression of CCR6 on B cells 
throughout the TD humoral response and its prominent increase on activated B cells, it is 
reasonable to propose that CCR6 also contributes to this process. In support of this, evidence from 
this study shows that CXCR5, CCR7 and CXCR4 surface expression is significantly reduced in 
CCR6-/- B cells compared to WT, after activation in vitro. Furthermore, CCR7 expression was 
significantly increased on CCR6-/- precursor B cell compared to WT B cells in vivo. This indicates 
that CCR6 may work with several chemokine receptors to correctly position B cells. This would be 
ideally confirmed using chemokine receptor deficient double knockouts or mixed adoptive transfer 
models. 
 
7.2. CCR6 contributes to efficient B cell differentiation  
The upregulation of CCR6 during B cell activation, in combination with its distinct expression on 
mature B cell subsets in response to TD antigens, indicates a critical role for CCR6 in B cell 
positioning. The extent of this role was examined in CCR6-/- mice immunised with NP-KLH. This 
study has demonstrated that in the absence of CCR6 there is a significant increase in the GC B cell 
response. The fact that this increase was observed only at day 3 and 5 post immunisation 
emphasises that CCR6 primarily acts early in the humoral response. There are several possible 
explanations for the increased GC response documented in the CCR6-/- mice. This alteration could 
be a result of either an increased number of B cells being activated, enhanced B cell proliferation, or 
alternatively, a defect in apoptosis resulting in the accumulation of GC B cells. 
 
A significant increase in total frequency of antigen-specific B cells was also observed in CCR6-/- 
mice 5 days after immunisation, correlating with the increase in GC B cells. This suggests that more 
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B cells undergo proliferation or expansion, rather than an inherent increase in the follicular B cell 
compartment in CCR6-/- mice. Furthermore, the significant reduction in the frequency of naïve B 
cells in CCR6-/- mice at days 3 and 5 post antigen challenge, suggests that more antigen-specific B 
cells are activated and recruited into B cell differentiation. This does not exclude the possibility that 
B cells are preferentially selected to expand into GCs. To determine if CCR6-/- B cells are 
preferentially recruited to undergo GC differentiation, the transcriptional profile of GC B cells was 
examined. This analysis demonstrated that CCR6 deficient GC B cells have an inherent increase in 
Bcl-6 expression – the master regulator of the GC reaction, indicating that activated B cells are 
encouraged to proliferate in the GC. Furthermore, this increase in Bcl-6 expression in GC B cells is 
likely caused by the increase in IL-21 production by TFH cells, as IL-21 is known to directly act on 
Bcl-6 in GC B cells121,122,279. In fact, it has been demonstrated that IL-21 mediated interactions 
between TFH cells and GC B cells, enable the selection of high-affinity B cells clones306. 
 
Given that CCR6 is expressed on naïve and activated B cells and is then downregulated on GC B 
cells, it is possible that Bcl-6 represses CCR6 expression during GC B cell differentiation. Bcl-6 is 
already known to repress the expression of genes associated with B cell differentiation142, and the 
reduction of CCR6 expression on GC B cells may enable B cells to migrate into the follicle to 
establish GC follicles. In this way, increased Bcl-6 levels would cause a reduction in CCR6 
expression, thereby enabling increased GC formation in a normal response. This theory is supported 
by the significant reduction in CCR6 gene expression detected during in vitro B cell activation. 
Indeed, this is also the case for EBI2. Whilst EBI2 expression is upregulated upon B cell activation, 
Bcl-6 represses EBI2 expression, allowing B cells to migrate into the follicle to form GCs142,304. 
Considering the analogous expression between CCR6 and EBI2, it is possible that both chemokine 
receptors have similar roles, or in fact, may work together to position B cells.  
 
Although the GC response was altered, there was, remarkably, no major effect on the quality or 
efficiency of the GC reaction. Notably, the light and dark zone structure of the GC was maintained 
in the absence of CCR6, indicating firstly that CCR6 is not required for the organisation of B cells 
within the GC and more importantly, that the GC reaction occurs as per normal. In support of this 
observation, there was no significant difference in the mRNA expression of AID, the enzyme 
responsible for initiating SHM and isotype switching, demonstrating that the expression of CCR6 
does not influence the genetic events of the GC reaction. While significantly higher levels of Id2 
were detected in CCR6-/- GC B cells, this did not seem to suppress AID expression or inhibit 
subsequent B cell differentiation. Furthermore, the increased production of IL-21 from TFH cells did 
not appear to induce plasma cell nor long term memory differentiation in this study, as would be 
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expected121,122,307. In agreement with these findings, plasma cell differentiation did not appear to be 
dysregulated, as indicated by the similar levels of Blimp-1 and IRF4 observed between WT and 
CCR6-/- GC B cells. This was substantiated by the similar frequency of plasma cells generated 
between CCR6-/- and WT mice. However, this was not the case for memory B cells. Brief, yet 
significant increases in the frequency of early memory B cells were observed in CCR6-/- mice, 
approximately correlating with the increased GC responses detected previously. Despite the altered 
GC response, there did not appear to be an alteration in the quantity of antibodies secreted. Antigen-
specific serum IgM and IgG levels were similar between CCR6-/- and WT mice. This did not though 
exclude the possibility that antibody affinity is altered in the absence of CCR6. With this in mind, 
the Körner laboratory has previously shown that more low-affinity than high-affinity antibody 
forming cells are present in CCR6-/- mice compared to WT mice, seven days after antigen 
challenge182. This result contradicts the expectation that an increased GC response would generate 
more high-affinity than low-affinity antibodies. Unfortunately, attempts in this study to 
conclusively demonstrate the quality of SHM in CCR6-/- GC B cells, which would have provided 
insights into the affinity of terminally differentiated B cells derived from the GC, were 
unsuccessful, due to the low frequency of the GC population. Given that AID expression was not 
altered in CCR6-/- GC B cells, it is likely that SHM is not impaired, but rather a defect in affinity 
selection is responsible for the altered antibody affinity in the absence of CCR6.  
 
Surprisingly, despite an increased GC response in the CCR6-/- mice, there was not a corresponding 
increase in the frequency of TFH cells nor FDCs, rather both populations occurred at a similar 
frequency between CCR6-/- and WT mice. There are two possible consequences of this finding. 
Firstly, the TFH cells and FDCs may be distributed equally between follicles, providing a greater 
selection pressure for GC B cells and theoretically favouring the production of high-affinity B cells. 
However, this is not the case, as evidenced by the increased frequency of low-affinity antibody 
forming cells in CCR6-/- mice182. Therefore it is more appropriate to speculate that the selection of 
B cells in CCR6-/- mice is less efficient, as the same number of TFH cells and FDCs are expected to 
serve an increased GC response in the CCR6-/- mice 5 days after antigen challenge. This would 
therefore offer an explanation for the increased number of low-affinity antibody forming cells in the 
CCR6-/- mice. Alternatively, the EF response could have accounted for the increased population of 
low-affinity antibody forming cells: however, this possibility was eliminated when it was 
demonstrated that the peak of the EF response was significantly reduced in CCR6-/- mice.  
 
Interestingly, the reduction of EF B cells observed in CCR6-/- mice indicates that EF B cells 
normally express CCR6. Of course, this needs to be substantiated in a WT model. Also, the 
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decrease in the EF population in the absence of CCR6 indicates that activated B cells fail to migrate 
to extrafollicular sites. Furthermore, the increased GC B cell response observed in the CCR6-/- 
mice, theoretically coincides with the rapid production of EF-derived antibody-secreting. It is 
possible that the increased GC response has actually compensated for the loss of the EF response, 
such that activated B cells deficient for CCR6 fail to migrate to extrafollicular sites, preferentially 
migrating into the B cell follicle. This can be reconciled when considering the expression of CCR6 
on EF and GC B cells. The GC B cells normally have a reduced expression of CCR6, suggesting 
that after activation, B cells selected to differentiate into GCs must downregulate CCR6 expression 
to enter the B cell follicle and establish GC follicles. Whereas B cells destined to form EF, must 
maintain CCR6 expression to migrate to extrafollicular sites that is, if EF B cells do indeed express 
CCR6. In this way, antibody-secreting cells of low-affinity may be quickly generated in the EF 
during a normal response.  
 
By the same token, EBI2 seems to perform a similar function to the one proposed here for CCR6. In 
the absence of EBI2, the EF response is diminished, while the GC response continues efficiently304. 
It will be necessary to determine whether the expression of EBI2 and CXCR4, the chemokine 
receptors that direct B cell migration to extrafollicular sites and thus EF formation, is altered in 
CCR6-/- mice. This will indicate whether CCR6 contributes to the migration of extrafollicular B 
cells. The fact that the extrafollicular response is not completely abolished in the CCR6-/- mice 
indicates that other chemokine receptors, such as EBI2 and CXCR4, are still able to direct B cell 
migration and the formation of EF. To clearly demonstrate that B cell migration is altered in the 
CCR6-/- mice, specifically that B cells are directed to the GC rather than the EF, will require the 
visualisation of B cells during TD humoral responses.  
 
As this study was initially focused on determining the impact of CCR6 on the GC reaction, the EF 
response was less well investigated. Granted the EF B cell population is more challenging to 
investigate due to the lack of definitive surface markers and lack of access to specialist mouse 
models, the EF response does need to be quantified in its entirety, such that a picture of both early 
and late B cell kinetics is collected. Such data would show whether the diminished EF response is 
sustained or transient, much in the same way that the GC response is transiently increased.  
 
Overall, no detrimental effects were observed on the outcome of the humoral response. CCR6 
appears to be solely involved in B cell positioning, which is crucial in establishing the humoral 
response and efficiently generating antibody-secreting cells to combat infection. Specifically, the 
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modulation of CCR6 surface expression on B cells appears to contribute to directing their migration 
to EF or GC sites, and consequently, their subsequent differentiation.  
 
7.3. CCR6 is associated with SLE  
The cause of SLE currently remains elusive. The hallmark production of autoreactive antibodies 
indicates a critical collapse in B cell tolerance, facilitating the expansion of autoreactive antibody-
secreting B cells. It is clear that early B cell interactions with antigen and Th cells are imperative to 
initiate and drive B cell differentiation, and thus would be prime targets of tolerance breakdowns. 
Indeed, it has emerged that breakdowns in SLE likely occur early, for instance during B cell 
development in the bone marrow308, T-B cell interactions309, and the precursor241 or GC 
stages310.Whatever the case may be, whether SLE is caused by a single error or multiple breakdown 
events, this dysfunction creates an environment fostering the survival of autoreactive B cells. The 
key aim of the present study was to identify whether CCR6 contributes to the pathophysiology of 
SLE. Although the results from this study are derived from small numbers of participants, they 
highlight the importance of CCR6 and represent the first investigation to correlate CCR6 expression 
with B cell dysregulation in SLE.  
 
The initial finding of a significant reduction in the frequency of circulatory pre-GC B cells in SLE 
participants, concurs with the general circulatory lymphopenia known to be associated with 
SLE228,311. However it has not yet been specifically described for this subset. The decrease in 
circulatory pre-GC and GC B cells may reflect increased recruitment of these cells to secondary 
lymphoid organs, where they can seed and differentiate into antibody-secreting cells. This theory is 
consistent with the increased populations of GC and memory B cells that have been reported in the 
tonsils of SLE participants compared to controls241. While pre-GC B cells have actually been 
documented to increase in children diagnosed with SLE312, the discrepancy in this study can be 
attributed to the variation in B cell populations between children and adults.  
 
Interestingly, the increased frequency of circulatory TFH cells observed in SLE participants in this 
study, could indicate that their absence from secondary lymphoid organs may cause a defect in B 
cell help and differentiation. Alternatively, it may reflect an increased GC response, whereby TFH 
cells migrate between multiple secondary lymphoid organs to seed and support other GC reactions. 
Regardless, this observation concurs with published data that suggests the increased circulating TFH 
cell population contributes to the pathogenesis of disease247,288. Consequently, this study suggests 
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that alterations in the pre-GC, GC and TFH cell populations contribute to the pathophysiology of 
SLE.  
 
Previously, the frequency of CCR6+ B cells, but not the intensity of CCR6 expression on B cells 
had been investigated in SLE. Specifically, Henneken and colleagues (2005) found that SLE 
participants tended to have fewer CCR6+ B cells, though this was not significant221. Likewise, in the 
current study, which recruited only a few more SLE participants (n=14 vs. n=11), the frequency of 
CCR6+ B cells during SLE was not significantly different from controls. This variation probably 
reflects the heterogeneous nature or different disease states of SLE. However, when the intensity of 
CCR6 expression was examined, a significant increase was observed on all B cells from SLE 
participants, which correlated with significant increases in the naïve and memory B cell 
populations. The expression of CCR6 also appeared to increase on pre-GC and GC B cells, however 
this was not significant. Nevertheless, the substantial upregulation of CCR6 on naïve and memory 
B cells could aid the migration of these B cells to activation sites in secondary lymphoid organs 
including the T-B border, resulting in a larger number of B cells being selected to differentiate into 
GCs. In addition, it is likely that the increased CCR6 expression observed on B cells in SLE is a 
consequence of the breakdown in tolerance, rather than a causative factor. Overall, this work 
suggests that CCR6 may contribute to B cell dysregulation and therefore is relevant to the 
pathophysiology of SLE. This is not the first time that CCR6 has been implicated in the 
pathophysiology of autoimmune disease. In fact, a similar role for CCR6 has been proposed in RA, 
whereby the CCR6-CCL20 axis mediates the recruitment of B cells218 and other mononuclear cells 
to the joints215, thereby contributing to inflammation. 
 
It is generally accepted that the lymphocyte populations of the blood reflect those in secondary 
lymphoid organs and by extension, disease state. The results presented in this study have 
demonstrated that CCR6 is an excellent candidate for use as a disease biomarker. Blocking of 
CCR6, or indeed other chemokine receptors imperative for B cell migration may prove valuable in 
preventing disease severity. However, for now, the clinical usefulness of CCR6 is proposed to 
mainly aid diagnosis and monitor disease severity. The most convenient method to analyse disease 
status in humans is through blood tests. Thus, it would be ideal to develop a flow cytometry panel 
that can be used to quantify the population frequency and chemokine receptor expression of B cells 
in the blood. Such a tool, similar to the one used in this study, would provide a clear and conclusive 
indication of disease, and could be used to tailor personalised medicine in the future. Accordingly, 
future research should focus on examining an array of chemokine receptor expression in SLE, to 
develop a more comprehensive profile of disease. Perhaps the best example of this novel idea is the 
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expression of CCR6, CCR7, CXCR4 CXCR5, CCR5 and CXCR3, that was recently documented in 
the blood and joints of RA patients218.  
 
To summarise, this work has provided insights into the pathophysiology of SLE and the usefulness 
of CCR6 in therapeutic applications. As this study was restricted to a small SLE population, it 
would be worthwhile to substantiate these findings in a larger cohort with well-defined disease 
activity. Finally, this work has paved the way for further investigations into the use of chemokine 
receptors as biomarkers of disease and the development of medications.  
 
7.4. Conclusion  
Chemokine receptors are crucial for the correct positioning of B cells in the humoral response, 
which is essential for the efficient differentiation of antibody-secreting cells. In this thesis, I have 
focused on uncovering the previously undefined role of CCR6 on B cells in the humoral response. I 
hypothesised that CCR6 expression contributes to the efficient differentiation of B cells during TD 
humoral immune responses. As a result of this investigation, this thesis has presented evidence 
supporting a role for CCR6 in the humoral response. Specifically, I have characterised the 
expression of CCR6 during B cell activation, the differentiation of B cells in the absence of CCR6, 
the mechanisms that underlie CCR6 deficient B cell differentiation and the relevance of CCR6 in B 
cell-mediated autoimmunity.  
 
This is the first study to examine the temporal kinetics of CCR6 expression, how this expression 
affects B cell fate, and the dynamics of CCR6 expression on circulating B cells in SLE. In doing so, 
this study has extended our previous understanding of the chemokine receptor driven spatial 
organisation of B cells in secondary lymphoid organs and provided great insight into the B cell 
dysregulation that occurs during autoimmune disease. As a result of this work, I propose that CCR6 
expression contributes to the organisation of B cells during activation, and that the subsequent 
modulation of CCR6 expression guides B cells to either follicular or extrafollicular sites, where 
they continue their terminal differentiation. This proposal complements the current model of B cell 
movement in the humoral response, whereby CCR6 would work in conjunction with CXCR5, 
CCR7, EBI2 and CXCR4, to correctly position B cells for differentiation in response to TD 
antigens.  
 
Overall, this study has conclusively demonstrated that CCR6 contributes to the efficient 
differentiation of B cells during the TD humoral response. While this thesis has made substantial 
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progress in defining the role of CCR6, it is imperative that further research be undertaken to 
visualise B cell localisation during the humoral response in the absence of CCR6. This will 
definitively show the role of CCR6 in B cell movement. In addition, research efforts should now 
focus on clearly defining the EF reaction and subsequently, the role of CCR6 in the EF 
differentiation pathway. Finally, it will be invaluable to compile profiles of chemokine receptor 
expression during autoimmune disease, as this information will be useful to direct the development 
of therapeutics and to diagnose disease. In conclusion, this thesis has demonstrated a critical role for 
CCR6 in the regulation of B cell differentiation in the humoral immune response.  
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